
<html lang="en"     class="pb-page"  data-request-id="bddd7dff-ae3d-4c42-a520-a606868f7b8a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-3;article:article:10.1021/acs.jmedchem.8b01391;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors" /></meta><meta name="dc.Creator" content="Romeo  Romagnoli" /></meta><meta name="dc.Creator" content="Filippo  Prencipe" /></meta><meta name="dc.Creator" content="Paola  Oliva" /></meta><meta name="dc.Creator" content="Stefania  Baraldi" /></meta><meta name="dc.Creator" content="Pier Giovanni  Baraldi" /></meta><meta name="dc.Creator" content="Santiago  Schiaffino Ortega" /></meta><meta name="dc.Creator" content="Mariem  Chayah" /></meta><meta name="dc.Creator" content="Maria  Kimatrai Salvador" /></meta><meta name="dc.Creator" content="Luisa Carlota  Lopez-Cara" /></meta><meta name="dc.Creator" content="Andrea  Brancale" /></meta><meta name="dc.Creator" content="Salvatore  Ferla" /></meta><meta name="dc.Creator" content="Ernest  Hamel" /></meta><meta name="dc.Creator" content="Roberto  Ronca" /></meta><meta name="dc.Creator" content="Roberta  Bortolozzi" /></meta><meta name="dc.Creator" content="Elena  Mariotto" /></meta><meta name="dc.Creator" content="Elena  Mattiuzzo" /></meta><meta name="dc.Creator" content="Giampietro  Viola" /></meta><meta name="dc.Description" content="The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal grow..." /></meta><meta name="Description" content="The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal grow..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 11, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01391" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01391" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01391" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01391" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01391" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0015.jpeg" /></meta><meta property="og:description" content="The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3′,4′,5′-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polymerization and EGFR kinase." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01391"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01391">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01391&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01391&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01391&amp;href=/doi/10.1021/acs.jmedchem.8b01391" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1274-1290</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01226" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01402" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-<i>d</i>]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Romeo Romagnoli</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Romeo Romagnoli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#681a051a281d06010e0d46011c"><span class="__cf_email__" data-cfemail="46342b340633282f2023682f32">[email protected]</span></a>. Phone: 39-(0)532-455303. Fax: 39-(0)532-455953 (R.R.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Romeo++Romagnoli">Romeo Romagnoli</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6374-773X" title="Orcid link">http://orcid.org/0000-0002-6374-773X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Filippo Prencipe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Filippo Prencipe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Filippo++Prencipe">Filippo Prencipe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paola Oliva</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paola Oliva</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paola++Oliva">Paola Oliva</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefania Baraldi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefania Baraldi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefania++Baraldi">Stefania Baraldi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pier Giovanni Baraldi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pier Giovanni Baraldi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pier+Giovanni++Baraldi">Pier Giovanni Baraldi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Santiago Schiaffino Ortega</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Santiago Schiaffino Ortega</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Santiago++Schiaffino+Ortega">Santiago Schiaffino Ortega</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mariem Chayah</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mariem Chayah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mariem++Chayah">Mariem Chayah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Kimatrai Salvador</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Kimatrai Salvador</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Kimatrai+Salvador">Maria Kimatrai Salvador</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luisa Carlota Lopez-Cara</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luisa Carlota Lopez-Cara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#620e0103100e0d16030e0d120718221705104c0711"><span class="__cf_email__" data-cfemail="aec2cdcfdcc2c1dacfc2c1decbd4eedbc9dc80cbdd">[email protected]</span></a>. Phone: 34-(0)958-243849. Fax: 34-(0)958-243845 (L.C.L.-C.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luisa+Carlota++Lopez-Cara">Luisa Carlota Lopez-Cara</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1142-6448" title="Orcid link">http://orcid.org/0000-0003-1142-6448</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Brancale</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Brancale</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Brancale">Andrea Brancale</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9728-3419" title="Orcid link">http://orcid.org/0000-0002-9728-3419</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Salvatore Ferla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Salvatore Ferla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Salvatore++Ferla">Salvatore Ferla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ernest Hamel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ernest Hamel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ernest++Hamel">Ernest Hamel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roberto Ronca</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roberto Ronca</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Traslazionale Unità di Oncologia Sperimentale ed Immunologia, Università di Brescia, 25123 Brescia, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roberto++Ronca">Roberto Ronca</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roberta Bortolozzi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roberta Bortolozzi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia, Università di Padova, 35131 Padova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roberta++Bortolozzi">Roberta Bortolozzi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Mariotto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Mariotto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia, Università di Padova, 35131 Padova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Mariotto">Elena Mariotto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Mattiuzzo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Mattiuzzo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia, Università di Padova, 35131 Padova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Mattiuzzo">Elena Mattiuzzo</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Giampietro Viola</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giampietro Viola</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia, Università di Padova, 35131 Padova, Italy</div><div class="loa-info-affiliations-info">Istituto di Ricerca Pediatrica (IRP), Corso Stati Uniti 4, 35128 Padova, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#791e10181409101c0d0b16570f1016151848390c1710091d57100d"><span class="__cf_email__" data-cfemail="1a7d737b776a737f6e6875346c7375767b2b5a6f74736a7e34736e">[email protected]</span></a>. Phone: 39-(0)49-8215485. Fax: 39-(0)49-8211462 (G.V.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giampietro++Viola">Giampietro Viola</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01391&amp;href=/doi/10.1021%2Facs.jmedchem.8b01391" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1274–1290</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 11, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 September 2018</li><li><span class="item_label"><b>Published</b> online</span>11 January 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 February 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01391" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01391</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1274%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRomeo%2BRomagnoli%252C%2BFilippo%2BPrencipe%252C%2BPaola%2BOliva%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D3%26contentID%3Dacs.jmedchem.8b01391%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B6-Substituted%2BThieno%255B3%252C2-d%255Dpyrimidine%2BAnalogues%2Bas%2BDual%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BKinase%2Band%2BMicrotubule%2BInhibitors%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1290%26publicationDate%3DFebruary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01391"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2833</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01391" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Romeo&quot;,&quot;last_name&quot;:&quot;Romagnoli&quot;},{&quot;first_name&quot;:&quot;Filippo&quot;,&quot;last_name&quot;:&quot;Prencipe&quot;},{&quot;first_name&quot;:&quot;Paola&quot;,&quot;last_name&quot;:&quot;Oliva&quot;},{&quot;first_name&quot;:&quot;Stefania&quot;,&quot;last_name&quot;:&quot;Baraldi&quot;},{&quot;first_name&quot;:&quot;Pier&quot;,&quot;last_name&quot;:&quot;Giovanni Baraldi&quot;},{&quot;first_name&quot;:&quot;Santiago&quot;,&quot;last_name&quot;:&quot;Schiaffino Ortega&quot;},{&quot;first_name&quot;:&quot;Mariem&quot;,&quot;last_name&quot;:&quot;Chayah&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Kimatrai Salvador&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;Carlota Lopez-Cara&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Brancale&quot;},{&quot;first_name&quot;:&quot;Salvatore&quot;,&quot;last_name&quot;:&quot;Ferla&quot;},{&quot;first_name&quot;:&quot;Ernest&quot;,&quot;last_name&quot;:&quot;Hamel&quot;},{&quot;first_name&quot;:&quot;Roberto&quot;,&quot;last_name&quot;:&quot;Ronca&quot;},{&quot;first_name&quot;:&quot;Roberta&quot;,&quot;last_name&quot;:&quot;Bortolozzi&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Mariotto&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Mattiuzzo&quot;},{&quot;first_name&quot;:&quot;Giampietro&quot;,&quot;last_name&quot;:&quot;Viola&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;1274-1290&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01391&quot;},&quot;abstract&quot;:&quot;The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3′,4′,5′-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polyme&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01391&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01391" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01391&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01391" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01391&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01391" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01391&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01391&amp;href=/doi/10.1021/acs.jmedchem.8b01391" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01391" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01391" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01391%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DRomagnoli%26date%3D2019%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B6-Substituted%2BThieno%255B3%252C2-d%255Dpyrimidine%2BAnalogues%2Bas%2BDual%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BKinase%2Band%2BMicrotubule%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D3%26spage%3D1274%26epage%3D1290%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292232" title="Polymerization">Polymerization</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/jmcmar.2019.62.issue-3/20190214/jmcmar.2019.62.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-<i>d</i>]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3′,4′,5′-trimethoxyanilino)-6-(<i>p</i>-tolyl)thieno[3,2-<i>d</i>]pyrimidine derivative <b>6g</b> was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC<sub>50</sub>) values in the single- or double-digit nanomolar range. Compound <b>6<u class="uu">g</u></b> bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC<sub>50</sub> value of 0.71 μM, and <b>6g</b> inhibited EGFR activity with an IC<sub>50</sub> value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of <b>6g</b> may be derived from its dual inhibition of tubulin polymerization and EGFR kinase.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50087" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50087" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cellular microtubules are formed by the noncovalent polymerization of α- and β-tubulin heterodimers and act as an essential element of the cytoskeleton. Microtubules are crucial for multiple functions in cells, especially the development and function of the mitotic spindle during mitosis, but also for establishing the shape of the cell, intracellular transport, secretion, and cell movement.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Their importance for cell structure and function, together with their long history of utility in cancer chemotherapy, has made microtubules important for anticancer drug discovery, and agents that target them are among the most reliable chemotherapeutics.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A substantial number of compounds, representing many chemotypes, bind to tubulin or microtubules and inhibit or enhance tubulin polymerization.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Moreover, several small molecules inhibiting tubulin polymerization are able to damage the already existing vasculature in developing tumors, acting as vascular-disrupting agents (VDAs).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Originally derived from a South African tree,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> combretastatin A-4 (CA-4, <b>1a</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is a widely studied molecule that inhibits tubulin assembly by binding to the colchicine site.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The disodium phosphate prodrug of CA-4 (CA-4P, <b>1b</b>) is water-soluble, and there have been promising results with <b>1b</b> as a tumor VDA in phase II clinical trials.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The properties of CA-4, including its simple structure and its potent destructive effects on tumor blood vessels, have made <b>1a</b> widely studied by medicinal chemists.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of tubulin-depolymerizing agents CA-4 and CA-4P and selected epidermal growth factor receptor (EGFR) (<b>2a</b>–<b>d</b>) and vascular endothelial growth factor receptor-2 (VEGFR-2) (<b>2e</b>) tyrosine kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A growing body of evidence has shown that antimitotic agents, and in particular microtubule-destabilizing drugs, have multiple effects beyond mitosis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Several lines of evidence suggested mixed mechanisms that are not so far fully understood to explain the activities of tubulin-binding agents, and these mechanisms probably extend beyond simple antimitotic effects. Moreover, there is evidence that the efficacy of microtubule-targeting agents also involves interphase effects.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Signal transduction in mammalian cells involves many receptor kinases. Particularly important is the epidermal growth factor receptor, which is a transmembrane-bound molecule that has important regulatory functions affecting tumor growth and progression. These include cell proliferation, differentiation, migration, apoptosis, and angiogenesis.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> EGFR kinase, consisting of ErB1 and HER1, belongs to the ErbB family of kinases, which also includes human epidermal growth factor receptor-2 (subunits: HER2 and ErbB-2), human epidermal growth factor receptor-3 (subunits: HER3 and ErbB-3), and human epidermal growth factor receptor-4 (subunits: HER4 and ErbB-4).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Among the known receptor tyrosine kinases (RTKs), those of the ErbB family, in particular, EGFR and HER2, have been extensively studied and clinically validated as targets for cancer therapies, being over-expressed in a wide number of human tumors and associated with cancer proliferation, angiogenesis, and metastasis.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> With no bound ligand, EGFR is in monomeric form of the cell surface. When ligand is bound, EGFR forms homodimers with itself and heterodimers with other ErbB family members.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> There are currently eight drugs approved by the Food and Drug Administration (FDA) targeting this family: four monoclonal antibodies (trastuzumab, cetuximab, panitumumab, and pertuzumab) and four small-molecule inhibitors based on a central 4-aminoarylquinazoline core [gefitinib (<b>2a</b>), erlotinib (<b>2b</b>), lapatinib (<b>2c</b>), and afatinib (<b>2d</b>)].<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> These latter synthetic EGFR inhibitors have been approved by the FDA for the treatment of patients with non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Unfortunately, the duration of benefit derived from the therapy based on tyrosine kinase inhibitors is relatively short because of the development of acquired resistance.<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a> The development of multitargeted inhibitors represents a valid approach to overcome the acquired drug resistance to tyrosine kinase inhibitors.<a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a> Twelve clinical trials were found on the clinicaltrials.gov site (accessed in October 2018) in which the FDA-approved EGFR kinase inhibitors gefitinib, erlotinib, and lapatinib were being used in combination with the microtubule-targeting agents docetaxel, vinorelbine, paclitaxel, and other chemotherapeutic agents for the treatment of a variety of cancers including lung cancer, head and neck cancer, and hepatocellular carcinoma.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">A large number of thienopyrimidine derivatives have been reported to show remarkable antitumor activity against different cancer types by means of inhibiting multiple enzymes, as well as by modulating the activity of many receptors.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In an effort to develop nonquinazoline EGFR inhibitors, using the strategy known as “scaffold hopping”, bioisosteric thieno[2,3-<i>d</i>]pyrimidine and thieno[3,2-<i>d</i>]pyrimidine scaffolds have been reported as interesting structural elements employed for the development of novel EGFR or EGFR with vascular endothelial growth factor receptor-2 (VEGFR-2) dual inhibition.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Munchhof et al. reported the design and structure–activity relationship (SAR) of a series of 6-aryl-substituted thieno[3,2-<i>d</i>]pyrimidines with general structure <b>3</b>, identified as VEGFR-2 and EGFR dual inhibitors (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Kemnitzer and his colleagues reported the discovery of <i>N</i>-methyl-4-(methoxyanilino)thieno[3,2-<i>d</i>]pyrimidine <b>4</b> as a potent apoptosis inducer through inhibition of tubulin assembly, with half-maximal inhibitory concentration (IC<sub>50</sub>) <1 μM in the tubulin polymerization assay.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This compound inhibited the growth of a panel of five cancer cell lines (T-47D, HT-29, H-1299, MX-1, and MDAAMB 435) with IC<sub>50</sub> values ranging from 4 to 40 nM. Much research has been conducted on the structural modification of the thieno[3,2-<i>d</i>]pyrimidine skeleton, with the 4-, 6-, and 7-positions as the main targets for chemical modifications to increase antitumor activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of representative thieno[3,2-<i>d</i>]pyrimidines and thiazolo[4,5-<i>d</i>]pyrimidines as known tubulin polymerization (<b>4</b>) and EGFR kinase (<b>3</b> and <b>5</b>) inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lin et al. have also reported a series of 2,7-diaminothiazolo[4,5-<i>d</i>]pyrimidines with general formula <b>5</b>, with various structural modifications at the 2- and 7-positions, as potent EGFR inhibitors, with IC<sub>50</sub> values ranging from micromolar to single-digit nanomolar.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compound <b>5a</b>, characterized by potent and selective EGFR activity (IC<sub>50</sub>: 12 nM), proved to be active in vitro as an antiproliferative agent against the human ovarian adenocarcinoma (SK-OV-3) cell line, with an IC<sub>50</sub> value of 0.57 μM. Unfortunately, compound <b>5a</b> showed no in vivo antitumor efficacy in a tumor xenograft model in nude mice.</div><div class="NLM_p">Our findings caused us to use the thieno[3,2-<i>d</i>]pyrimidine scaffold for optimization of the pharmacophore, which was maintained for the discovery of new antitumor agents. We replaced the 5′-aminoindole side chain at the C-4 position of 6-phenylthieno[2,3-<i>d</i>]pyrimidine derivatives with general structure <b>3</b> with a 3′,4′,5′-trimethoxyanilino moiety to furnish a first series of 4-(3′,4′,5′-trimethoxyanilino)-6-aryl/heteroaryl-thieno[3,2-<i>d</i>]pyrimidine derivatives with general structure <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). By maintaining the 3′,4′,5′-trimethoxyanilino group at the 4-position, the first stage of our study was to evaluate the steric and electronic effects of different substituents on the benzene portion at the C-6 position of the 4-(3′,4′,5′-trimethoxyanilino)thieno[2,3-<i>d</i>]pyrimidine nucleus. Besides hydrogen, the examined substituents included electron-withdrawing groups (EWGs), such as F, Cl, Br, I, and NO<sub>2</sub>, and the electron-releasing methyl and methoxy groups (electron-releasing groups (ERGs)). The bioisosteric replacement of phenyl with the thien-2-yl ring was also explored.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy for thieno[3,2-<i>d</i>]pyrimidines <b>6a</b>–<b>j</b>. Target compounds containing the thiazolo[4,5-<i>d</i>]pyrimidine (<b>7a</b>–<b>d</b>) and thieno[2,3-<i>d</i>]pyrimidine (<b>8a</b>–<b>l</b>) scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All of the newly synthesized agents contained the 3′,4′,5′-trimethoxyanilino moiety at the common C-4 position of the thieno[2,3-<i>d</i>]pyrimidine nucleus and isomeric thieno[3,2-<i>d</i>]pyrimidine nucleus, as well as at the C-7 position of the thiazolo[4,5-<i>d</i>]pyrimidine system. The rationale for this was the well-documented requirement for a trimethoxyphenyl group in numerous colchicine site inhibitors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">In the second small series of compounds, the thiophene nucleus was replaced by the bioisosteric thiazole ring to obtain the derivatives <b>7a</b>–<b>d</b>, characterized by the presence of an anilino moiety at its C-7 position. The electron-withdrawing chlorine atom (<b>7b</b>) and the electron-releasing methyl and methoxy groups (<b>7c</b> and <b>7d</b>, respectively) were introduced at the para-position of the phenyl portion of the anilino moiety.</div><div class="NLM_p">In a third series of compounds, <b>8a</b>–<b>l</b>, we explored the replacement of the thieno[3,2-<i>d</i>]pyrimidine system, which characterizes derivatives with general structure <b>6</b>, by the isomeric thieno[2,3-<i>d</i>]pyrimidine nucleus. The SAR was investigated by the insertion of different substituents (Cl, Me, or OMe) on the phenyl ring at the C-5 or C-6 position of the 4-(3′,4′,5′-trimethoxyanilino)thieno[2,3-<i>d</i>]pyrimidine core.</div><div class="NLM_p">These three series of compounds, obtained by replacing the thieno[3,2-<i>d</i>]pyrimidine scaffold with the isomeric thieno[2,3-<i>d</i>]pyrimidine and the bioisosteric thiazolo[4,5-<i>d</i>]pyrimidine skeletons, were designed to determine the potential of incorporating in a single molecule both VEGFR-2 and/or EGFR kinase inhibition and antitubulin activity.</div><div class="NLM_p last">The bioisosteric replacement of the thiophene ring of the structure motif of the thieno[2,3-<i>d</i>]pyrimidine nucleus with a furan or pyrrole provided two series of furo[2,3-<i>d</i>]pyrimidine and pyrrolo[3,2-<i>d</i>]pyrimidine derivatives, respectively, identified by Gangjee et al. as multitarget receptor tyrosine kinase and microtubule inhibitors.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26−28)</a> A literature search also revealed that recent studies have yielded different series of chemically diverse small molecules acting as EGFR kinase and tubulin polymerization inhibitors derived from anthranilic acid<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> or benzo[<i>b</i>]furan<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> or obtained by replacing the quinazoline core of compounds <b>2a</b>–<b>d</b> with a quinazolinone<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> or triazolo[4,3-<i>a</i>]quinoxaline<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> scaffold.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Preparation of thieno[3,2-<i>d</i>] pyrimidine and thiazolo[4,5-<i>d</i>]pyrimidine derivatives <b>6a</b>–<b>j</b> and <b>7a</b>–<b>d</b>, respectively, was accomplished using the general convergent synthetic route shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Cyclization of methyl 5-aryl/heteroayl-3-aminothiophene-2-carboxylate and ethyl 2-anilino-4-aminothiazole-5-carboxylate <b>9a</b>–<b>j</b> and <b>9k</b>–<b>n</b>, respectively, with formamide (HCONH<sub>2</sub>) yielded the corresponding 6-aryl/heteroaryl-thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-ones <b>10a</b>–<b>j</b> and 2-arylaminothiazolo[4,5-<i>d</i>]pyrimidin-7(6<i>H</i>)-ones <b>10k</b>–<b>n</b>. The subsequent chlorination of the carbonyl group with phosphorus oxychloride (POCl<sub>3</sub>) provided 4-chlorothieno[3,2-<i>d</i>]pyrimidine and 7-chlorothiazolo[4,5-<i>d</i>]pyrimidine derivatives <b>11a</b>–<b>j</b> and <b>11k</b>–<b>n</b>, respectively. Finally, the nucleophilic substitution with 3,4,5-trimethoxyaniline in refluxing isopropanol furnished the final compounds <b>6a</b>–<b>j</b> and <b>7a</b>–<b>d</b>, respectively.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0013.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Thieno[3,2-<i>d</i>]pyrimidines <b>6a</b>–<b>j</b> and Thiazolo[4,5-<i>d</i>]pyrimidines <b>7a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) HCONH<sub>2</sub>, 180 °C; (b) POCl<sub>3</sub>, 110 °C; (c) 3,4,5-trimethoxyaniline, isopropanol, reflux.</p></p></figure><div class="NLM_p">The isomeric 4-(3′,4′,5′-trimethoxyanilino)-thieno[2,3-<i>d</i>]pyrimidine derivatives <b>8a</b>–<b>l</b> were synthesized following the procedure reported in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one derivatives <b>13a</b>–<b>l</b> variously substituted at their C-5 or C-6 position were prepared by cyclocondensation of ethyl 2-aminothiophene-3-carboxylate derivatives <b>12a</b>–<b>l</b> with HCONH<sub>2</sub> at 180 °C for 8–12 h. These intermediates were subjected to chlorination by the action of POCl<sub>3</sub> at reflux to furnish the 4-chlorothieno[2,3-<i>d</i>]pyrimidine analogues <b>14a</b>–<b>l</b>. The final step of the synthesis involved nucleophilic displacement of the 4-chloride atom of <b>14a</b>–<b>l</b> with 3,4,5-trimethoxyaniline in refluxing isopropanol to obtain the 4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-<i>d</i>]pyrimidine derivatives <b>8a</b>–<b>l</b>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0014.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Thieno[2,3-<i>d</i>]pyrimidines (<b>8a</b>–<b>l</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) HCONH<sub>2</sub>, 180 °C; (b) POCl<sub>3</sub>, 110 °C; (c) 3,4,5-trimethoxyaniline, isopropanol, reflux.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro Antiproliferative Activities</h3><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> summarizes the antiproliferative effects of 4-(3′,4′,5′-trimethoxyanilino)-6-substituted thieno[3,2-<i>d</i>]pyrimidine derivatives <b>6a</b>–<b>j</b> against a panel of five human cancer cell lines [including EGFR wild-type (EGFR<sup>wt</sup>) NSCLC A549 cells], using CA-4 as the reference compound. The corresponding thieno[2,3-<i>d</i>]pyrimidine isomers <b>7a</b>–<b>d</b> and the 2-anilino-7-(3′,4′,5′-trimethoxyanilino)thiazolo[4,5-<i>d</i>]pyrimidines <b>8a</b>–<b>l</b> were also evaluated for their activities on the same panel of cells, but because they were all inactive (IC<sub>50</sub> > 10 μM), with only a few exceptions on selected cancer cell lines (derivatives <b>6h</b>, <b>6k</b>, and <b>6l</b>), these biological data are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_001.pdb" class="ext-link">Tables 1S and 2S</a> (Supporting Information), respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Cell Growth Inhibitory Effects of Compounds <b>6a</b>–<b>j</b> and CA-</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">IC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">A549</th><th class="colsep0 rowsep0" align="center" char="±">HeLa</th><th class="colsep0 rowsep0" align="center" char="±">HT-29</th><th class="colsep0 rowsep0" align="center" char="±">Jurkat</th><th class="colsep0 rowsep0" align="center" char="±">RS4;11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.35 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.01 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.26 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.36 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="char" char="±">13.5 ± 3.0</td><td class="colsep0 rowsep0" align="char" char="±">0.45 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">0.26 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.60 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.087 ± 0.033</td><td class="colsep0 rowsep0" align="char" char="±">0.003 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.005 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.53 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">0.22 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.03 ± 0.005</td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.77 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">0.25 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">0.30 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.019 ± 0.008</td><td class="colsep0 rowsep0" align="char" char="±">0.001 ± 0.0005</td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.007</td><td class="colsep0 rowsep0" align="char" char="±">0.001 ± 0.0005</td><td class="colsep0 rowsep0" align="char" char="±">0.002 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.43 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.005 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.004 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6i</b></td><td class="colsep0 rowsep0" align="char" char="±">8.8 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">3.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">5.4 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6j</b></td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.004 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.005 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char="±">0.001 ± 0.0001</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> = compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± standard error (SE) from the dose–response curves of at least three independent experiments.</p></div></div></div><div class="NLM_p">The unsubstituted phenyl derivative <b>6a</b> was weakly active (IC<sub>50</sub>: 2.3 μM) against A549, moderately potent against HeLa, HT-29, and RS4;11 with IC<sub>50</sub> values of 0.17, 0.35, and 0.26 μM, respectively, but showed high activity (IC<sub>50</sub>: 10 nM) against Jurkat cells. The bioisosteric 2-thienyl analogue <b>6b</b> was 2-, 8-, and 10-fold less active than <b>6a</b> against A549, Jurkat, and HeLa cells, respectively, whereas the difference in potency between <b>6a</b> and <b>6b</b> was minimal in RS4;11 cells. <b>6a</b> was less active than <b>6b</b> only in HT-29 cells, with IC<sub>50</sub> values of 0.35 and 0.21 μM, respectively.</div><div class="NLM_p">The introduction of electron-releasing or electron-withdrawing substituents at the para-position of the phenyl ring at the C-6 position of the thieno[3,2-<i>d</i>]pyrimidine nucleus appeared to have considerable biological effects, enhancing antiproliferative activity compared to that of the unsubstituted phenyl analogue <b>6a</b>. These compounds include the <i>p</i>-Cl (<b>6d</b>; IC<sub>50</sub>: 3–600 nM), <i>p</i>-Me (<b>6g</b>; IC<sub>50</sub>: 1–20 nM), and <i>p</i>-OMe (<b>6h</b>; IC<sub>50</sub>: 4–430 nM) derivatives. The <i>p</i>-tolyl derivative <b>6g</b> displayed the strongest growth inhibitory activity against A549, HeLa, HT-29, Jurkat, and RS4;11, with IC<sub>50</sub> values of 19, 1, 20, 1, and 2 nM, respectively.</div><div class="NLM_p">A <i>para</i>-fluoro group in the phenyl ring (compound <b>6c</b>) caused a reduction of activity by 2–26-fold relative to that of the unsubstituted phenyl derivative <b>6a</b>, whereas the presence of other halogen groups led to an improvement in antiproliferative activity. As the bulk of the halide group increased from a fluoro to a chloro moiety, the resulting compound <b>6d</b> produced a 5- to 87-fold increase in antiproliferative activity in the five cell lines. Replacing chlorine with bromine (<b>6e</b>) reduced the activity by 2–38-fold against four of the five cancer cell lines, but <b>6d</b> and <b>6e</b> were equally potent against A549 cells. For the <i>p</i>-Br and <i>p</i>-I derivatives <b>6e</b> and <b>6f</b>, respectively, nearly identical activities were observed in three of the five cancer cell lines, the exception being the HT-29 and Jurkat cells, in which <b>6f</b> was 2- and 10-fold more potent than <b>6e</b>, respectively.</div><div class="NLM_p">The small and weak electron-releasing methyl group at the para-position of the phenyl ring, to yield derivative <b>6g</b>, improved the antiproliferative activity significantly relative to that of <b>6a</b>. Derivative <b>6g</b> exhibited the greatest cell growth inhibitory effects among the tested compounds, with IC<sub>50</sub> values of 1–20 nM against all cell lines, as compared with the range 0.8–3100 nM obtained with CA-4. Compound <b>6g</b> was equipotent with CA-4 against RS4;11 cells, whereas it was from 2- to 1.5 × 10<sup>5</sup> times more active against the other four cancer cell lines.</div><div class="NLM_p">A <i>para</i>-methoxy group in the phenyl ring (<b>6h</b>), a more potent electron-releasing group than the methyl of <b>6h</b>, caused a marked reduction (2–170-fold) in activity against the tumor cell lines. Thus, the two substituents, despite their structural similarity, are not biologically equivalent. The reduction in activity was more evident, 23- and 170-fold, against A549 and HeLa, respectively, whereas only a 2-, 3-, and 5-fold reduced activity was observed against RS4;11, HT-29, and Jurkat cells, respectively.</div><div class="NLM_p">Compound <b>6i</b>, with a methoxy group at the meta-position of the phenyl ring, was 1–4 orders of magnitude less active than the <i>para</i>-methoxy isomer <b>6h</b>, indicating that the position of the methoxy group was important for in vitro activity.</div><div class="NLM_p last">Among the strong electron-withdrawing groups, the small polar nitro substituent, intermediate in size between those of chlorine and bromine, when placed in the para-position of the phenyl ring, furnished a compound (<b>6j</b>) with reduced antiproliferative activity (IC<sub>50</sub>: 1.1–6.3 μM) relative to that of the unsubstituted phenyl derivative <b>6a</b>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Inhibition of Tubulin Polymerization and Colchicine Binding</h3><div class="NLM_p">We anticipated that at least some of the compounds would have antitubulin activity, and <b>6a</b>–<b>b</b> and <b>6d</b>–<b>h</b> were examined for inhibitory effects on tubulin assembly and on the binding of colchicine to tubulin in comparison with CA-4 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of Tubulin Polymerization and Colchicine Binding by Compounds <b>6a</b>–<b>b</b>, <b>6d</b>–<b>h</b>, and CA-4 (<b>1a</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">tubulin assembly,<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> IC<sub>50</sub> ± SD (μM)</th><th class="colsep0 rowsep0" align="center">colchicine binding,<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> % inhibition ± SD</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 2</td><td class="colsep0 rowsep0" align="left">n.d.<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="char" char="±">18 ± 1</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">36 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.3</td><td class="colsep0 rowsep0" align="left">35 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.2</td><td class="colsep0 rowsep0" align="left">35 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.71 ± 0.05</td><td class="colsep0 rowsep0" align="left">76 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.2</td><td class="colsep0 rowsep0" align="left">31 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-4</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.1</td><td class="colsep0 rowsep0" align="left">98 ± 0.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Inhibitory effects on the assembly of 10 μM purified tubulin.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">In the experiments to evaluate compound effects on the binding of [<sup>3</sup>H]colchicine to purified tubulin, the protein was 1.0 μM and the radiolabeled colchicine and inhibitory compound were both at 5.0 μM.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">n.d.: not done.</p></div></div></div><div class="NLM_p last">Compounds <b>6e</b>–<b>h</b> strongly inhibited tubulin assembly, with derivative <b>6g</b> as the most active of the series, being almost 2-fold more active than CA-4 in this assay (IC<sub>50</sub>: 0.71 and 1.2 μM for <b>6g</b> and CA-4, respectively). Compounds <b>6e</b>, <b>6f</b>, and <b>6h</b> were half as active (IC<sub>50</sub>: 2.5, 2.5, and 2.8 μM, respectively) and <b>6d</b> about one-third as active (IC<sub>50</sub>: 3.3 μM) as CA-4. Compounds <b>6a</b> and <b>6b</b> showed weak antitubulin polymerization activities (IC<sub>50</sub>: 10 and 18 μM, respectively), which were consistent with their low antiproliferative activity. Thus, in the two tubulin biochemical assays, compound activities were similar, with <b>6g</b> the most active (even more active than CA-4 in the polymerization assay) and <b>6a</b> and <b>6b</b> the least active in the polymerization assay. These data are consistent with the conclusion that tubulin was an intracellular target of the tested compounds.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> EGFR and VEGFR-2 Kinase Inhibitory Activity Assay</h3><div class="NLM_p">Compounds <b>6a</b>–<b>b</b> and <b>6d</b>–<b>h</b> were further evaluated for their EGFR and VEGFR-2 kinase inhibitory activities. The approved VEGFR-2 and EGFR inhibitory agents sunitinib and erlotinib (<b>2b</b>), respectively, were used as positive controls. The data compiled in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> showed potent inhibition of EGFR<sup>wt</sup> kinase by compounds <b>6a</b>–<b>b</b> and <b>6f</b>–<b>h</b>, but no inhibition of VEGFR-2 (IC<sub>50</sub> > 1 μM) was observed. All tested molecules, with the exception of <b>6d</b> and <b>6e</b>, were more potent than sunitinib as EGFR kinase inhibitors, with the 2-thienyl derivative <b>6b</b> as the most potent compound of the series. All evaluated molecules showed lower potency than erlotinib, with <b>6b</b> about 1.7-fold less potent. Three of these compounds (<b>6f</b>–<b>h</b>) were discovered to possess dual EGFR and tubulin polymerization inhibitory activity, and the good correlation between cytotoxicity and antitubulin activity extends to inhibition of EGFR activity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. EGFR Inhibitory Activities by Compounds <b>6a</b>–<b>b</b>, <b>6e</b>–<b>h</b>, Sunitinib, and Erlotinib (<b>2b</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">inhibition of EGFR<sup>wt</sup> kinase,<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> IC<sub>50</sub> ± SD (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char="±">23 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="char" char="±">273 ± 35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="char" char="±">326 ± 46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="char" char="±">30 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="char" char="±">52 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib (<b>2e</b>)</td><td class="colsep0 rowsep0" align="char" char="±">140 ± 19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib (<b>2b</b>)</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values are expressed as the mean ± standard deviation (SD) from the dose–response curves of at least two independent experiments.</p></div></div></div><div class="NLM_p last">Compound <b>6g</b>, with the most potent effect on tubulin polymerization, also exhibited excellent EGFR inhibitory activity, with IC<sub>50</sub> values of 0.71 μM and 30 nM, respectively. In contrast, compound <b>6b</b>, the most active compound as an EGFR inhibitor (IC<sub>50</sub>: 2.5 nM), was less potent as an inhibitor of tubulin polymerization (IC<sub>50</sub>: 18 μM). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, compounds <b>6d</b> and <b>6e</b> showed moderate EGFR inhibitory activities (IC<sub>50</sub>: 273 and 326 nM, respectively) and similar potent antitubulin potency (IC<sub>50</sub>: 3.3 and 2.5 μM), whereas for compound <b>6h</b>, a good correlation was observed between both its EGFR and antitubulin activities. The SAR analysis derived from the antiproliferative activities of compounds <b>6d</b> and <b>6e</b> was more consistent with their tubulin inhibition activities, probably due to their potent inhibitory activities against tubulin polymerization but moderate activities against EGFR.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Compound 6g Induced Inhibition of EGFR Activation in HeLa Cells</h3><div class="NLM_p">To test the inhibition of the phosphorylation of EGFR and the downstream signaling pathway, we evaluated by Western blot analysis the inhibition of EGFR phosphorylation by <b>6g</b> in HeLa cells. The cells were treated with different concentrations of <b>6g</b> (10–1000 nM) and then stimulated with the epidermal growth factor (EGF) (50 ng/mL) for 15 min. The results (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) showed that <b>6g</b> strongly inhibited the phosphorylation of EGFR in a concentration-dependent manner starting at 50 nM. Erlotinib (1 μM) was taken as a reference compound, and erlotinib showed similar inhibitory activity to that of compound <b>6g</b>. These results demonstrated that <b>6g</b>, in addition to its antimitotic activity (see below), is also a potent EGFR inhibitor.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of <b>6g</b> on EGFR signaling in HeLa cells. Cells were treated with the indicated concentrations of <b>6g</b> for 6 h and then stimulated by EGF (30 ng/mL) for 15 min. Cells were harvested for Western blot analysis for both EGFR and its phosphorylation at Y1068. Erlotinib (Erl) was used as the reference compound. We established that each gel lane had similar quantities of protein by determining their β-actin content.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Molecular Modeling</h3><div class="NLM_p">A series of docking simulations were conducted on the newly designed 4-(3′,4′,5′-trimethoxyanilino)-6-substituted thieno[3,2-<i>d</i>]pyrimidines to evaluate their potential interaction at the binding site for colchicine on tubulin.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The results showed that the compounds bind at the active site with considerable overlap with <i>N</i>-deacetyl-<i>N</i>-(2-mercaptoacetyl)-colchicine (DAMA-colchicine), which was the ligand in the crystal structure, and the binding mode is consistent with the one previously reported for a thieno[2,3-<i>b</i>]pyridine series,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> with the trimethoxyphenyl group in proximity of βCys241. The thieno[3,2-<i>d</i>]pyrimidine core overlapped with the central part of DAMA-colchicine, with the substituted phenyl ring placed in a small hydrophobic subpocket, potentially interacting with the surrounding amino acids βThr314, βVal181, and especially βMet259. This small subpocket appears to be able to interact with phenyl rings bearing different substituents, but only the <i>para</i>-methyl derivative <b>6g</b> has the correct combination of size/electronic properties to stably occupy and properly fit that area of the binding site (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C), suggesting a better inhibition of tubulin assembly. Replacement with a larger methoxy group (<b>6h</b>) does not allow the efficient occupation of the subpocket, indicating a potential reduction of the inhibition of tubulin polymerization. A similar decrease in activity is seen when the methyl group is replaced by different electron-withdrawing atoms (<b>6d</b>–<b>f</b>), but in this case, the decrease in activity could be associated with the electronic properties of the substituent rather than its size because they can occupy the subpocket very similarly to <b>6g</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Compounds in which the para substituent has been removed (<b>6a</b>) or the phenyl ring has been replaced with a smaller five-member thiophene ring do not entirely fill the subpocket, potentially causing the 10–18-fold activity reduction found for these derivatives (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proposed binding modes for compounds <b>6b</b> (A), <b>6e</b> (B), and <b>6g</b> (C) in comparison with DAMA-colchicine at the colchicine site (Protein Data Bank (PDB) ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0">1SA0</a>). Carbons are shown in green for the cocrystallized DAMA-colchicine, in purple for compound <b>6b</b>, in orange for compound <b>6e</b>, and in turquoise for compound <b>6g</b>. The residues from the α-tubulin chain are shown in salmon, whereas residues from β-tubulin are colored in teal. The subpocket is highlighted with a red surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an attempt to clarify the binding mode of the new derivatives in the EGFR kinase domain, docking of the new molecules was performed using the crystal structure of the EGFR kinase domain in complex with the inhibitor (<i>R</i>)-6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-<i>N</i>-(1-phenylethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (AEE788).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The 6-phenyl-thieno[3,2-<i>d</i>]pyrimidine core of the molecules perfectly overlaps with the phenyl pyrrolo[2,3-<i>d</i>]pyrimidine core of the cocrystallized inhibitor, making the same interactions with Gln791, Met793, and Leu844 that seem to anchor the molecule to the binding site (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The trimethoxyphenyl group is placed in the same area occupied by the methyl moiety of AEE788, in proximity of Asp855.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed binding modes for compounds <b>6b</b> (A) and <b>6e</b> (B) in comparison with those for the inhibitor AEE788 in the crystal structure of the EGFR kinase domain (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M">2J6M</a>). The carbons are shown in green for cocrystallized AEE788, in purple for compound <b>6b</b>, and in orange for compound <b>6e</b>. The phenyl ring of <b>6e</b> and the thiophene of <b>6b</b> are not involved in any interaction with the surrounding residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Overall, the binding mode proposed for these compounds is very similar to that of the cocrystallized ligand and also to that of another previously published thienopyrimidine EGFR inhibitor.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> All of the new compounds occupy the active site in an identical manner. However, from these results, it is not possible to fully rationalize the role of the substitution on the phenyl ring in the anti-EGFR activity because that part of the molecule does not seem to be involved in any specific interactions with the binding pocket.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Effects of Compound 6g on the Cell Cycle</h3><div class="NLM_p">Cell cycle effects of the highly active <b>6g</b> were examined in HeLa and Jurkat cells, using flow cytometry (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). After 24 h, G2/M arrest occurred in both cell lines at 25 nM <b>6g</b>, as shown by propidium iodide (PI) staining. That the arrest occurred in mitosis was established by staining the cells with an immunofluorescent antibody to <i>p</i>-histone H3.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Typical histograms show that HeLa cells arrested in mitosis by <b>6g</b> are easily distinguished from G2 cells with the <i>p</i>-histone H3 stain (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). The increase in mitotic cells (from 1.5% in the control) was especially dramatic with 50 (38%) and 100 (50%) nM <b>6g</b>.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle effects caused by <b>6g</b>: (A) HeLa cells treated with varying concentrations of <b>6g</b>, stained with PI, and examined by flow cytometry. (B) Jurkat cells treated with varying concentrations of <b>6g</b>, stained with PI, and examined by flow cytometry. G1 cells are indicated by the symbol ■, G2/M cells, by the symbol ●, and S cells, by the symbol ▲. Three independent experiments were performed, and the standard error of the mean (SEM) values are indicated. (C) Typical flow cytometric patterns of mitotic HeLa cells immunofluorescently stained with an antibody to <i>p</i>-histone H3, following treatment with 0 (left-hand pattern), 50 (middle pattern), or 100 (right-hand pattern) nM <b>6g</b>. (D) Histogram presentation of the data from (C) (two experiments, with SEM values indicated).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Compound 6g Induced Apoptosis in Different Cell Lines</h3><div class="NLM_p">The mechanism of cell death was evaluated by two-dimensional cell sorting by staining DNA with PI and staining phosphatidylserine (PS) with a fluorescent annexin V derivative. We used two cell lines, Hela and Jurkat, in which we evaluated the effects of compound <b>6g</b> after both 24 and 48 h treatments. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, in both cell lines, <b>6g</b> caused apoptosis that increased with time and with <b>6g</b> concentration, with an apoptotic effect observed at 50 nM, the lowest concentration used, shown in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) test (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Apoptotic effects caused by <b>6g</b>: (A) Apoptosis examined by flow cytometry after treatment of HeLa cells for 24 h with <b>6g</b>, as indicated. (B) Apoptosis examined by flow cytometry after treatment of HeLa cells for 48 h with <b>6g</b>, as indicated. (C) Apoptosis examined by flow cytometry after treatment of Jurkat cells for 24 h with <b>6g</b>, as indicated. (D) Apoptosis examined by flow cytometry after treatment of Jurkat cells for 48 h with <b>6g</b>, as indicated. In all cases, cells were stained with annexin V linked to fluorescene and with PI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Mitochondrial Depolarization and Formation of Reactive Oxygen Species Caused by Treatment with 6g</h3><div class="NLM_p">Mitochondria are critical for the occurrence of apoptosis.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Early in the process, the mitochondrial transmembrane potential (Δψ<sub>mt</sub>) changes. We measured these changes by flow cytometry through use of 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine (JC-1). As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A, cells treated with different concentrations of <b>6g</b> (50, 100, and 250 nM) showed a concentration- and a time-dependent increase in the percentage of cells with low Δψ<sub>mt</sub>. The depolarization of the mitochondrial membrane is already evident at early times of drug exposure (3–6 h), in good agreement with findings of many microtubule-active agents that a fall in Δψ<sub>mt</sub> occurs early in apoptosis in many types of cells.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> We also established that this drop in Δψ<sub>mt</sub> is associated with generation of reactive oxygen species (ROS)<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) following <b>6g</b> treatment for as short a time as 12 h with as little as 50 nM <b>6g</b>.</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Flow cytometric measurement of Δψ<sub>mt</sub> and ROS following treatment of HeLa cells with <b>6g</b>. Treatment times and <b>6g</b> concentrations are indicated: (A) Measurement of Δψ<sub>mt</sub> by JC-1 fluorescence. (B) Measurement of ROS by fluorescence of 2,7-dichlorodihydrofluorescein diacetate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound 6g Induced Poly(ADP-ribose) Polymerase (PARP) Activation and Caused a Decrease in the Expression of Antiapoptotic Proteins</h3><div class="NLM_p">To gain a better insight into the mechanism of action of <b>6g</b>, we evaluated the cleavage of poly(ADP-ribose) polymerase (PARP) during the apoptotic process induced by this compound. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, compound <b>6g</b> in HeLa cells caused a concentration- and time-dependent cleavage of PARP, confirming its proapoptotic activity. Moreover, the expression of two antiapoptotic proteins, Bcl-2 and Mcl-1, was also studied.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Immunoblot analysis, shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, demonstrated that the expression of the antiapoptotic protein Bcl-2 was decreased, starting after a 24 h treatment at both 50 and 100 nM. The decrease in the expression of Mcl-1 was even greater, both at the lowest concentration and after the 24 h treatment.</div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Western blot demonstrating PARP, Bcl-2, and Mcl-1 levels. HeLa cells were treated with <b>6g</b> as indicated. Equivalent protein loading was confirmed by evaluating anti-β-actin levels in the gel slots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Antivascular Activity of 6g</h3><div class="NLM_p">Combined use of cytotoxic drugs with agents showing antiangiogenic or antivascular effects to increase treatment effects is a relatively recent therapeutic strategy.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Many antitubulin drugs, especially CA-4P, were found to have vascular-disrupting effects against tumor endothelial cells.<a onclick="showRef(event, 'ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48 ref49">(46−49)</a> We therefore examined effects of <b>6g</b> on human umbilical vein endothelial cells (HUVECs) to evaluate potential effects on angiogenesis. We specifically studied HUVECs growing in Matrigel, a substance rich in proangiogenic compounds, for their ability to alter their shape to resemble capillaries. Preliminary experiments carried out on these cells, with the aim to evaluate the cytotoxicity of the test compound, indicated that <b>6g</b> had a GI<sub>50</sub> of 56 nM after a 48 h treatment. Thus, to evaluate antivascular activity, we used a concentration of <b>6g</b> that did not induce cellular death.</div><div class="NLM_p">We examined the effects of 10 nM (noncytotoxic concentration) and 100 nM (cytotoxic concentration) <b>6g</b> on HUVECs after a 1 h treatment (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). Both concentrations of <b>6g</b> disrupted the network formation observed in the untreated HUVECs. Standard image analysis<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> was performed to obtain the parameters usually evaluated: (1) nodes (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B), (2) master junctions (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>C), (3) segment length (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>D), (4) total branching length (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>E), (5) number of meshes (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>F), and (6) mesh area (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>G).</div><figure id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Antivascular effects of <b>6g</b> treatment on HUVECs. (A) Typical images after 1 h of growth on Matrigel of untreated cells (left-hand image), of cells treated with 10 nM <b>6g</b> (middle image), and of cells treated with 100 nM <b>6g</b> (right-hand image). (B–G) Quantitative evaluation of <b>6g</b> on standard parameters of HUVEC tubule formation, as indicated, at the indicated <b>6g</b> concentrations. Mean ± SEM, three experiments. ** <i>p</i> < 0.01; *** <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The results for segment length and mesh area showed statistically significant effects for the lowest concentration used, suggesting the high potential of the vascular-disrupting activity of <b>6g</b>.</div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 6g Induced Tumor Growth Reduction in a Mouse Allograft Tumor Model</h3><div class="NLM_p">In in vivo studies, tumor-bearing animals were dosed with <b>6g</b> every other day (q.o.d.) intraperitoneally, beginning on day 9. Two different doses (3.0 and 7.5 mg/kg) were studied, and CA-4P (30 mg/kg) was used as a reference compound. The murine allograft model was B16 murine melanoma cells injected into the flanks of mice.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> The B16 melanoma cell line was used because it has high levels of EFGR kinase,<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> and, in initial experiments, we had found that the IC<sub>50</sub> of <b>6g</b> was 23.4 ± 3.8 nM (MTT assay).</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A demonstrates that after four doses of <b>6g</b>, given on days 9, 11, 13, and 15, tumor burden was reduced 28% with 3.0 mg/kg and 52.5% with 7.5 mg/kg, as compared with a 34.9% reduction with 30 mg/kg CA-4P. No toxicity, based on no weight loss, was observed in any of the experimental groups (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B).</div><figure id="fig12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0012.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. In vivo activity of <b>6g</b> in the treatment of murine B16 melanoma in an allograft model. (A) Each male C57BL/6 mouse was injected subcutaneously (s.c.) in its dorsum with 2.5 × 10<sup>5</sup> murine melanoma cells. On the days indicated by the arrows, mice were administered intraperitoneally (i.p.) with either vehicle 3.0 mg/kg <b>6g</b>, 7.5 mg/kg <b>6g</b>, or 30 mg/kg CA-4P. (B) Body weight variation after treatment with compound <b>6g</b> or CA-4P as described above. The data are plotted as mean ± SEM of tumor volume at each time point for five animals per group, * <i>p</i> < 0.05; *** <i>p</i> < 0.001 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An effective strategy to develop anticancer agents is the discovery of synergistic multitargeting properties of new molecules. The thiophene ring has been employed as an isostere for benzene-fused pyrimidines in the design of molecules that possess tyrosine kinase inhibitory activity. In this study, we report the design and synthesis of a new series of 4-(3′,4′,5′-trimethoxyanilino)-6-substituted thieno[3,2-<i>d</i>]pyrimidines, some of which possess both tubulin polymerization and EGFR kinase inhibitory properties. The optimal structure at the phenyl ring at the C-6 position of the 4-(3′,4′,5′-trimethoxyanilino)-thieno[3,2-<i>d</i>]pyrimidine system was explored by various substituents, with either electron-releasing or electron-withdrawing properties. The importance of the specific substituent is demonstrated by the data summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_p">Three of the 4-(3′,4′,5′-trimethoxyanilino)-6-substituted thieno[3,2-<i>d</i>]pyrimidine derivatives, corresponding to <i>p</i>-Cl (<b>6d</b>), <i>p</i>-Me (<b>6g</b>), and <i>p</i>-OMe (<b>6h</b>), were the most potent compounds found in this study, with IC<sub>50</sub> values of, respectively, 3–600, 1–20, and 4–430 nM in the five cell lines. The 4-(3′,4′,5′-trimethoxyanilino)-6-(<i>p</i>-tolyl)thieno[3,2-<i>d</i>]pyrimidine derivative <b>6g</b> was the most potent compound of the whole series, exhibiting an IC<sub>50</sub> value of 19 nM against the NSCLC A549 cell line, which harbors EGFR<sup>wt</sup> and K-ras mutations. Comparing the <i>p</i>-tolyl derivative <b>6g</b> with the <i>p</i>-methoxy phenyl compound <b>6h</b>, the latter was found to be 2–170-fold less active than <b>6g</b>, with the greatest differences in activity being 23- and 170-fold in A549 and Hela cells, respectively.</div><div class="NLM_p">The corresponding thieno[2,3-<i>d</i>]pyrimidine isomers and the 2-anilino-7-(3′,4′,5′-trimethoxyanilino)thiazolo[4,5-<i>d</i>]pyrimidine derivatives generally had little activity, with IC<sub>50</sub> values usually greater than 10 μM. There was a considerable difference in potency between 4-(3′,4′,5′-trimethoxyanilino)-6-arylthieno[3,2-<i>d</i>]pyrimidine derivatives <b>6a</b>, <b>6d</b> (<i>p</i>-Cl), <b>6g</b> (<i>p</i>-Me), and <b>6h</b> (<i>p</i>-OMe) and the regioisomeric 4-(3′,4′,5′-trimethoxyanilino)-6-arylthieno[2,3-<i>d</i>]pyrimidine analogues <b>8d</b>, <b>8f</b>, <b>8i</b>, and <b>8k</b>, respectively, with these latter being considerably less active than the former in all cancer cell lines examined.</div><div class="NLM_p">The inhibitory activity against EGFR and VEGFR-2 kinases of selected compounds <b>6a</b>–<b>b</b> and <b>6d</b>–<b>h</b> showed that these molecules were selective EGFR inhibitors. Compounds <b>6f</b>–<b>h</b> inhibited both EGFR kinase and tubulin polymerization, whereas derivative <b>6b</b> only inhibited EGFR kinase. Compounds <b>6a</b>–<b>b</b> and <b>6d</b>–<b>h</b> showed lower potency than erlotinib, with derivative <b>6b</b> having the greatest inhibitory activity against EGFR kinase, being only slightly less potent than erlotinib (IC<sub>50</sub>: 2.5 and 1.5 nM, respectively). Besides its potent antiproliferative activity and high competitive inhibitory activity on EGFR, compound <b>6g</b> also inhibited tubulin assembly through an interaction at the colchicine site, thereby combining EGFR inhibition with antitubulin activity. The IC<sub>50</sub> of 0.7 μM obtained with <b>6g</b> in the tubulin assembly assay was almost half of that obtained in simultaneous experiments with CA-4 (IC<sub>50</sub>: 1.2 μM).</div><div class="NLM_p last">In our results with compounds <b>6f</b>–<b>h</b>, there was a high correlation between the in vitro antiproliferative activity against the cancer cell lines and inhibition of tubulin polymerization and EGFR kinase, which suggested that targeting both tubulin and EGFR kinase played major roles in the cancer cell growth inhibitory effects of these three molecules.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Materials and Methods</h4><div class="NLM_p last">A Varian VXR 200 spectrometer was used to obtain <sup>1</sup>H NMR data; a Varian Mercury Plus 400 spectrometer was used to obtain <sup>13</sup>C NMR data. Peak positions are provided in ppm (δ) downfield and <i>J</i> values in hertz. Mass spectra were obtained on a Waters ZQ 2000 electrospray ionization (ESI) single quadrupole mass spectrometer, with values given as [M + 1]<sup>+</sup>. Melting points (mp) (uncorrected) were obtained on a Buchi–Tottoli instrument. Purity (≥95%) was verified by combustion elemental analyses performed at the Microanalytical Laboratory of the Department of Chemistry and Pharmaceutical Sciences of the University of Ferrara using a Yanagimoto MT-5 CHN recorder elemental analyzer. Thin-layer chromatography was performed on glass plates from Merck coated with silica gel 60 F<sub>254</sub>, with compounds visualized by UV detection or with aqueous KMnO<sub>4</sub>. Flash column chromatography was performed with 230–400-mesh silica gel and solvents as indicated. Organic solutions were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Commercial solvents and reagents were from Aldrich (Sigma-Aldrich) or Alfa Aesar (Johnson Matthey Company) and were used as supplied. Compounds <b>12a</b> and <b>12b</b> are commercially available. General procedures and references related to the preparation of methyl 3-aminothiophene-5-aryl/heteroaryl-2-carboxylate <b>9a</b>–<b>j</b>, ethyl 5-amino-2-anilinothiazole-4-carboxylate <b>9k</b>–<b>n</b>, and ethyl 2-aminothiophene-3-carboxylate <b>12c</b>–<b>l</b> derivatives are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_001.pdb" class="ext-link">Supporting Information</a> section. Active compounds were not recognized as pan-assay interference compounds according to the free ADME-tox filtering tool (FAF-Drugs4) program (<a href="http://fafdrugs4.mti.univ-paris-diderot.fr/" class="extLink">http://fafdrugs4.mti.univ-paris-diderot.fr/</a>).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure for the Synthesis of Compounds 6a–j, 7a–d, and 8a–l </h4><div class="NLM_p">A mixture of the appropriate 4-chlorothieno[3,2-<i>d</i>]pyrimidine <b>11a</b>–<b>j</b>, 7-chlorothiazolo[4,5-<i>d</i>]pyrimidine <b>11k</b>–<b>n</b>, or 4-chlorothieno[2,3-<i>d</i>]pyrimidine <b>14a</b>–<b>l</b> (1 mmol) and 3,4,5-trimethoxyaniline (2 mmol, 366 mg, 2 equiv) in isopropanol (5 mL) with a drop of concentrated HCl was refluxed for 18 h and then evaporated to dryness in vacuo. The residue was dissolved with dichloromethane, the organic solution was washed with water followed by brine and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated. The crude residue was purified by column chromatography on silica gel to furnish the desired compound.</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 6-Phenyl-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6a)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6a</b> as a yellow solid. Yield: 80%, mp 176 °C. <sup>1</sup>H NMR (dimethyl sulfoxide (DMSO)<i>-d</i><sub>6</sub>) δ: 3.67 (s, 3H), 3.79 (s, 6H), 7.22 (s, 2H), 7.51 (m, 3H), 7.85 (m, 2H), 7.90 (s, 1H), 8.59 (s, 1H), 9.64 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 55.84 (2C), 60.16, 100.17 (2C), 114.74, 120.50, 126.26 (2C), 129.42 (2C), 129.73, 132.62, 133.91, 135.03, 149.41, 152.57 (2C), 154.46, 154.81, 161.03. Mass spectrometry (MS) (ESI): [M + 1]<sup>+</sup> = 394.5. Anal. (C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S) C, H, N.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 6-(Thiophen-2-yl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6b)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate/petroleum ether 9:1 (v/v) as eluent, to furnish <b>6b</b> as a yellow solid. Yield: 69%, mp 211 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.67 (s, 3H), 3.79 (s, 6H), 7.21 (s, 2H), 7.62 (dd, <i>J</i> = 5.0 and 1.2 Hz, 1H), 7.76 (m, 1H), 7.78 (s, 1H), 8.06 (dd, <i>J</i> = 5.0 and 1.2 Hz, 1H), 8.57 (s, 1H), 9.59 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ: 55.73 (2C), 60.06, 99.97 (2C), 113.98, 120.09, 123.76, 126.04, 128.28, 133.74, 134.07, 135.00, 144.26, 152.47 (2C), 154.36, 154.67, 160.94. MS (ESI): [M + 1]<sup>+</sup> = 400.5. Anal. (C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S<sub>2</sub>) C, H, N.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 6-(4-Fluorophenyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6c)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6c</b> as a brown solid. Yield: 68%, mp 192 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.65 (s, 3H), 3.77 (s, 6H), 7.19 (s, 2H), 7.37 (t, <i>J</i> = 9.2 Hz, 2H), 7.86 (s, 1H), 7.88 (m, 2H), 8.57 (s, 1H), 9.63 (bs, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 56.30 (2C), 60.62, 10.67 (2C), 115.18, 116.81, 117.03, 121.13, 128.95, 129.04, 129.75, 134.38, 135.44, 148.68, 153.02, 154.97, 155.26, 161.54, 162.07, 164.53. MS (ESI): [M + 1]<sup>+</sup> = 412.4. Anal. (C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub>S) C, H, N.</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 6-(4-Chlorophenyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6d)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6d</b> as a white solid. Yield: 65%, mp 215 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.67 (s, 3H), 3.79 (s, 6H), 7.20 (s, 2H), 7.58 (d, <i>J</i> = 7.2 Hz, 2H), 7.86 (d, <i>J</i> = 7.2 Hz, 2H), 7.93 (s, 1H), 8.59 (s, 1H), 9.66 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 55.74 (2C), 60.06, 100.14 (2C), 114.80, 121.08 (2C), 127.86 (2C), 129.34 (2C), 131.43, 133.78, 134.18, 134.84, 147.80, 152.47, 154.44, 154.74, 160.87. MS (ESI): [M + 1]<sup>+</sup> = 428.9. Anal. (C<sub>21</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>3</sub>S) C, H, N.</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 6-(4-Bromophenyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6e)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6e</b> as a yellow solid. Yield: 68%, mp 219 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.67 (s, 3H), 3.79 (s, 6H), 7.20 (s, 2H), 7.71 (d, <i>J</i> = 7.8 Hz, 2H), 7.80 (d, <i>J</i> = 7.8 Hz, 2H), 7.95 (s, 1H), 8.59 (s, 1H), 9.66 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 55.75 (2C), 60.06, 100.14 (2C), 114.81, 121.08, 122.86, 128.09 (2C), 131.79, 132.25 (2C), 133.87, 134.86, 147.88, 152.47 (2C), 154.46, 154.75, 160.89. MS (ESI): [M + 1]<sup>+</sup> = 520.4. Anal. (C<sub>21</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>3</sub>S) C, H, N.</div></div><div id="sec4_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 6-(4-Iodophenyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6f)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate/petroleum ether 8:2 (v/v) as eluent, to furnish <b>6f</b> as a yellow solid. Yield: 61%, mp 199 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.67 (s, 3H), 3.79 (s, 6H), 7.20 (s, 2H), 7.84 (d, <i>J</i> = 8.4 Hz, 2H), 7.88 (d, <i>J</i> = 8.4 Hz, 2H), 7.94 (s, 1H), 8.59 (s, 1H), 9.65 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 55.73 (2C), 60.05, 100.11 (2C), 114.72, 120.91 (2C), 126.14, 127.98 (2C), 129.33, 132.03, 133.84, 134.85, 138.07, 148.14, 152.46, 154.43, 154.72, 160.87. MS (ESI): [M + 1]<sup>+</sup> = 520.4. Anal. (C<sub>21</sub>H<sub>18</sub>IN<sub>3</sub>O<sub>3</sub>S) C, H, N.</div></div><div id="sec4_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 6-(<i>p</i>-Tolyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6g)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6g</b> as a yellow solid. Yield: 75%, mp 202 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 2.37 (s, 3H), 3.67 (s, 3H), 3.79 (s, 6H), 7.22 (s, 2H), 7.33 (d, <i>J</i> = 8.0 Hz, 2H), 7.74 (d, <i>J</i> = 8.0 Hz, 2H), 7.83 (s, 1H), 8.58 (s, 1H), 9.60 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 20.77, 55.73 (2C), 60.05, 99.99 (2C), 114.32, 119.63, 126.04 (2C), 129.78, 129.97 (2C), 133.75, 134.99, 139.47, 149.51, 152.46 (2C), 154.30, 154.64, 161.02. MS (ESI): [M + 1]<sup>+</sup> = 408.5. Anal. (C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>S) C, H, N.</div></div><div id="sec4_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 6-(4-Methoxyphenyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6h)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6h</b> as a brown solid. Yield: 54%, mp 182 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.67 (s, 3H), 3.79 (s, 6H), 3.83 (s, 3H), 7.07 (d, <i>J</i> = 8.4 Hz, 2H), 7.21 (s, 2H), 7.76 (s, 1H), 7.83 (d, <i>J</i> = 8.8 Hz, 2H), 8.56 (s, 1H), 9.56 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 55.31, 55.75 (2C), 60.08, 99.97 (2C), 105.88, 109.63, 114.73 (2C), 118.87 (2C), 125.06, 127.64 (2C), 135.06, 149.46, 152.49, 154.30, 154.58, 160.39, 161.22. MS (ESI): [M + 1]<sup>+</sup> = 424.5. Anal. (C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>S) C, H, N.</div></div><div id="sec4_1_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 6-(3-Methoxyphenyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6i)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6i</b> as a yellow solid. Yield: 62%, mp 163 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.67 (s, 3H), 3.78 (s, 6H), 3.86 (s, 3H), 7.08 (m, 1H), 7.14 (s, 2H), 7.43 (m, 3H), 7.94 (s, 1H), 8.59 (s, 1H), 9.63 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ: 55.35, 55.85 (2C), 60.16, 100.05 (2C), 111.47, 114.77, 115.56, 118.55, 120.85, 130.61, 133.86, 133.95, 135.08, 149.22, 152.57 (2C), 154.48, 154.78, 159.86, 160.95. MS (ESI): [M + 1]<sup>+</sup> = 424.5. Anal. (C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>S) C, H, N.</div></div><div id="sec4_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 6-(4-Nitrophenyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4-amine (6j)</h5><div class="NLM_p last">The crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish <b>6j</b> as a yellow solid. Yield: 79%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.67 (s, 3H), 3.80 (s, 6H), 7.21 (s, 3H), 8.12 (d, <i>J</i> = 9.0 Hz, 2H), 8.17 (s, 1H), 8.35 (d, <i>J</i> = 9.0 Hz, 2H), 8.63 (s, 1H), 9.78 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ: 55.77 (2C), 60.06, 78.53, 78.86, 79.19, 100.32 (2C), 123.48, 124.54 (2C), 127.27 (2C), 134.67, 138.68, 147.53, 152.50 (2C), 154.68, 154.91, 160.63. MS (ESI): [M + 1]<sup>+</sup> = 439.4. Anal. (C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>O<sub>5</sub>S) C, H, N.</div></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure for the Preparation of Compounds 10a–n and 13a–l </h4><div class="NLM_p">A mixture of the appropriate methyl 3-aminothiophene-5-aryl/heteroaryl-2-carboxylate <b>9a</b>–<b>j</b>, ethyl 5-amino-2-anilinothiazole-4-carboxylate <b>9k</b>–<b>n</b> or ethyl 2-aminothiophene-3-carboxylate derivatives <b>12a</b>–<b>l</b> (10 mmol) and formamide (15 mL) was heated at 180 °C for 18 h. After cooling to room temperature, cooled water (15 mL) was added to the reaction mixture. The solid was removed by filtration, washed with water and dried under vacuum for 12 h. The crude residue was suspended in ethyl ether, stirred for 30 min and filtered. The solid was used for the next reaction without further purification.</div><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 6-Phenylthieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10a)</h5><div class="NLM_p last">Yellow solid, yield: 71%, mp 294 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.48 (m, 3H), 7.35 (m, 3H), 8.17 (s, 1H), 12.6 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 229.3.</div></div><div id="sec4_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 6-(Thiophen-2-yl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10b)</h5><div class="NLM_p last">Black solid, yield: 95%, mp 170 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.63 (dd, <i>J</i> = 2.6 and 1.6 Hz, 1H), 7.74 (dd, <i>J</i> = 2.6 and 1.6 Hz, 1H), 8.01 (s, 1H), 8.10 (m, 1H), 8.15 (s, 1H), 12.2 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 235.3.</div></div><div id="sec4_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 6-(4-Fluorophenyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10c)</h5><div class="NLM_p last">Brown solid, yield: 81%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.34 (d, <i>J</i> = 8.8 Hz, 2H), 7.83 (s, 1H), 7.93 (m, 2H), 8.17 (s, 1H), 12.6 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 247.3.</div></div><div id="sec4_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 6-(4-Chlorophenyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10d)</h5><div class="NLM_p last">Brown solid, yield: 89%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.54 (d, <i>J</i> = 8.8 Hz, 2H), 7.87 (m, 3H), 8.17 (s, 1H), 11.6 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 263.7.</div></div><div id="sec4_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 6-(4-Bromophenyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10e)</h5><div class="NLM_p last">Yellow solid, yield: 78%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.67 (d, <i>J</i> = 8.6 Hz, 2H), 7.80 (d, <i>J</i> = 8.6 Hz, 2H), 7.90 (s, 1H), 8.17 (s, 1H), 12.6 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 308.2.</div></div><div id="sec4_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 6-(4-Iodophenyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10f)</h5><div class="NLM_p last">Yellow solid, yield: 95%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.63 (d, <i>J</i> = 8.8 Hz, 2H), 7.87 (m, 3H), 8.17 (s, 1H), 11.4 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 279.7.</div></div><div id="sec4_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 6-(4-Tolyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10g)</h5><div class="NLM_p last">Brown solid, yield: 83%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 2.36 (s, 3H), 7.29 (d, <i>J</i> = 7.8 Hz, 2H), 7.73 (m, 3H), 8.15 (s, 1H), 12.5 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 243.3.</div></div><div id="sec4_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 6-(4-Methoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10h)</h5><div class="NLM_p last">Brown solid, yield: >95%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.82 (s, 3H), 7.03 (d, <i>J</i> = 8.8 Hz, 2H), 7.71 (s, 1H), 7.78 (d, <i>J</i> = 8.8 Hz, 2H), 8.14 (s, 1H), 11.8 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 259.3.</div></div><div id="sec4_1_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 6-(3-Methoxyphenyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10i)</h5><div class="NLM_p last">Brown solid, yield: >95%, mp 212 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 3.84 (s, 3H), 7.04 (m, 1H), 7.39 (m, 2H), 7.88 (s, 1H), 7.94 (d, <i>J</i> = 8.6 Hz, 1H), 8.17 (s, 1H), 12.0 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 259.3.</div></div><div id="sec4_1_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 6-(4-Nitrophenyl)thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (10j)</h5><div class="NLM_p last">Brown solid, yield: >95% yield, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.18 (d, <i>J</i> = 8.8 Hz, 2H), 7.43 (d, <i>J</i> = 8.8 Hz, 2H), 7.94 (s, 1H), 10.5 (bs, 1H), 11.4 (bs, 1H). MS (ESI): [M + 1]<sup>+</sup> = 274.3.</div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> General Procedure for the Preparation of Compounds 11a–n and 14a–l </h4><div class="NLM_p">A mixture of the appropriate thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>10a</b>–<b>j</b>, thiazolo[4,5-<i>d</i>]pyrimidin-7(6<i>H</i>)-one <b>10k</b>–<b>n</b>, or thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>13a</b>–<b>l</b> (5 mmol) and POCl<sub>3</sub> (30 mL) with two to three drops of dimethylformamide was refluxed for 6 h. The mixture was cooled, POCl<sub>3</sub> was removed under vacuum, the residue obtained was poured into a saturated solution of NaHCO<sub>3</sub>, and the suspension was neutralized with solid NaHCO<sub>3</sub>. The mixture was extracted with dichloromethane and the organic phase was washed with water followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude product was stirred for 15 min with ethyl ether (15 mL), and the desired product was obtained after removal of the ether by filtration.</div><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 4-Chloro-6-phenylthieno[3,2-<i>d</i>]pyrimidine (11a)</h5><div class="NLM_p last">Brown solid, yield: 71%, mp 152 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.57 (m, 3H), 6.01 (m, 2H), 8.25 (s, 1H), 9.03 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 247.7.</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 4-Chloro-6-(thiophen-2-yl)thieno[3,2-<i>d</i>]pyrimidine (11b)</h5><div class="NLM_p last">Orange solid, yield: 60%, mp 176 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.79 (m, 2H), 8.11 (s, 1H), 8.36 (dd, <i>J</i> = 2.6 and 1.6 Hz, 1H), 9.00 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 252.7.</div></div><div id="sec4_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 4-Chloro-6-(4-fluorophenyl)thieno[3,2-<i>d</i>]pyrimidine (11c)</h5><div class="NLM_p last">Brown solid, yield: 83%, mp > 300 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.37 (d, <i>J</i> = 8.8 Hz, 2H), 8.04 (m, 2H), 8.11 (s, 1H), 9.03 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 265.7.</div></div><div id="sec4_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 4-Chloro-6-(4-chlorophenyl)thieno[3,2-<i>d</i>]pyrimidine (11d)</h5><div class="NLM_p last">Yellow solid, yield: 68%, mp 188 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.47 (d, <i>J</i> = 8.8 Hz, 2H), 7.69 (m, 3H), 8.96 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 282.2.</div></div><div id="sec4_1_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 6-(4-Bromophenyl)-4-chlorothieno[3,2-<i>d</i>]pyrimidine (11e)</h5><div class="NLM_p last">Yellow solid, yield: 55%, mp 201 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 7.75 (d, <i>J</i> = 9.0 Hz, 2H), 7.93 (d, <i>J</i> = 9.0 Hz, 2H), 8.29 (s, 1H), 9.04 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 326.6.</div></div><div id="sec4_1_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 4-Chloro-6-(4-iodophenyl)thieno[3,2-<i>d</i>]pyrimidine (11f)</h5><div class="NLM_p last">Yellow solid, yield: 54%, mp > 300 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.81 (d, <i>J</i> = 8.4 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 8.29 (s, 1H), 9.04 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 373.6.</div></div><div id="sec4_1_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 4-Chloro-6-(<i>p</i>-tolyl)thieno[3,2-<i>d</i>]pyrimidine (11g)</h5><div class="NLM_p last">Brown solid, yield: 84%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 2.39 (s, 3H), 7.36 (d, <i>J</i> = 7.8 Hz, 2H), 7.87 (d, <i>J</i> = 7.8 Hz, 2H), 8.18 (s, 1H), 9.01 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 261.7.</div></div><div id="sec4_1_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 4-Chloro-6-(4-methoxyphenyl)thieno[3,2-<i>d</i>]pyrimidine (11h)</h5><div class="NLM_p last">Yellow solid, yield: 72%, mp 181 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.89 (s, 3H), 7.04 (d, <i>J</i> = 8.8 Hz, 2H), 7.69 (s, 1H), 7.71 (d, <i>J</i> = 8.8 Hz, 2H), 8.93 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 277.7.</div></div><div id="sec4_1_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 4-Chloro-6-(3-methoxyphenyl)thieno[3,2-<i>d</i>]pyrimidine (11i)</h5><div class="NLM_p last">Brown solid, yield: 61%, mp 153 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.87 (s, 3H), 7.14 (m, 1H), 7.76 (m, 3H), 8.29 (s, 1H), 9.04 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 277.7.</div></div><div id="sec4_1_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 4-Chloro-6-(4-nitrophenyl)thieno[3,2-<i>d</i>]pyrimidine (11j)</h5><div class="NLM_p last">Orange solid, yield: >95%, mp > 300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 8.32 (d, <i>J</i> = 8.8 Hz, 2H), 8.36 (d, <i>J</i> = 8.8 Hz, 2H), 8.51 (s, 1H), 9.10 (s, 1H). MS (ESI): [M + 1]<sup>+</sup> = 292.7.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Biology and Materials and Methods</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Cytotoxicity Assays</h4><div class="NLM_p last">The cell lines and culture media used were described previously, as were the cell culture methodologies.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The 10 mM compound stock solutions were prepared with DMSO, and the DMSO concentration in cytotoxicity and all cell-based assays was always ≤0.25%.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Tubulin Assays</h4><div class="NLM_p last">Assessment of compound effects on tubulin polymerization was described in detail previously,<a onclick="showRef(event, 'cit53a'); return false;" href="javascript:void(0);" class="ref cit53a">(53a)</a> as was measurement of the binding of [<sup>3</sup>H]colchicine to tubulin.<a onclick="showRef(event, 'cit53b'); return false;" href="javascript:void(0);" class="ref cit53b">(53b)</a> For the polymerization assay, 10 μM purified bovine brain tubulin was used, and the extent of assembly after a 20 min incubation at 30 °C was the parameter measured. The reaction components in the colchicine assay included 1.0 μM tubulin, 5.0 μM [<sup>3</sup>H]colchicine, and 1.0 or 5.0 μM potential inhibitors.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> EGFR and VEGFR Kinase Activity Assays</h4><div class="NLM_p last">Kinase assays were performed using the bioluminescent ADP-Glo kinase assay (Promega, Milano Italy), following the manufacturer’s instructions. The assay was performed with the test compounds at different scalar concentrations. The IC<sub>50</sub> values reported are based on the average of at least two titration curves. As reference compounds, erlotinib (Sigma-Aldrich) and sunitinib (Selleckchem) were used.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Molecular Modeling</h4><div class="NLM_p last">Hardware, software, and general methodology were described in detail previously.<a onclick="showRef(event, 'ref51 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref54 ref55">(51,54,55)</a> Protein structures were downloaded from the PDB (<a href="http://www.rcsb.org/" class="extLink">http://www.rcsb.org/</a>; PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0">1SA0</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M">2J6M</a>, respectively, for tubulin and the EGFR kinase domain). The two proteins were preprocessed using the Schrödinger protein preparation wizard by assigning bond orders, adding hydrogens, and performing a restrained energy minimization of the added hydrogens using the OPLS_2005 force field. Ligand structures were built with molecular operating environment (MOE) and minimized using the MMFF94x force field. The ligands were then prepared using the Maestro LigPrep tool by energy minimizing the structures (OPLS_2005 force filed), generating possible ionization states at pH 7 ± 2 and generating tautomers and low-energy ring conformers. A 12 Å docking grid (inner box 10 Å and outer box 22 Å) was prepared using as centroid the cocrystallized DAMA-colchicine for the tubulin structure. A 15 Å docking grid (inner box 10 Å and outer box 25 Å) was prepared using as centroid the cocrystallized AEE788 for the EGFR structure. Molecular docking was performed using Glide SP keeping the default parameters and setting 5 as the number of output poses per input ligand to include in the solution. The docking results were visually inspected on MOE for the ability of molecules to bind the active sites.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Cell Cycle Distribution Evaluated by Flow Cytometry</h4><div class="NLM_p last">HeLa or Jurkat cells (50 000 cells) were exposed to compounds for 24 h. Cells were harvested by centrifugation and fixed with 70% (v/v) ethanol (0 °C). Cells were lysed with 0.1% (v/v) Triton X-100 containing RNase A and stained with PI. A Beckman Coulter Cytomics FC500 instrument and MultiCycle for Windows software from Phoenix Flow Systems were used to analyze the cells.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Measurement of Apoptosis by Flow Cytometry</h4><div class="NLM_p last">In these studies, the Cytomics FC500 instrument was used. The cells were stained with both PI, to stain DNA, and annexin V-fluorescein isothiocyanate, to stain membrane PS on the cell surface (which occurs in apoptosis). The latter was done following the instructions of the manufacturer (Roche Diagnostics) of the Annexin-V-Fluos reagent.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Evaluation of Cellular Protein Expression with Western Blots</h4><div class="NLM_p last">Following growth for various times in the presence of <b>6g</b>, HeLa cells were harvested by centrifugation and washed twice in 0 °C phosphate-buffered saline (PBS). In some experiments, Hela cells were treated with <b>6g</b> or erlotinib (Sigma-Aldrich) and stimulated with EGF (R&D Systems, Minneapolis, MN), 50 ng/mL, for 15 min and then processed as described above. Cells were lysed with 0.1% (v/v) Triton X-100 containing RNase A at 0 °C, and supernatants were obtained by centrifuging the lysed cells at 15 000<i>g</i> for 10 min at 4 °C. The protein content of the solutions was measured, and 10 μg of protein from each sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred by electroblotting to a poly(vinylidene difluoride) Hybond-P membrane from GE Healthcare. The membranes were treated with 5% bovine serum albumin in PBS containing 0.1% Tween 20 overnight at 4 °C. The membranes were then exposed for 2 h at room temperature to primary antibodies directed against PARP, Mcl-1, Bcl-2 (all from Cell Signaling), or β-actin (Sigma-Aldrich; to verify equal protein loading) and subsequently for 1 h to peroxidase-labeled secondary antibodies. The membranes were visualized using ECL select (GE Healthcare), and images were acquired using an Uvitec-Alliance imaging system.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Use of HUVECs as a Model for Antivascular Activity</h4><div class="NLM_p">Adherent HUVECs were obtained and cultured as before.<a onclick="showRef(event, 'ref46 ref49'); return false;" href="javascript:void(0);" class="ref ref46 ref49">(46,49)</a> Once confluent, the cells were removed from the culture matrix with a trypsin–ethylenediaminetetraacetic acid solution and used up to the sixth passage.</div><div class="NLM_p last">Matrigel matrix (Basement Membrane Matrix, BD Biosciences) was prepared and left for 3 h at 4 °C. At this point, 230 μL of the matrix preparation was added to each well of a 24-well plate. The matrix was allowed to gel at 37 °C for 30 min. The matrix in each well was overlaid with 500 μL of medium containing 6000 HUVECs, which was incubated for 6 h to allow the formation of capillary tubes. Different concentrations of <b>6g</b> were added, and the cultures were incubated for another hour to monitor the disappearance of existing vasculature. The cultures were photographed (the four quadrants and the center of each well) at 10× magnification (phase contrast). The images were saved as TIFF files and anfalyzed with ImageJ image analysis software. Standard dimensional parameters (percent area covered by HUVECs and total length of the HUVEC network per field) were noted, and standard topological parameters (number of meshes and branching points per field) were estimated.<a onclick="showRef(event, 'ref46 ref49'); return false;" href="javascript:void(0);" class="ref ref46 ref49">(46,49)</a></div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> In Vivo Activity of 6g </h4><div class="NLM_p last">Animal procedures and care were performed in accord with institutional guidelines complying with all national and international laws and policies (EEC Council Directive 86/609, OJ L 358, December 12, 1987) and with “ARRIVE” guidelines (Animals in Research Reporting in Vivo Experiments). Six-week old C57BL/6 mice (from Charles River) were injected s.c. into the dorsolateral flank with 200 μL of PBS containing 25 000 BL6–B16 murine melanoma cells. Tumors became palpable on the 9th day, and animals were given q.o.d. × 4 i.p. injections of test compounds dissolved in 50 μL of DMSO at desired doses. Tumors were measured in two dimensions, and tumor volume was calculated using the formula <i>V</i> = (<i>D</i> × <i>d</i><sup>2</sup>)/2, where <i>D</i> and <i>d</i> are the major and minor perpendicular tumor diameters.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01391" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01391" class="ext-link">10.1021/acs.jmedchem.8b01391</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Antiproliferative activities of compounds <b>7a</b>–<b>d</b> (Table 1S) and <b>8a</b>–<b>l</b> (Table 2S); general procedures and references related to the preparation of methyl 3-aminothiophene-5-aryl/heteroaryl-2-carboxylate <b>9a</b>–<b>j</b>, ethyl 5-amino-2-anilinothiazole-4-carboxylate <b>9k</b>–<b>n</b>, and ethyl 2-aminothiophene-3-carboxylate <b>12c</b>–<b>l</b> derivatives; spectral data for the newly synthesized compounds <b>7a</b>–<b>d</b>, <b>10k</b>–<b>n</b>, <b>11k</b>–<b>n</b>, <b>13a</b>–<b>l</b>, and <b>14a</b>–<b>l</b>; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compounds <b>6a</b>–<b>j</b>; elemental microanalyses for compounds <b>6a</b>–<b>j</b>, <b>7a</b>–<b>d</b>, and <b>8a</b>–<b>l</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_003.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline"><b>6b</b>–<b>e</b>–<b>g</b>-docking-<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0">1SA0</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline"><b>6b</b>–<b>e</b>-docking-<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M">2J6M</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_004.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_001.pdb">jm8b01391_si_001.pdb (355.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_002.pdb">jm8b01391_si_002.pdb (438.66 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_003.pdf">jm8b01391_si_003.pdf (2.54 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_004.csv">jm8b01391_si_004.csv (3.14 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01391" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26111" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26111" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Romeo Romagnoli</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di
Scienze Chimiche e Farmaceutiche, Università
degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6374-773X" title="Orcid link">http://orcid.org/0000-0002-6374-773X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#62100f1022170c0b04074c0b16"><span class="__cf_email__" data-cfemail="8ffde2fdcffae1e6e9eaa1e6fb">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa Carlota Lopez-Cara</span> - <span class="hlFld-Affiliation affiliation">Departamento de
Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1142-6448" title="Orcid link">http://orcid.org/0000-0003-1142-6448</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b27282a3927243f2a27243b2e310b3e2c39652e38"><span class="__cf_email__" data-cfemail="e18d8280938d8e95808d8e91849ba1948693cf8492">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giampietro Viola</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Salute della Donna e del Bambino, Laboratorio
di Oncoematologia, Università di
Padova, 35131 Padova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Istituto di Ricerca
Pediatrica (IRP), Corso
Stati Uniti 4, 35128 Padova, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#492e20282439202c3d3b26673f2026252878093c2720392d67203d"><span class="__cf_email__" data-cfemail="6d0a040c001d0408191f02431b0402010c5c2d1803041d09430419">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Filippo Prencipe</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di
Scienze Chimiche e Farmaceutiche, Università
degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paola Oliva</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di
Scienze Chimiche e Farmaceutiche, Università
degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefania Baraldi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di
Scienze Chimiche e Farmaceutiche, Università
degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pier Giovanni Baraldi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di
Scienze Chimiche e Farmaceutiche, Università
degli Studi di Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Santiago Schiaffino Ortega</span> - <span class="hlFld-Affiliation affiliation">Departamento de
Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mariem Chayah</span> - <span class="hlFld-Affiliation affiliation">Departamento de
Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Kimatrai Salvador</span> - <span class="hlFld-Affiliation affiliation">Departamento de
Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja s/n, 18071 Granada, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Brancale</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy
and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9728-3419" title="Orcid link">http://orcid.org/0000-0002-9728-3419</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Salvatore Ferla</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy
and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ernest Hamel</span> - <span class="hlFld-Affiliation affiliation">Screening Technologies Branch, Developmental Therapeutics
Program, Division of Cancer Treatment and Diagnosis, Frederick National
Laboratory for Cancer Research, National
Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roberto Ronca</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Traslazionale Unità di Oncologia Sperimentale
ed Immunologia, Università di Brescia, 25123 Brescia, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roberta Bortolozzi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Salute della Donna e del Bambino, Laboratorio
di Oncoematologia, Università di
Padova, 35131 Padova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Mariotto</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Salute della Donna e del Bambino, Laboratorio
di Oncoematologia, Università di
Padova, 35131 Padova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Mattiuzzo</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Salute della Donna e del Bambino, Laboratorio
di Oncoematologia, Università di
Padova, 35131 Padova, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">The content of this paper is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.</p></div></li></ul></div><div class="ack" id="ACK-d7e4217-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We wish to thank Alberto Casolari for technical assistance. We also acknowledge the support of the Life Science Research Network Wales grant no. NRNPGSep14008, an initiative funded through the Welsh Government’s Ser Cymru program, and “Proyecto de Excelencia de la Consejería de Innovación y Ciencia de la Junta de Andalucía, Spain ref P12-CTS-696,” for its financial support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CA-4</td><td class="NLM_def"><p class="first last">combretastatin A-4</p></td></tr><tr><td class="NLM_term">CA-4P</td><td class="NLM_def"><p class="first last">combretastain A-4 disodium phosphate</p></td></tr><tr><td class="NLM_term">Δψ<sub>mt</sub></td><td class="NLM_def"><p class="first last">mitochondrial transmembrane potential</p></td></tr><tr><td class="NLM_term">DAMA-colchicine</td><td class="NLM_def"><p class="first last"><i>N</i>-deacetyl-<i>N</i>-(2-mercaptoacetyl)-colchicine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">EGFR<sup>wt</sup></td><td class="NLM_def"><p class="first last">epidermal growth factor receptor wild type</p></td></tr><tr><td class="NLM_term">ERG</td><td class="NLM_def"><p class="first last">electron-releasing group</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">EWG</td><td class="NLM_def"><p class="first last">electron-withdrawing group</p></td></tr><tr><td class="NLM_term">HER</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">JC-1</td><td class="NLM_def"><p class="first last">5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cell</p></td></tr><tr><td class="NLM_term">VEGFR-2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor-2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34878" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34878" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Control of microtubule organization and dynamics: two ends in the limelight</span>. <i>Nat. Rev. Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1038/nrm4084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnrm4084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=26562752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=711-726&author=A.+Akhmanovaauthor=M.+O.+Steinmetz&title=Control+of+microtubule+organization+and+dynamics%3A+two+ends+in+the+limelight&doi=10.1038%2Fnrm4084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Control of microtubule organization and dynamics: two ends in the limelight</span></div><div class="casAuthors">Akhmanova, Anna; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">711-726</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules have fundamental roles in many essential biol. processes, including cell division and intracellular transport.  They assemble and disassemble from their two ends, denoted the plus end and the minus end.  Significant advances have been made in our understanding of microtubule plus-end-tracking proteins (+TIPs) such as end-binding protein 1 (EB1), XMAP215, selected kinesins and dynein.  By contrast, information on microtubule minus-end-targeting proteins (-TIPs), such as the calmodulin-regulated spectrin-assocd. proteins (CAMSAPs) and Patronin, has only recently started to emerge.  Here, we review our current knowledge of factors, including microtubule-targeting agents, that assoc. with microtubule ends to control the dynamics and function of microtubules during the cell cycle and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps4xzvh0o6PbVg90H21EOLACvtfcHk0ljraEoVdYgp3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI&md5=7c941bcce8d5d51aef6a8deb140356d3</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrm4084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm4084%26sid%3Dliteratum%253Aachs%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DControl%2520of%2520microtubule%2520organization%2520and%2520dynamics%253A%2520two%2520ends%2520in%2520the%2520limelight%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D711%26epage%3D726%26doi%3D10.1038%2Fnrm4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brouhard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. M.</span></span> <span> </span><span class="NLM_article-title">The contribution of αβ-tubulin curvature to microtubule dynamics</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1083/jcb.201407095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1083%2Fjcb.201407095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25385183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2014&pages=323-334&author=G.+J.+Brouhardauthor=L.+M.+Rice&title=The+contribution+of+%CE%B1%CE%B2-tubulin+curvature+to+microtubule+dynamics&doi=10.1083%2Fjcb.201407095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The contribution of αβ-tubulin curvature to microtubule dynamics</span></div><div class="casAuthors">Brouhard, Gary J.; Rice, Luke M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-334</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic polymers of αβ-tubulin that form diverse cellular structures, such as the mitotic spindle for cell division, the backbone of neurons, and axonemes.  To control the architecture of microtubule networks, microtubule-assocd. proteins (MAPs) and motor proteins regulate microtubule growth, shrinkage, and the transitions between these states.  Recent evidence shows that many MAPs exert their effects by selectively binding to distinct conformations of polymd. or unpolymd. αβ-tubulin.  The ability of αβ-tubulin to adopt distinct conformations contributes to the intrinsic polymn. dynamics of microtubules.  αβ-Tubulin conformation is a fundamental property that MAPs monitor and control to build proper microtubule networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGyoU-iIkFELVg90H21EOLACvtfcHk0lgSXFHtqFh-Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE&md5=5ff241f0a021843f7678daec3f7476f1</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201407095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201407095%26sid%3Dliteratum%253Aachs%26aulast%3DBrouhard%26aufirst%3DG.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DThe%2520contribution%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520curvature%2520to%2520microtubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D207%26spage%3D323%26epage%3D334%26doi%3D10.1083%2Fjcb.201407095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vindya, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethiraj, K. R.</span></span> <span> </span><span class="NLM_article-title">Tubulins-the target for anticancer therapy</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150112115805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1568026615666150112115805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25579568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=73-82&author=N.+G.+Vindyaauthor=N.+Sharmaauthor=M.+Yadavauthor=K.+R.+Ethiraj&title=Tubulins-the+target+for+anticancer+therapy&doi=10.2174%2F1568026615666150112115805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulins - The Target for Anticancer Therapy</span></div><div class="casAuthors">Vindya, N. G.; Sharma, Nishant; Yadav, Mukesh; Ethiraj, K. R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tubulin has picked up great focus as a major target in drug discovery and consequently, tubulin inhibitors have pulling in a considerable attention as anticancer agents.  Numerable naturally occurring agents have focused on tubulin system act as an imperative target of cancer chemotherapy.  Substantial no. of tubulin inhibitors has been discovered so far and these agents are classified as indicated by their interaction.  They are colchicine site binder, vinca- alkaloid related drugs and those interacting with the Taxol binding site and functioning as stabilizing agents.  We review the recent advances in the advancement of tubulin interfering agents and will render the current trend in the improvement of tubulin inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tIyc1PffELVg90H21EOLACvtfcHk0lgSXFHtqFh-Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D&md5=8805a32e1f038693336ceb464c67193d</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150112115805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150112115805%26sid%3Dliteratum%253Aachs%26aulast%3DVindya%26aufirst%3DN.%2BG.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DYadav%26aufirst%3DM.%26aulast%3DEthiraj%26aufirst%3DK.%2BR.%26atitle%3DTubulins-the%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D73%26epage%3D82%26doi%3D10.2174%2F1568026615666150112115805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nitika, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapil, K.</span></span> <span> </span><span class="NLM_article-title">Microtubule targeting agents: a benchmark in cancer therapy</span>. <i>Curr. Drug Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.2174/15748855113086660011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F15748855113086660011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=189-196&author=V.+Nitikaauthor=K.+Kapil&title=Microtubule+targeting+agents%3A+a+benchmark+in+cancer+therapy&doi=10.2174%2F15748855113086660011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F15748855113086660011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748855113086660011%26sid%3Dliteratum%253Aachs%26aulast%3DNitika%26aufirst%3DV.%26aulast%3DKapil%26aufirst%3DK.%26atitle%3DMicrotubule%2520targeting%2520agents%253A%2520a%2520benchmark%2520in%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D189%26epage%3D196%26doi%3D10.2174%2F15748855113086660011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naphade, S. S.</span></span> <span> </span><span class="NLM_article-title">Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.2174/1871520615666150526141259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1871520615666150526141259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=955-969&author=P.+O.+Patilauthor=A.+G.+Patilauthor=R.+A.+Raneauthor=P.+C.+Patilauthor=P.+K.+Deshmukhauthor=S.+B.+Bariauthor=D.+A.+Patilauthor=S.+S.+Naphade&title=Recent+advancement+in+discovery+and+development+of+natural+product+combretastatin-inspired+anticancer+agents&doi=10.2174%2F1871520615666150526141259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150526141259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150526141259%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DPatil%26aufirst%3DA.%2BG.%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DPatil%26aufirst%3DP.%2BC.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26aulast%3DNaphade%26aufirst%3DS.%2BS.%26atitle%3DRecent%2520advancement%2520in%2520discovery%2520and%2520development%2520of%2520natural%2520product%2520combretastatin-inspired%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D955%26epage%3D969%26doi%3D10.2174%2F1871520615666150526141259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0lgSXFHtqFh-Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.MCT-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Recent advances in vascular disrupting agents in cancer therapy</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.4155%2Ffmc.14.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25365233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1485-1498&author=E.+Porc%C3%B9author=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Recent+advances+in+vascular+disrupting+agents+in+cancer+therapy&doi=10.4155%2Ffmc.14.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in vascular disrupting agents in cancer therapy</span></div><div class="casAuthors">Porcu, Elena; Bortolozzi, Roberta; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1485-1498</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are an important class of compds. that exhibit selective activity against pre-existing tumor vasculature, causing rapid shutdown of the tumor blood flow and consequent necrosis of the tumor mass.  The VDAs can be divided into flavonoid compds., which are related to flavone acetic acid, and tubulin-binding agents.  Tubulin-binding agents represent the largest group of VDAs and are characterized by different chem. structures, although most of them are derivs. of the lead compd. combretastatin (CA-4).  They demonstrated clin. activity, although recent findings have established that they have insufficient activity as single agents.  Several resistance mechanisms occur, such as the resistance of the tumor rim cells, while promising results have been described in combination with other chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG_xRqLIL1wrVg90H21EOLACvtfcHk0lgfP8KXv63ywg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN&md5=daf2387ad5729d02e889bf0301dac807</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.104%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DRecent%2520advances%2520in%2520vascular%2520disrupting%2520agents%2520in%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1485%26epage%3D1498%26doi%3D10.4155%2Ffmc.14.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargsyan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, M.</span></span> <span> </span><span class="NLM_article-title">Vascular disrupting agents in oncology</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1517/13543784.2013.759557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1517%2F13543784.2013.759557" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=317-328&author=M.+M.+Mitaauthor=L.+Sargsyanauthor=A.+C.+Mitaauthor=M.+Spear&title=Vascular+disrupting+agents+in+oncology&doi=10.1517%2F13543784.2013.759557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.759557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.759557%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DSargsyan%26aufirst%3DL.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DSpear%26aufirst%3DM.%26atitle%3DVascular%2520disrupting%2520agents%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D317%26epage%3D328%26doi%3D10.1517%2F13543784.2013.759557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Kendall, D.</span></span> <span> </span><span class="NLM_article-title">Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4</span>. <i>Experientia</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1007/BF01954881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2FBF01954881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=2920809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADyaL1MXktVShtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1989&pages=209-211&author=G.+R.+Pettitauthor=S.+B.+Singhauthor=E.+Hamelauthor=C.+M.+Linauthor=D.+S.+Albertsauthor=D.+Garcia-Kendall&title=Isolation+and+structure+of+the+strong+cell+growth+and+tubulin+inhibitor+combretastatin+A-4&doi=10.1007%2FBF01954881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4</span></div><div class="casAuthors">Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D.</div><div class="citationInfo"><span class="NLM_cas:title">Experientia</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-11</span>CODEN:
                <span class="NLM_cas:coden">EXPEAM</span>;
        ISSN:<span class="NLM_cas:issn">0014-4754</span>.
    </div><div class="casAbstract">From Combretum caffrum were isolated combretastatin A-4 (I, R1 = R2 = Me, R3 = H), combretastatin A-5 (I, R1 = H, R2 = R3 = Me), and combretastatin A-6 (II, R1 = H and R3 = Me) (the latter as the silyl ether).  The structures of these compds. detd. by spectroscopic methods were confirmed by total syntheses.  Combretastatins A-4, A-5 and A-6 were significantly active against murine L1210 and P388 lymphocytic leukemia cell lines with esp., combretastatin A-4 competing with combretastatin A-1 as the most inhibitor of colchicine binding to tubulin yet described.  Combretastatin A-4 was an inhibitor of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt_PDOS8sCIrVg90H21EOLACvtfcHk0lgvE3JFFLys2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXktVShtbg%253D&md5=5f9cda9322b202960705a92aa1a751ff</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1007%2FBF01954881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01954881%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DAlberts%26aufirst%3DD.%2BS.%26aulast%3DGarcia-Kendall%26aufirst%3DD.%26atitle%3DIsolation%2520and%2520structure%2520of%2520the%2520strong%2520cell%2520growth%2520and%2520tubulin%2520inhibitor%2520combretastatin%2520A-4%26jtitle%3DExperientia%26date%3D1989%26volume%3D45%26spage%3D209%26epage%3D211%26doi%3D10.1007%2FBF01954881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragg, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herald, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohavanijaya, P.</span></span> <span> </span><span class="NLM_article-title">Isolation and structure of combretastatin</span>. <i>Can. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1376</span>, <span class="refDoi"> DOI: 10.1139/v82-202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1139%2Fv82-202" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1982&pages=1374-1376&author=G.+R.+Pettitauthor=G.+M.+Craggauthor=D.+L.+Heraldauthor=J.+M.+Schmidtauthor=P.+Lohavanijaya&title=Isolation+and+structure+of+combretastatin&doi=10.1139%2Fv82-202"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1139%2Fv82-202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fv82-202%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DLohavanijaya%26aufirst%3DP.%26atitle%3DIsolation%2520and%2520structure%2520of%2520combretastatin%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1982%26volume%3D60%26spage%3D1374%26epage%3D1376%26doi%3D10.1139%2Fv82-202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">6984</span>– <span class="NLM_lpage">6991</span>, <span class="refDoi"> DOI: 10.1021/bi00443a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00443a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=6984-6991&author=C.+M.+Linauthor=H.+H.+Hoauthor=G.+R.+Pettitauthor=E.+Hamel&title=Antimitotic+natural+products+combretastatin+A-4+and+combretastatin+A-2%3A+studies+on+the+mechanism+of+their+inhibition+of+the+binding+of+colchicine+to+tubulin&doi=10.1021%2Fbi00443a031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antimitotic natural products combretastatin A-4 and combretastatin A-2:  studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span></div><div class="casAuthors">Lin, Chii M.; Ho, Holly H.; Pettit, George R.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6984-91</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The mechanism of the binding of combretastatin A-4 (CS-A4) and combretastatin A-2 (CS-A2), isolated from Combretum caffrum, to tubulin was examd. indirectly by evaluating their effects on the binding of radiolabeled colchicine to the protein.  There was rapid binding of both compds. to tubulin even at 0° (binding was complete at the earliest times examd.), in contrast to the relatively slow and temp.-dependent binding of colchicine.  Although the binding of the C. caffrum compds. to tubulin was quite tight, permitting ready isolation of near-stoichiometric amts. of drug-tubulin complex even in the absence of free drug, both CS-A4 and CS-A2 dissocd. rapidly from tubulin in the presence of high concns. of radiolabeled colchicine.  Apparent rate consts. for drug dissocn. from tubulin at 37° were 3.2 × 10-3/s for CS-A4, 4.8 × 10-3/s for CS-A2, and 2.9 × 10-5/s for colchicine (half-lives of 3.6, 2.4, and 405 min, resp.).  Thus, the effectiveness of the C. caffrum compds. as antimitotic agents appears to derive primarily from the rapidity of their binding to tubulin.  A new model for the colchicine binding site on tubulin is proposed which envisages A-ring and C-ring subsites in homologous locations on the 2 tubulin subunits, with Ph rings binding as well as or better than the tropolone ring of colchicine in the C-ring subsite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVM6YQr13WbVg90H21EOLACvtfcHk0lgvE3JFFLys2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D&md5=4fc9bd899f65be38961729d7c51a6b16</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fbi00443a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00443a031%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHo%26aufirst%3DH.%2BH.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DAntimitotic%2520natural%2520products%2520combretastatin%2520A-4%2520and%2520combretastatin%2520A-2%253A%2520studies%2520on%2520the%2520mechanism%2520of%2520their%2520inhibition%2520of%2520the%2520binding%2520of%2520colchicine%2520to%2520tubulin%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D6984%26epage%3D6991%26doi%3D10.1021%2Fbi00443a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1097%2FCAD.0000000000000070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24500030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=462-471&author=P.+Liuauthor=Y.+Qinauthor=L.+Wuauthor=S.+Yangauthor=N.+Liauthor=H.+Wangauthor=H.+Xuauthor=K.+Sunauthor=S.+Zhangauthor=X.+Hanauthor=Y.+Sunauthor=Y.+Shi&title=A+phase+I+clinical+trial+assessing+the+safety+and+tolerability+of+combretastatin+A4+phosphate+injections&doi=10.1097%2FCAD.0000000000000070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span></div><div class="casAuthors">Liu, Peng; Qin, Yan; Wu, Lingying; Yang, Sheng; Li, Nan; Wang, Haijun; Xu, Haiyan; Sun, Kelin; Zhang, Shuxiang; Han, Xiaohong; Sun, Yan; Shi, Yuankai</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-471</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clin. trials.  The aims of this single-center, open label, phase I clin. trial were to investigate the safety and tolerability of CA4P administered i.v. to patients aged 18-65 years with advanced solid tumors.  Using a dose-escalation protocol, patients were assigned to five groups that received injections with 20 (n=3), 33 (n=3), 50 (n=11), 65 (n=6), or 85 (n=2) mg/m CA4P.  Patients in the 20 and 85 mg/m groups received a single dose and the other groups received multiple doses.  Adverse events (AE), cardiovascular parameters, and biochem. investigations were studied, and the max. tolerated dose was detd.  Of twenty-five patients enrolled, eight were withdrawn/excluded (not because of AE).  There were no deaths.  A total of 394 AE occurred in the 25 patients, with 89.3% considered related/possibly related to the drug.  AE included headache and dizziness (19.8%), tumor-induced pain (14.2%), vascular vagal excitation (10.7%), and vomiting (9.4%).  Ninety-five percent of AE were mild (grades 0-II), with only 5% being grade III-IV.  Drug administration was assocd. with biphasic changes in heart rate and blood pressure, and only limited abnormalities in the lab. investigations performed.  The max. tolerated dose was 65 mg/m.  We conclude that CA4P is generally well tolerated, with the vast majority of AE that occurred being of mild severity.  Further studies will establish the role of CA4P in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvmdFO81FLLVg90H21EOLACvtfcHk0liCmyPCoqdj3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D&md5=1573e6f13d625ddc78fdac4ffff13181</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000070%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520assessing%2520the%2520safety%2520and%2520tolerability%2520of%2520combretastatin%2520A4%2520phosphate%2520injections%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D462%26epage%3D471%26doi%3D10.1097%2FCAD.0000000000000070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naphade, S. S.</span></span> <span> </span><span class="NLM_article-title">Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.2174/1871520615666150526141259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1871520615666150526141259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=955-969&author=P.+O.+Patilauthor=A.+G.+Patilauthor=R.+A.+Raneauthor=P.+C.+Patilauthor=P.+K.+Deshmukhauthor=S.+B.+Bariauthor=D.+A.+Patilauthor=S.+S.+Naphade&title=Recent+advancement+in+discovery+and+development+of+natural+product+combretastatin-inspired+anticancer+agents&doi=10.2174%2F1871520615666150526141259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150526141259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150526141259%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DPatil%26aufirst%3DA.%2BG.%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DPatil%26aufirst%3DP.%2BC.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26aulast%3DNaphade%26aufirst%3DS.%2BS.%26atitle%3DRecent%2520advancement%2520in%2520discovery%2520and%2520development%2520of%2520natural%2520product%2520combretastatin-inspired%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D955%26epage%3D969%26doi%3D10.2174%2F1871520615666150526141259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rajak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewangan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerasamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, A.</span></span> <span> </span><span class="NLM_article-title">design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1923</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.2174/1381612811319100013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1381612811319100013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=23237054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1923-1955&author=H.+Rajakauthor=P.+K.+Dewanganauthor=V.+Patelauthor=D.+K.+Jainauthor=A.+Singhauthor=R.+Veerasamyauthor=P.+C.+Sharmaauthor=A.+Dixit&title=design+of+combretastatin+A-4+analogs+as+tubulin+targeted+vascular+disrupting+agent+with+special+emphasis+on+their+cis-restricted+isomers&doi=10.2174%2F1381612811319100013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span></div><div class="casAuthors">Rajak, Harish; Dewangan, Pramod Kumar; Patel, Vijay; Jain, Deepak Kumar; Singh, Avineesh; Veerasamy, Ravichandran; Sharma, Prabodh Chander; Dixit, Anshuman</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1923-1955</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is a highly imperative and feasible goal for anticancer drug discovery.  Hundreds of naturally occurring, semi synthetic and synthetic antitubulin agents have been reported till now.  Among these, Combretastatin A - 4 (CA - 4) is effective antimitotic agent possessing potent cytotoxicity against a panel of cancer cells, including multi-drug resistant cancer cell lines.  The inadequate water soly. and inactivation of these analogs during storage limit their use as clin. anticancer agents.  To overcome these short-comings, numerous water sol. amino analogs, amino acid deriv., phosphate prodrug (CA - 4P) and cis-locked CA - 4 have been developed with distinctive attributes of antitubulin and antivascular properties in a wide variety of preclin. tumor models.  Subsequently, several heterocycle based cis restricted CA - 4 analogs are being reported for antitumor activity against collection of cancer cell lines.  This review recapitulates the rational design, structure activity relationship, pharmacokinetic and pharmacodynamic profile of synthesized cis restricted CA - 4 analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVkQxS7xaDPLVg90H21EOLACvtfcHk0liCmyPCoqdj3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D&md5=4aaa3f776e46ef2c0e4b18e8a163dee2</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.2174%2F1381612811319100013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319100013%26sid%3Dliteratum%253Aachs%26aulast%3DRajak%26aufirst%3DH.%26aulast%3DDewangan%26aufirst%3DP.%2BK.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DD.%2BK.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DVeerasamy%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DP.%2BC.%26aulast%3DDixit%26aufirst%3DA.%26atitle%3Ddesign%2520of%2520combretastatin%2520A-4%2520analogs%2520as%2520tubulin%2520targeted%2520vascular%2520disrupting%2520agent%2520with%2520special%2520emphasis%2520on%2520their%2520cis-restricted%2520isomers%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D1923%26epage%3D1955%26doi%3D10.2174%2F1381612811319100013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span> <span> </span><span class="NLM_article-title">Combretastatins: more than just vascular targeting agents?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.226225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1124%2Fjpet.115.226225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=26354991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=212-227&author=L.+M.+Greeneauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatins%3A+more+than+just+vascular+targeting+agents%3F&doi=10.1124%2Fjpet.115.226225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatins: more than just vascular targeting agents?</span></div><div class="casAuthors">Greene, Lisa M.; Meegan, Mary J.; Zisterer, Daniela M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-227</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several prodrugs of the naturally occurring combretastatins have undergone extensive clin. evaluation as vascular targeting agents (VTAs).  Their increased selectivity toward endothelial cells together with their innate ability to rapidly induce vascular shutdown and inhibit tumor growth at doses up to 10-fold less than the max. tolerated dose led to the clin. evaluation of combretastatins as VTAs.  Tubulin is well established as the mol. target of the combretastatins and the vast majority of its synthetic derivs.  Furthermore, tubulin is a highly validated mol. target of many direct anticancer agents routinely used as front-line chemotherapeutics.  The unique vascular targeting properties of the combretastatins have somewhat overshadowed their development as direct anticancer agents and the delineation of the various cell death pathways and anticancer properties assocd. with such chemotherapeutics.  Moreover, the ongoing clin. trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclin. evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins.  In this review, we discuss the development of the combretastatins from nature to the clinic.  The various mechanisms underlying combretastatin-induced cell cycle arrest, mitotic catastrophe, cell death, and survival are also reviewed in an attempt to further enhance the clin. prospects of this unique class of VTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKpiV5x3vPLVg90H21EOLACvtfcHk0liCmyPCoqdj3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D&md5=7e965d3cd51715cec3f84fde9cd6e88e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226225%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatins%253A%2520more%2520than%2520just%2520vascular%2520targeting%2520agents%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D212%26epage%3D227%26doi%3D10.1124%2Fjpet.115.226225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakkanthara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. H.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5050</span>– <span class="NLM_lpage">5059</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2014.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24650703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5050-5059&author=J.+J.+Fieldauthor=A.+Kanakkantharaauthor=J.+H.+Miller&title=Microtubule-targeting+agents+are+clinically+successful+due+to+both+mitotic+and+interphase+impairment+of+microtubule+function&doi=10.1016%2Fj.bmc.2014.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span></div><div class="casAuthors">Field, Jessica J.; Kanakkanthara, Arun; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5050-5059</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microtubules undergo continual dynamic changes in mitotic cells as the mitotic spindle forms and is broken down and in interphase cells where they play a central role in intracellular trafficking, cell signaling, cell migration, and angiogenesis.  Compds. that target the microtubule have been hugely successful in the clinic as chemotherapeutics, and this success is likely due to their ability to target cells regardless of their cell cycle stage.  Addnl., new generation antibody-conjugated microtubule-targeting agents are improving the targeting of these drugs to tumors.  Microtubule-targeting agents have been shown to have anti-angiogenic and vascular-disrupting properties as well as effects on cellular migration, intracellular trafficking, and cell secretion.  There are a no. of these compds. in development that target the vasculature, and different formulations of clin. used drugs are being developed to take advantage of these anti-angiogenic properties.  Microtubule-targeting agents have also been shown to have the potential to treat neurodegenerative diseases, such as Alzheimer's disease.  Thus, drugs that target the microtubule will continue to have a major impact in oncol. not only as anti-mitotics but also as potent inhibitors of interphase functions, and in future may also prove to be effective in reducing the consequences of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d-DR0ciixrVg90H21EOLACvtfcHk0lhXqpnyhsEvwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D&md5=e3ec8c5c15dfe25d1c527cecaec20d2f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DKanakkanthara%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520are%2520clinically%2520successful%2520due%2520to%2520both%2520mitotic%2520and%2520interphase%2520impairment%2520of%2520microtubule%2520function%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5050%26epage%3D5059%26doi%3D10.1016%2Fj.bmc.2014.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbuk, K.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor: pathway, therapies, and pipeline</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1282</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2013.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.clinthera.2013.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24054705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyltbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=1282-1303&author=J.+R.+Goffinauthor=K.+Zbuk&title=Epidermal+growth+factor+receptor%3A+pathway%2C+therapies%2C+and+pipeline&doi=10.1016%2Fj.clinthera.2013.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline</span></div><div class="casAuthors">Goffin, John R.; Zbuk, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1282-1303</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) pathway is important in tumor growth, survival, and metastasis and is now the target of several therapeutic agents.  This paper seeks to review the EGFR pathway, the study and use of EGFR-directed agents in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC), and related new drug development.  PubMed was searched for English-language articles by MeSH and title terms of EGFR published from 2006 to 2013, using the limits of clin. trials as well as reviews.  Ref. lists were assessed for relevant articles, and guidelines were searched.  Clinicaltrials.gov and meeting abstrs. were queried for investigational agents.  Eligible papers included those concerning EGFR biol., NSCLC or CRC studies involving EGFR-directed agents, and/or investigational drugs targeting EGFR and/or assocd. pathways.  The activity of oral tyrosine kinase inhibitors (TKIs) against EGFR has improved survival in NSCLC, and these agents particularly effective in cancers with an EGFR mutation.  Resistance to TKIs is most commonly related to a second, T790M, mutation, or to MET amplification, with newer agents directed against these mechanisms.  Conversely, in CRC, TKIs have been ineffective, whereas monoclonal antibodies have improved survival.  Both primary and secondary KRAS mutations in CRC abrogate mAb effectiveness.  Several targets, including MET, BRAF, and PI3K, may serve useful in combination with anti-EGFR drugs.  Exploitation of EGFR-directed therapies has offered improvement in survival and quality of life in NSCLC and CRC.  New therapies directed at EGFR may offer further improvements.  However, resistance mechanisms suggest that combination therapies or multitargeted agents will be crucial in making significant future advances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6LWzUjeEPfbVg90H21EOLACvtfcHk0lhXqpnyhsEvwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyltbrJ&md5=25b4b4240668193a3238c85121d2968d</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2013.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2013.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoffin%26aufirst%3DJ.%2BR.%26aulast%3DZbuk%26aufirst%3DK.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%253A%2520pathway%252C%2520therapies%252C%2520and%2520pipeline%26jtitle%3DClin.%2520Ther.%26date%3D2013%26volume%3D35%26spage%3D1282%26epage%3D1303%26doi%3D10.1016%2Fj.clinthera.2013.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinghoff, I. K.</span></span> <span> </span><span class="NLM_article-title">Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">viii7</span>– <span class="NLM_lpage">viii13</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nou232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1093%2Fneuonc%2Fnou232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25342602" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=viii7-viii13&author=D.+A.+Reardonauthor=P.+Y.+Wenauthor=I.+K.+Mellinghoff&title=Targeted+molecular+therapies+against+epidermal+growth+factor+receptor%3A+past+experiences+and+challenges&doi=10.1093%2Fneuonc%2Fnou232"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnou232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnou232%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26atitle%3DTargeted%2520molecular%2520therapies%2520against%2520epidermal%2520growth%2520factor%2520receptor%253A%2520past%2520experiences%2520and%2520challenges%26jtitle%3DNeuro%2520Oncol.%26date%3D2014%26volume%3D16%26spage%3Dviii7%26epage%3Dviii13%26doi%3D10.1093%2Fneuonc%2Fnou232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olayioye, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badache, A.</span></span> <span> </span><span class="NLM_article-title">The ErbB receptor tyrosine family as signal integrators</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0080151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1677%2Ferc.0.0080151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=151-159&author=N.+E.+Hynesauthor=K.+Horschauthor=M.+A.+Olayioyeauthor=A.+Badache&title=The+ErbB+receptor+tyrosine+family+as+signal+integrators&doi=10.1677%2Ferc.0.0080151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0080151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0080151%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DHorsch%26aufirst%3DK.%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DBadache%26aufirst%3DA.%26atitle%3DThe%2520ErbB%2520receptor%2520tyrosine%2520family%2520as%2520signal%2520integrators%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2001%26volume%3D8%26spage%3D151%26epage%3D159%26doi%3D10.1677%2Ferc.0.0080151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lhXqpnyhsEvwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor dependence in human tumors: more than just expression?</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.7-suppl_4-31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1634%2Ftheoncologist.7-suppl_4-31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=12202786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFOiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=31-39&author=C.+L.+Arteaga&title=Epidermal+growth+factor+receptor+dependence+in+human+tumors%3A+more+than+just+expression%3F&doi=10.1634%2Ftheoncologist.7-suppl_4-31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor dependence in human tumors: more than just expression?</span></div><div class="casAuthors">Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a rational target for antitumor strategies.  EGFR signaling causes increased proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis.  The EGFR is expressed or highly expressed in a variety of human tumors of epithelial origin.  ZD1839 (Iressa) is an orally active, selective EGFR tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells.  The lack of a consistent method of evaluating levels of EGFR has caused a disparity in reports of the EGFR as a prognostic factor; however, for some tumors, EGFR is a strong prognostic indicator assocd. with more aggressive disease and reduced survival.  So far, no clear assocn. between EGFR levels and response to EGFR-targeted agents has been found.  Preclin. studies with ZD1839 have noted a relationship between the two in some cases, but not others.  EGFR signaling may be increased by a no. of mechanisms in addn. to high expression levels of EGFR, including receptor mutations, heterodimerization with other members of this receptor family such as HER2 (erbB2), increased expression of (autocrine/paracrine) ligands, and alterations in mols. that control receptor signaling output.  Each of these components could be assessed to give an indication of the magnitude of EGFR signal amplification.  Evaluation of signaling components downstream from EGFR should provide information on the activation of the EGFR pathway.  Until EGFR-based assays predictive of a response to receptor-targeted therapies are available, there is no clear justification for stratifying patients by EGFR status or excluding patients with low EGFR levels from trials with ZD1839 or other EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq11PFZoC2MDLVg90H21EOLACvtfcHk0lhSqJ4fyoXopg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFOiurg%253D&md5=624685036112bb7925cbc5870744c9fc</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.7-suppl_4-31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.7-suppl_4-31%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520dependence%2520in%2520human%2520tumors%253A%2520more%2520than%2520just%2520expression%253F%26jtitle%3DOncologist%26date%3D2002%26volume%3D7%26spage%3D31%26epage%3D39%26doi%3D10.1634%2Ftheoncologist.7-suppl_4-31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olayioye, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span> <span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3159</span>– <span class="NLM_lpage">3167</span>, <span class="refDoi"> DOI: 10.1093/emboj/19.13.3159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+N.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer&doi=10.1093%2Femboj%2F19.13.3159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0lhSqJ4fyoXopg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%2BN.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167%26doi%3D10.1093%2Femboj%2F19.13.3159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3867</span>– <span class="NLM_lpage">3872</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S119162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2147%2FDDDT.S119162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27920501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyis7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=3867-3872&author=H.+Zhang&title=Three+generations+of+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+developed+to+revolutionize+the+therapy+of+lung+cancer&doi=10.2147%2FDDDT.S119162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer</span></div><div class="casAuthors">Zhang, Haijun</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3867-3872</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Lung cancer, ∼80%-85% of which is non-small-cell lung cancer (NSCLC), is the leading cause of cancer-related mortality worldwide.  Sensitizing mutations in epidermal growth factor receptor (EGFR) gene (EGFRm♂), such as exon 19 deletions and exon 21 L858R point mutations, are the most important drivers in NSCLC patients.  In this respect, small-mol. EGFR tyrosine kinase inhibitors (TKIs) have been designed and developed, which launched the era of targeted, personalized and precise medicine for lung cancer.  Patients with EGFRm♂ could achieve good responses to the treatment with the first-generation EGFR TKIs, such as erlotinib and gefitinib.  However, most patients develop acquired drug resistance mostly driven by the T790M mutation occurring within exon 20.  Although the second-generation EGFR TKIs, such as afatinib, dacomitinib and neratinib, demonstrated promising activity against T790M in preclin. models, they have failed to overcome resistance in patients due to dose-limiting toxicity.  Recently, the third-generation EGFR TKIs have shown to be effective against cell lines and murine models harboring T790M mutations while sparing wild-type EGFR, which represents a promising breakthrough approach in overcoming T790M-mediated resistance in NSCLC patients.  This article provides a comprehensive review of the therapy revolution for NSCLC with three generations of EGFR TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF_iaNrFGZHLVg90H21EOLACvtfcHk0lhSqJ4fyoXopg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyis7rI&md5=c50ca45f94b1babed9350c8759284235</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S119162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S119162%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThree%2520generations%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520developed%2520to%2520revolutionize%2520the%2520therapy%2520of%2520lung%2520cancer%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D3867%26epage%3D3872%26doi%3D10.2147%2FDDDT.S119162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hossam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A.</span></span> <span> </span><span class="NLM_article-title">Covalent EGFR inhibitors: binding mechanisms, synthetic approaches, and clinical profiles</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1002/ardp.201600063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1002%2Fardp.201600063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27258393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVGmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2016&pages=573-593&author=M.+Hossamauthor=D.+S.+Lasheenauthor=K.+A.+Abouzid&title=Covalent+EGFR+inhibitors%3A+binding+mechanisms%2C+synthetic+approaches%2C+and+clinical+profiles&doi=10.1002%2Fardp.201600063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles</span></div><div class="casAuthors">Hossam, Monia; Lasheen, Deena S.; Abouzid, Khaled A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-593</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Being overexpressed in several types of cancer, the epidermal growth factor receptor (EGFR) is considered one of the key therapeutic targets in oncol.  Although many first-generation EGFR inhibitors had been FDA approved for the treatment of certain types of cancer, patients soon developed resistance to these reversible ATP competitive inhibitors via mutations in the kinase domain of EGFR.  A new trend was adopted to design covalent irreversible inhibitors, i.e., second- and third-generation inhibitors.  Second-generation inhibitors can inhibit the mutant forms but, unfortunately, they had dose limiting side effects due to wild-type EGFR inhibition.  Third-generation inhibitors emerged shortly, which were capable of inhibiting the mutant forms exclusively while sparing the wild type.  Many other strategies have also been developed to reduce the risk of covalent interactions with off-targets, thus improving the pharmacokinetic and/or pharmacodynamic profile of the antiproliferative agents.  In this review, the authors focused mainly on second- and third-generation EGFR inhibitors, their binding mechanisms (either docking studies or co-crystd. structures), their synthetic approaches, clin. profiles, and limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo81VTxrg7O67Vg90H21EOLACvtfcHk0ljIFBcUZdlaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVGmsbY%253D&md5=cf777cc2bd1891fd4cc039e4dcb3d5c2</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1002%2Fardp.201600063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201600063%26sid%3Dliteratum%253Aachs%26aulast%3DHossam%26aufirst%3DM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%26atitle%3DCovalent%2520EGFR%2520inhibitors%253A%2520binding%2520mechanisms%252C%2520synthetic%2520approaches%252C%2520and%2520clinical%2520profiles%26jtitle%3DArch.%2520Pharm.%26date%3D2016%26volume%3D349%26spage%3D573%26epage%3D593%26doi%3D10.1002%2Fardp.201600063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">4-Anilinoquinazoline derivatives with epidermal growth factor receptor inhibitor activity</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1652</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.2174/1871520616666160404113141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1871520616666160404113141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27039919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOhu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1652-1664&author=F.+Liuauthor=B.+Tangauthor=H.+Liuauthor=L.+Liauthor=G.+Liuauthor=Y.+Chengauthor=Y.+Xuauthor=W.+Chenauthor=Y.+Huang&title=4-Anilinoquinazoline+derivatives+with+epidermal+growth+factor+receptor+inhibitor+activity&doi=10.2174%2F1871520616666160404113141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity</span></div><div class="casAuthors">Liu, Fang; Tang, Baoding; Liu, Hao; Li, Leina; Liu, Gang; Cheng, Yun; Xu, Yan; Chen, Wenwen; Huang, Yinjiu</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1652-1664</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline derivs. possess high anti-cancer activities.  Many of them are highly selective tyrosine kinase inhibitors (TKI), particularly against epidermal growth factor receptor (EGFR).  EGFRs are overexpressed or mutated in most carcinomas and are required for tumor progression.  The efficacy of EGFR-targeted anti-tumor drugs is impaired by drug-induced acquired resistance.  Therefore, there is urgency to find better anti-cancer agents with novel effects on EGFR.  4-Anilinoquinazolines are small mol. EGFR inhibitors that have been synthesized and assessed for their anti-tumor bioactivity.  In this paper, we review the 4-anilinoquinazoline derivs. with EGFR inhibitor activity reported in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnNzV0P4o42LVg90H21EOLACvtfcHk0ljIFBcUZdlaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOhu7rN&md5=85f6a1219aee1b23639bb854cfbc3239</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.2174%2F1871520616666160404113141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520616666160404113141%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26atitle%3D4-Anilinoquinazoline%2520derivatives%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520activity%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1652%26epage%3D1664%26doi%3D10.2174%2F1871520616666160404113141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, S. M.</span></span> <span> </span><span class="NLM_article-title">Lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1380</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0802714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1056%2FNEJMra0802714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=18815398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1367-1380&author=R.+S.+Herbstauthor=J.+V.+Heymachauthor=S.+M.+Lippman&title=Lung+cancer&doi=10.1056%2FNEJMra0802714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular origins of cancer: lung cancer</span></div><div class="casAuthors">Herbst, Roy S.; Heymach, John V.; Lippman, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1367-1380</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The altered mol. genetics of non-small-cell lung cancer is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxvIgLl4BT2LVg90H21EOLACvtfcHk0ljIFBcUZdlaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM&md5=a5968124ab5b0807e9a1b89e5e2dad51</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0802714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0802714%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26atitle%3DLung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1367%26epage%3D1380%26doi%3D10.1056%2FNEJMra0802714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normanno, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span> <span> </span><span class="NLM_article-title">Trying to compose the puzzle with all the pieces: epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1002/jcp.20402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1002%2Fjcp.20402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=15895392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Shtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2005&pages=355-363&author=M.+Di+Maioauthor=C.+Gridelliauthor=N.+Normannoauthor=F.+Perroneauthor=F.+Ciardiello&title=Trying+to+compose+the+puzzle+with+all+the+pieces%3A+epidermal+growth+factor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer&doi=10.1002%2Fjcp.20402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Di Maio, Massimo; Gridelli, Cesare; Normanno, Nicola; Perrone, Francesco; Ciardiello, Fortunato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Small mol. epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown promising activity in patients with non-small cell lung cancer (NSCLC).  Gefitinib has been the first of these drugs to be licensed for third-line treatment of advanced NSCLC patients.  More recently, erlotinib has been shown to be more effective than placebo in increasing overall survival (OAS) and has been approved for NSCLC patients after failure of chemotherapy.  However, a large body of clin. and exptl. evidence suggests that the benefit from these drugs is limited to a subgroup of patients.  The availability of clin. or mol. criteria for predicting sensitivity to EGFR-TKIs is the most relevant issue for their correct use and for planning future research.  Detn. of EGFR expression is not sufficient to predict sensitivity to EGFR-TKIs.  However, several clin. features (female gender, adenocarcinoma/bronchioloalveolar histotype, never-smoking status, Oriental Asian origin) are assocd. with major clin. responses.  The identification of somatic mutations in the tyrosine kinase domain of the EGFR gene represents the most important mol. marker of sensitivity to EGFR-TKIs.  These "activating" mutations can be found in a high proportion of gefitinib- or erlotinib-responding patients.  However, clin. effectiveness might not be limited to patients carrying EGFR mutations, in which the objective response is probably the detectable effect of apoptosis induction in cancer cells.  In fact, clin. efficacy with gefitinib or erlotinib is also obsd. in another subgroup of patients, in which a tumor growth delay, detd. by a block in cancer cell proliferation, could induce a prolonged and clin. relevant disease stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_n0iYGK5fULVg90H21EOLACvtfcHk0ljeQUk1sWzPAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Shtr7K&md5=5454676bceaedb2d8a7e6a1c6534f34c</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20402%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMaio%26aufirst%3DM.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DCiardiello%26aufirst%3DF.%26atitle%3DTrying%2520to%2520compose%2520the%2520puzzle%2520with%2520all%2520the%2520pieces%253A%2520epidermal%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D205%26spage%3D355%26epage%3D363%26doi%3D10.1002%2Fjcp.20402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Soler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1056/NEJMct0807960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1056%2FNEJMct0807960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21388312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=947-955&author=V.+D.+Cataldoauthor=D.+L.+Gibbonsauthor=R.+Perez-Solerauthor=A.+Quintas-Cardama&title=Treatment+of+non-small-cell+lung+cancer+with+erlotinib+or+gefitinib&doi=10.1056%2FNEJMct0807960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span></div><div class="casAuthors">Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintas-Cardama, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDIxHbNbHr7Vg90H21EOLACvtfcHk0ljeQUk1sWzPAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D&md5=5030feb97e5b6b09e3e11d6946cde577</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0807960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0807960%26sid%3Dliteratum%253Aachs%26aulast%3DCataldo%26aufirst%3DV.%2BD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DPerez-Soler%26aufirst%3DR.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520non-small-cell%2520lung%2520cancer%2520with%2520erlotinib%2520or%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D947%26epage%3D955%26doi%3D10.1056%2FNEJMct0807960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljeQUk1sWzPAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Trusolino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertotti, A.</span></span> <span> </span><span class="NLM_article-title">Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1158%2F2159-8290.CD-12-0400" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=876-880&author=L.+Trusolinoauthor=A.+Bertotti&title=Compensatory+pathways+in+oncogenic+kinase+signaling+and+resistance+to+targeted+therapies%3A+six+degrees+of+separation&doi=10.1158%2F2159-8290.CD-12-0400"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0400%26sid%3Dliteratum%253Aachs%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DBertotti%26aufirst%3DA.%26atitle%3DCompensatory%2520pathways%2520in%2520oncogenic%2520kinase%2520signaling%2520and%2520resistance%2520to%2520targeted%2520therapies%253A%2520six%2520degrees%2520of%2520separation%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D876%26epage%3D880%26doi%3D10.1158%2F2159-8290.CD-12-0400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>The identification numbers in <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a> websites are: NCT02326285, NCT00720304, NCT00049283, NCT02319577,
NCT00083057, NCT01405079, NCT01755923, NCT00532441, NCT01749072, NCT01050322,
NCT00446225, and NCT00553358 (accessed Oct 25, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+identification+numbers+in+https%3A%2F%2Fclinicaltrials.gov+websites+are%3A+NCT02326285%2C+NCT00720304%2C+NCT00049283%2C+NCT02319577%2C%0ANCT00083057%2C+NCT01405079%2C+NCT01755923%2C+NCT00532441%2C+NCT01749072%2C+NCT01050322%2C%0ANCT00446225%2C+and+NCT00553358+%28accessed+Oct+25%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Litvinov, V. P.</span></span> <span> </span><span class="NLM_article-title">The chemistry of thienopyrimidines</span>. <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2006&pages=83-143&author=V.+P.+Litvinov&title=The+chemistry+of+thienopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLitvinov%26aufirst%3DV.%2BP.%26atitle%3DThe%2520chemistry%2520of%2520thienopyrimidines%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D2006%26volume%3D92%26spage%3D83%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ansary, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ghorafi, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 4-anilinoquinazoline bioisosteres as potential anti-breast cancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2014.08.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=202-210&author=A.+K.+El-Ansaryauthor=A.+M.+Kamalauthor=M.+A.+Al-Ghorafi&title=Synthesis+and+evaluation+of+4-anilinoquinazoline+bioisosteres+as+potential+anti-breast+cancer+agents&doi=10.1016%2Fj.ejmech.2014.08.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ansary%26aufirst%3DA.%2BK.%26aulast%3DKamal%26aufirst%3DA.%2BM.%26aulast%3DAl-Ghorafi%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25204-anilinoquinazoline%2520bioisosteres%2520as%2520potential%2520anti-breast%2520cancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D202%26epage%3D210%26doi%3D10.1016%2Fj.ejmech.2014.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel thieno[3,2-<i>d</i>]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2014.10.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=782-799&author=Z.+Liuauthor=S.+Wuauthor=Y.+Wangauthor=R.+Liauthor=J.+Wangauthor=L.+Wangauthor=Y.+Zhaoauthor=P.+Gong&title=Design%2C+synthesis+and+biological+evaluation+of+novel+thieno%5B3%2C2-d%5Dpyrimidine+derivatives+possessing+diaryl+semicarbazone+scaffolds+as+potent+antitumor+agents&doi=10.1016%2Fj.ejmech.2014.10.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520thieno%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520possessing%2520diaryl%2520semicarbazone%2520scaffolds%2520as%2520potent%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D782%26epage%3D799%26doi%3D10.1016%2Fj.ejmech.2014.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bugge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspersen, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonstad, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjørkøy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, B. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2014.01.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24556149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1Ojs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2014&pages=354-374&author=S.+Buggeauthor=S.+J.+Kaspersenauthor=S.+Larsenauthor=U.+Nonstadauthor=G.+Bj%C3%B8rk%C3%B8yauthor=E.+Sundbyauthor=B.+H.+Hoff&title=Structure-activity+study+leading+to+identification+of+a+highly+active+thienopyrimidine+based+EGFR+inhibitor&doi=10.1016%2Fj.ejmech.2014.01.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor</span></div><div class="casAuthors">Bugge, Steffen; Kaspersen, Svein Jacob; Larsen, Synne; Nonstad, Unni; Bjoerkoey, Geir; Sundby, Eirik; Hoff, Baard Helge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354-374</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Based on the thieno[2,3-d]pyrimidine scaffold, a series of new 4-amino-6-aryl thienopyrimidines have been prepd. and evaluated as EGFR tyrosine kinase inhibitors.  The in vitro activity was found to depend strongly on the substitution pattern in the 6-aryl ring, the stereochem., and the basicity at the secondary 4-amino group.  A stepwise optimization by combination of active fragments led to the discovery of three structures with EGFR IC50 < 1 nM.  The most potent drug candidate had an IC50 of 0.3 nM towards EGFR and its mutants L858R and L861Q.  Studies using human cancer cell lines and an EGFR-L858R reporter cell system revealed good cellular potency, verifying the identified thienopyrimidines as promising lead structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqIJzK2_3fLVg90H21EOLACvtfcHk0li7zq0wYLv5kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1Ojs7s%253D&md5=1a639bc8b6ea6b5996db573099bb5d6a</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.042%26sid%3Dliteratum%253Aachs%26aulast%3DBugge%26aufirst%3DS.%26aulast%3DKaspersen%26aufirst%3DS.%2BJ.%26aulast%3DLarsen%26aufirst%3DS.%26aulast%3DNonstad%26aufirst%3DU.%26aulast%3DBj%25C3%25B8rk%25C3%25B8y%26aufirst%3DG.%26aulast%3DSundby%26aufirst%3DE.%26aulast%3DHoff%26aufirst%3DB.%2BH.%26atitle%3DStructure-activity%2520study%2520leading%2520to%2520identification%2520of%2520a%2520highly%2520active%2520thienopyrimidine%2520based%2520EGFR%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D75%26spage%3D354%26epage%3D374%26doi%3D10.1016%2Fj.ejmech.2014.01.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rheault, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caferro, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spehar, G. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2008.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=817-820&author=T.+R.+Rheaultauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=K.+H.+Donaldsonauthor=M.+D.+Gaulauthor=A.+S.+Goetzauthor=R.+J.+Mullinauthor=O.+B.+McDonaldauthor=K.+G.+Petrovauthor=D.+W.+Rusnakauthor=L.+M.+Shewchukauthor=G.+H.+M.+Speharauthor=A.+T.+Truesdaleauthor=D.+E.+Vanderwallauthor=E.+R.+Woodauthor=D.+E.+Uehling&title=Thienopyrimidine-based+dual+EGFR%2FErbB-2+inhibitors&doi=10.1016%2Fj.bmcl.2008.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%2BD.%26aulast%3DGoetz%26aufirst%3DA.%2BS.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DSpehar%26aufirst%3DG.%2BH.%2BM.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DThienopyrimidine-based%2520dual%2520EGFR%252FErbB-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D817%26epage%3D820%26doi%3D10.1016%2Fj.bmcl.2008.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaechtele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totzke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krumbach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span> <span> </span><span class="NLM_article-title">Novel inhibitors of epidermal growth factor receptor: (4-(arylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-yl)(1<i>H</i>-indol-2-yl)methanones and (1<i>H</i>-indol-2-yl)(4-(phenylamino) thieno[2,3-<i>d</i>]pyrimidin-6-yl)methanones</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2011.11.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=125-136&author=T.+Beckersauthor=A.+Sellmerauthor=E.+Eichhornauthor=H.+Pongratzauthor=C.+Schaechteleauthor=F.+Totzkeauthor=G.+Kelterauthor=R.+Krumbachauthor=H.+H.+Fiebigauthor=F.+D.+Boehmerauthor=S.+Mahboobi&title=Novel+inhibitors+of+epidermal+growth+factor+receptor%3A+%284-%28arylamino%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-6-yl%29%281H-indol-2-yl%29methanones+and+%281H-indol-2-yl%29%284-%28phenylamino%29+thieno%5B2%2C3-d%5Dpyrimidin-6-yl%29methanones&doi=10.1016%2Fj.bmc.2011.11.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DBeckers%26aufirst%3DT.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DSchaechtele%26aufirst%3DC.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DKrumbach%26aufirst%3DR.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DBoehmer%26aufirst%3DF.%2BD.%26aulast%3DMahboobi%26aufirst%3DS.%26atitle%3DNovel%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%253A%2520%25284-%2528arylamino%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-6-yl%2529%25281H-indol-2-yl%2529methanones%2520and%2520%25281H-indol-2-yl%2529%25284-%2528phenylamino%2529%2520thieno%255B2%252C3-d%255Dpyrimidin-6-yl%2529methanones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D125%26epage%3D136%26doi%3D10.1016%2Fj.bmc.2011.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Milik, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serya, R. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-<i>d</i>]pyrimidine-based dual EGFR/HER2 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2018.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=29902719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFemsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=316-336&author=S.+N.+Milikauthor=A.+K.+Abdel-Azizauthor=D.+S.+Lasheenauthor=R.+A.+T.+Seryaauthor=S.+Minucciauthor=K.+A.+M.+Abouzid&title=Surmounting+the+resistance+against+EGFR+inhibitors+through+the+development+of+thieno%5B2%2C3-d%5Dpyrimidine-based+dual+EGFR%2FHER2+inhibitors&doi=10.1016%2Fj.ejmech.2018.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors</span></div><div class="casAuthors">Milik, Sandra N.; Abdel-Aziz, Amal Kamal; Lasheen, Deena S.; Serya, Rabah A. T.; Minucci, Saverio; Abouzid, Khaled A. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">316-336</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In light of the emergence of resistance against the currently available EGFR inhibitors, our study focuses on tackling this problem through the development of dual EGFR/HER2 inhibitors with improved enzymic affinities.  Guided by the binding mode of the marketed dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors based on the 6-phenylthieno[2,3-d]pyrimidine as a core scaffold and hinge binder.  After two cycles of screening aiming to identify the optimum aniline headgroup and solubilizing group, we eventually identified 27b as a dual EGFR/HER2 inhibitor with IC50 values of 91.7 nM and 1.2 μM, resp.  Notably, 27b dramatically reduced the viability of various patient-derived cancer cells preferentially overexpressing EGFR/HER2 (A431, MDA-MBA-361 and SKBr3 with IC50 values of 1.45, 3.5 and 4.83 μM, resp.).  Addnl., 27b efficiently thwarted the proliferation of lapatinib-resistant human non-small lung carcinoma (NCI-H1975) cells, harboring T790 M mutation, with IC50 of 4.2 μM.  Consistently, 27b significantly blocked EGF-induced EGFR activation and inactivated its downstream AKT/mTOR/S6 signalling pathway triggering apoptotic cell death in NCI-H1975 cells.  The present study presents a promising candidate for further design and development of novel EGFR/HER2 inhibitors capable of overcoming EGFR TKIs resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR7DEfVDfa_rVg90H21EOLACvtfcHk0lg-cqodvC7Lng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFemsbzK&md5=d4c6b29330f43b8ca3f7f3f6e2e85f8c</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DMilik%26aufirst%3DS.%2BN.%26aulast%3DAbdel-Aziz%26aufirst%3DA.%2BK.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DSerya%26aufirst%3DR.%2BA.%2BT.%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DSurmounting%2520the%2520resistance%2520against%2520EGFR%2520inhibitors%2520through%2520the%2520development%2520of%2520thieno%255B2%252C3-d%255Dpyrimidine-based%2520dual%2520EGFR%252FHER2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D316%26epage%3D336%26doi%3D10.1016%2Fj.ejmech.2018.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higdon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillerman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderstrom, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauth, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolov, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2003.10.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=21-24&author=M.+J.+Munchhofauthor=J.+S.+Beebeauthor=J.+M.+Casavantauthor=B.+A.+Cooperauthor=J.+L.+Dotyauthor=R.+C.+Higdonauthor=S.+M.+Hillermanauthor=C.+I.+Soderstromauthor=E.+A.+Knauthauthor=M.+A.+Marxauthor=A.+M.+Rossiauthor=S.+B.+Sobolovauthor=J.+Sun&title=Design+and+SAR+of+thienopyrimidine+and+thienopyridine+inhibitors+of+VEGFR-2+kinase+activity&doi=10.1016%2Fj.bmcl.2003.10.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DHigdon%26aufirst%3DR.%2BC.%26aulast%3DHillerman%26aufirst%3DS.%2BM.%26aulast%3DSoderstrom%26aufirst%3DC.%2BI.%26aulast%3DKnauth%26aufirst%3DE.%2BA.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DSobolov%26aufirst%3DS.%2BB.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520SAR%2520of%2520thienopyrimidine%2520and%2520thienopyridine%2520inhibitors%2520of%2520VEGFR-2%2520kinase%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D21%26epage%3D24%26doi%3D10.1016%2Fj.bmcl.2003.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kemnitzer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisoma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S. X.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-anilino-<i>N</i>-methylthieno[3,2-<i>d</i>]pyrimidines and 4-anilino-<i>N</i>-methylthieno[2,3-<i>d</i>]pyrimidines as potent apoptosis inducers</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3536</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2009.04.145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3536-3540&author=W.+Kemnitzerauthor=N.+Sirisomaauthor=C.+Mayauthor=B.+Tsengauthor=J.+Dreweauthor=S.+X.+Cai&title=Discovery+of+4-anilino-N-methylthieno%5B3%2C2-d%5Dpyrimidines+and+4-anilino-N-methylthieno%5B2%2C3-d%5Dpyrimidines+as+potent+apoptosis+inducers&doi=10.1016%2Fj.bmcl.2009.04.145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.145%26sid%3Dliteratum%253Aachs%26aulast%3DKemnitzer%26aufirst%3DW.%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DMay%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DDiscovery%2520of%25204-anilino-N-methylthieno%255B3%252C2-d%255Dpyrimidines%2520and%25204-anilino-N-methylthieno%255B2%252C3-d%255Dpyrimidines%2520as%2520potent%2520apoptosis%2520inducers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3536%26epage%3D3540%26doi%3D10.1016%2Fj.bmcl.2009.04.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bugge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buene, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurisch-Yaksi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moen, I. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skjønsfjell, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, B. H.</span></span> <span> </span><span class="NLM_article-title">Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2015.11.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=255-274&author=S.+Buggeauthor=A.+F.+Bueneauthor=N.+Jurisch-Yaksiauthor=I.+U.+Moenauthor=E.+M.+Skj%C3%B8nsfjellauthor=E.+Sundbyauthor=B.+H.+Hoff&title=Extended+structure-activity+study+of+thienopyrimidine-based+EGFR+inhibitors+with+evaluation+of+drug-like+properties&doi=10.1016%2Fj.ejmech.2015.11.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DBugge%26aufirst%3DS.%26aulast%3DBuene%26aufirst%3DA.%2BF.%26aulast%3DJurisch-Yaksi%26aufirst%3DN.%26aulast%3DMoen%26aufirst%3DI.%2BU.%26aulast%3DSkj%25C3%25B8nsfjell%26aufirst%3DE.%2BM.%26aulast%3DSundby%26aufirst%3DE.%26aulast%3DHoff%26aufirst%3DB.%2BH.%26atitle%3DExtended%2520structure-activity%2520study%2520of%2520thienopyrimidine-based%2520EGFR%2520inhibitors%2520with%2520evaluation%2520of%2520drug-like%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D107%26spage%3D255%26epage%3D274%26doi%3D10.1016%2Fj.ejmech.2015.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetter, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binnun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Mazza, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes-Pesquera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, S. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-<i>d</i>]pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2333</span>– <span class="NLM_lpage">2337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2009.02.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2333-2337&author=R.+Linauthor=S.+G.+Johnsonauthor=P.+J.+Connollyauthor=S.+K.+Wetterauthor=E.+Binnunauthor=T.+V.+Hughesauthor=W.+V.+Murrayauthor=N.+B.+Pandeyauthor=S.+J.+Moreno-Mazzaauthor=M.+Adamsauthor=A.+R.+Fuentes-Pesqueraauthor=S.+A.+Middleton&title=Synthesis+and+evaluation+of+2%2C7-diamino-thiazolo%5B4%2C5-d%5Dpyrimidine+analogues+as+anti-tumor+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2009.02.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.067%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DS.%2BG.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DWetter%26aufirst%3DS.%2BK.%26aulast%3DBinnun%26aufirst%3DE.%26aulast%3DHughes%26aufirst%3DT.%2BV.%26aulast%3DMurray%26aufirst%3DW.%2BV.%26aulast%3DPandey%26aufirst%3DN.%2BB.%26aulast%3DMoreno-Mazza%26aufirst%3DS.%2BJ.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25202%252C7-diamino-thiazolo%255B4%252C5-d%255Dpyrimidine%2520analogues%2520as%2520anti-tumor%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2333%26epage%3D2337%26doi%3D10.1016%2Fj.bmcl.2009.02.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of analogues of (<i>Z</i>)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2293</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1021/jm00090a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00090a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2293-2306&author=M.+Cushmanauthor=D.+Nagarathnamauthor=D.+Gopalauthor=H.-M.+Heauthor=C.+M.+Linauthor=E.+Hamel&title=Synthesis+and+evaluation+of+analogues+of+%28Z%29-1-%284-methoxyphenyl%29-2-%283%2C4%2C5-trimethoxyphenyl%29ethene+as+potential+cytotoxic+and+antimitotic+agents&doi=10.1021%2Fjm00090a021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Fjm00090a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00090a021%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DGopal%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.-M.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520analogues%2520of%2520%2528Z%2529-1-%25284-methoxyphenyl%2529-2-%25283%252C4%252C5-trimethoxyphenyl%2529ethene%2520as%2520potential%2520cytotoxic%2520and%2520antimitotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2293%26epage%3D2306%26doi%3D10.1021%2Fjm00090a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nihei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span> <span> </span><span class="NLM_article-title">Novel B-ring modified combretastatin analogues: synthesis and antineoplastic activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3371</span>– <span class="NLM_lpage">3374</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00622-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2FS0960-894X%2898%2900622-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3371-3374&author=T.+Hatanakaauthor=K.+Fujitaauthor=K.+Ohsumiauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=Y.+Niheiauthor=Y.+Sugaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Novel+B-ring+modified+combretastatin+analogues%3A+synthesis+and+antineoplastic+activity&doi=10.1016%2FS0960-894X%2898%2900622-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900622-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900622-2%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DNovel%2520B-ring%2520modified%2520combretastatin%2520analogues%253A%2520synthesis%2520and%2520antineoplastic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3371%26epage%3D3374%26doi%3D10.1016%2FS0960-894X%2898%2900622-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luqman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konwar, R.</span></span> <span> </span><span class="NLM_article-title">Natural antitubulin agents: Importance of 3,4,5-trimethoxyphenyl fragment</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2014.12.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=373-389&author=A.+S.+Negiauthor=Y.+Gautamauthor=S.+Alamauthor=D.+Chandaauthor=S.+Luqmanauthor=J.+Sarkarauthor=F.+Khanauthor=R.+Konwar&title=Natural+antitubulin+agents%3A+Importance+of+3%2C4%2C5-trimethoxyphenyl+fragment&doi=10.1016%2Fj.bmc.2014.12.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.027%26sid%3Dliteratum%253Aachs%26aulast%3DNegi%26aufirst%3DA.%2BS.%26aulast%3DGautam%26aufirst%3DY.%26aulast%3DAlam%26aufirst%3DS.%26aulast%3DChanda%26aufirst%3DD.%26aulast%3DLuqman%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DF.%26aulast%3DKonwar%26aufirst%3DR.%26atitle%3DNatural%2520antitubulin%2520agents%253A%2520Importance%2520of%25203%252C4%252C5-trimethoxyphenyl%2520fragment%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D373%26epage%3D389%26doi%3D10.1016%2Fj.bmc.2014.12.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devambatla, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and preclinical evaluation of 5-methyl-N<sup>4</sup>-aryl-furo[2,3-<i>d</i>]pyrimidines as single agents with combination chemotherapy potential</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3085</span>– <span class="NLM_lpage">3093</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2018.07.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3085-3093&author=R.+K.+V.+Devambatlaauthor=S.+Choudharyauthor=M.+Ihnatauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=Design%2C+synthesis+and+preclinical+evaluation+of+5-methyl-N4-aryl-furo%5B2%2C3-d%5Dpyrimidines+as+single+agents+with+combination+chemotherapy+potential&doi=10.1016%2Fj.bmcl.2018.07.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DDevambatla%26aufirst%3DR.%2BK.%2BV.%26aulast%3DChoudhary%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520preclinical%2520evaluation%2520of%25205-methyl-N4-aryl-furo%255B2%252C3-d%255Dpyrimidines%2520as%2520single%2520agents%2520with%2520combination%2520chemotherapy%2520potential%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3085%26epage%3D3093%26doi%3D10.1016%2Fj.bmcl.2018.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavana, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical evaluation of 7-benzyl-<i>N</i>-(substituted)-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2016.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27894589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=545-556&author=R.+K.+Pavanaauthor=S.+Choudharyauthor=A.+Bastianauthor=M.+A.+Ihnatauthor=R.+Baiauthor=E.+Hamelauthor=A.+Gangjee&title=Discovery+and+preclinical+evaluation+of+7-benzyl-N-%28substituted%29-pyrrolo%5B3%2C2-d%5Dpyrimidin-4-amines+as+single+agents+with+microtubule+targeting+effects+along+with+triple-acting+angiokinase+inhibition+as+antitumor+agents&doi=10.1016%2Fj.bmc.2016.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span></div><div class="casAuthors">Pavana, Roheeth Kumar; Choudhary, Shruti; Bastian, Anja; Ihnat, Michael A.; Bai, Ruoli; Hamel, Ernest; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The utility of cytostatic antiangiogenic agents (AA) in cancer chemotherapy lies in their combination with cytotoxic chemotherapeutic agents.  Clin. combinations of AA with microtubule targeting agents (MTAs) have been particularly successful.  The discovery, synthesis and biol. evaluations of a series of 7-benzyl-N-substituted-pyrrolo[3,2-d]pyrimidin-4-amines are reported.  Novel compds. which inhibit proangiogenic receptor tyrosine kinases (RTKs) including vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β) and epidermal growth factor receptor (EGFR), along with microtubule targeting in single mols. are described.  These compds. also inhibited blood vessel formation in the chicken chorioallantoic membrane (CAM) assay, and some potently inhibited tubulin assembly (with activity comparable to that of combretastatin A-4 (CA)).  In addn., some of the analogs circumvent the most clin. relevant tumor resistance mechanisms (P-glycoprotein and β-III tubulin expression) to microtubule targeting agents (MTA).  These MTAs bind at the colchicine site on tubulin.  Two analogs displayed two to three digit nanomolar GIC50 values across the entire NCI 60 tumor cell panel and one of these, compd. 7, freely water sol. as its HCl salt, afforded excellent in vivo antitumor activity against an orthotopic triple neg. 4T1 breast cancer model and was superior to doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwGOvmBOf0h7Vg90H21EOLACvtfcHk0lifjbptM3lIvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM&md5=9fd3c0008bda8c9222761f9d344610e6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DPavana%26aufirst%3DR.%2BK.%26aulast%3DChoudhary%26aufirst%3DS.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520preclinical%2520evaluation%2520of%25207-benzyl-N-%2528substituted%2529-pyrrolo%255B3%252C2-d%255Dpyrimidin-4-amines%2520as%2520single%2520agents%2520with%2520microtubule%2520targeting%2520effects%2520along%2520with%2520triple-acting%2520angiokinase%2520inhibition%2520as%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D545%26epage%3D556%26doi%3D10.1016%2Fj.bmc.2016.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-<i>d</i>]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2015.03.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25882519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2408-2423&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=E.+Hamelauthor=C.+Zammielloauthor=A.+Bastianauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design%2C+synthesis+and+biological+evaluation+of+conformationally+restricted+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multi-targeted+receptor+tyrosine+kinase+and+microtubule+inhibitors+as+potential+antitumor+agents&doi=10.1016%2Fj.bmc.2015.03.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Hamel, Ernest; Zammiello, Cynthia; Bastian, Anja; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2423</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of eleven conformationally restricted, 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines was designed to explore the bioactive conformation required for dual inhibition of microtubule assembly and receptor tyrosine kinases (RTKs), and their biol. activities are reported.  All three rotatable single bonds in the lead compd. were sequentially restricted to address the role of each in SAR for microtubule and RTK inhibitory effects.  Several compds. showed microtubule depolymg. activity comparable to or better than the lead compd., some with nanomolar EC50 values.  One compd. had no effect on microtubules, others showed potent RTK inhibition with nanomolar IC50s.  These compds. confirm that the bioactive conformation for RTK inhibition is different from that for tubulin inhibition.  A tetrahydroquinoline analog showed the most potent dual tubulin inhibitors (i.e., tubulin polymn. inhibitors, microtubule-disrupting agents) and RTK inhibitory activities [i.e., low nanomolar inhibition of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFR-β)].  The tetrahydroquinoline analog has highly potent activity against many NCI cancer cell lines, including several chemo-resistant cell lines, and could serve as a lead for further preclin. studies.  The synthesis of the target compds. was achieved by a reaction of 4-chloro-2,6-dimethylfuro[2,3-d]pyrimidine with amine derivs., such as benzenamine derivs., benzofuranamine derivs., tetrahydroquinoline derivs., indole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3IUVQLu9YarVg90H21EOLACvtfcHk0liTVjs4seEhbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D&md5=4a6d65424606155db3ab4ec5751ad213</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DZammiello%26aufirst%3DC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multi-targeted%2520receptor%2520tyrosine%2520kinase%2520and%2520microtubule%2520inhibitors%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2408%26epage%3D2423%26doi%3D10.1016%2Fj.bmc.2015.03.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, M. F.</span></span> <span> </span><span class="NLM_article-title">The design and development of potent small molecules as anticancer agents targeting EGFR TK and tubulin polymerization</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">408</span>, <span class="refDoi"> DOI: 10.3390/ijms19020408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fijms19020408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=408&author=S.+Ihmaidauthor=H.+E.+A.+Ahmedauthor=M.+F.+Zayed&title=The+design+and+development+of+potent+small+molecules+as+anticancer+agents+targeting+EGFR+TK+and+tubulin+polymerization&doi=10.3390%2Fijms19020408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The design and development of potent small molecules as anticancer agents targeting EGFR TK and tubulin polymerization</span></div><div class="casAuthors">Ihmaid, Saleh; Ahmed, Hany E. A.; Zayed, Mohamed F.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">408/1-408/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Some novel anthranilate diamides derivs. 4a-e, 6a-c and 9a-d were designed and synthesized to be evaluated for their in vitro anticancer activity.  Structures of all newly synthesized compds. were confirmed by infra-red (IR), high-resoln. mass (HR-MS) spectra, 1H NMR (NMR) and 13C NMR (NMR) analyses.  Cytotoxic screening was performed according to (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium (MTT) assay method using erlotinib as a ref. drug against two different types of breast cancer cells.  The mol. docking study was performed for representative compds. against two targets, epidermal growth factor receptor (EGFR) and tubulin in colchicine binding site to assess their binding affinities in order to rationalize their anticancer activity in a qual. way.  The data obtained from the mol. modeling was correlated with that obtained from the biol. screening.  These data showed considerable anticancer activity for these newly synthesized compds.  Biol. data for most of the anthranilate diamide showed excellent activity with nanomolar or sub nanomolar half maximal inhibitory concn. (IC50) values against tumor cells.  EGFR tyrosine kinase (TK) inhibition assay, tubulin inhibition assay and apoptosis anal. were performed for selected compds. to get more details about their mechanism of action.  Extensive structure activity relationship (SAR) analyses were also carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Hwp1J1XowrVg90H21EOLACvtfcHk0liTVjs4seEhbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7bJ&md5=c1eb543d1cac9d6f6a39d8ec807ac70d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3390%2Fijms19020408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19020408%26sid%3Dliteratum%253Aachs%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DH.%2BE.%2BA.%26aulast%3DZayed%26aufirst%3DM.%2BF.%26atitle%3DThe%2520design%2520and%2520development%2520of%2520potent%2520small%2520molecules%2520as%2520anticancer%2520agents%2520targeting%2520EGFR%2520TK%2520and%2520tubulin%2520polymerization%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D408%26doi%3D10.3390%2Fijms19020408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mphahlele, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maluleka, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parbhoo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malindisa, S. T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, evaluation for cytotoxicity and molecular docking studies of benzo[<i>c</i>]furan-chalcones for potential to inhibit tubulin polymerization and/or EGFR-tyrosine kinase phosphorylation</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2552</span>, <span class="refDoi"> DOI: 10.3390/ijms19092552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fijms19092552" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2552&author=M.+J.+Mphahleleauthor=M.+M.+Malulekaauthor=N.+Parbhooauthor=S.+T.+Malindisa&title=Synthesis%2C+evaluation+for+cytotoxicity+and+molecular+docking+studies+of+benzo%5Bc%5Dfuran-chalcones+for+potential+to+inhibit+tubulin+polymerization+and%2For+EGFR-tyrosine+kinase+phosphorylation&doi=10.3390%2Fijms19092552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3390%2Fijms19092552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19092552%26sid%3Dliteratum%253Aachs%26aulast%3DMphahlele%26aufirst%3DM.%2BJ.%26aulast%3DMaluleka%26aufirst%3DM.%2BM.%26aulast%3DParbhoo%26aufirst%3DN.%26aulast%3DMalindisa%26aufirst%3DS.%2BT.%26atitle%3DSynthesis%252C%2520evaluation%2520for%2520cytotoxicity%2520and%2520molecular%2520docking%2520studies%2520of%2520benzo%255Bc%255Dfuran-chalcones%2520for%2520potential%2520to%2520inhibit%2520tubulin%2520polymerization%2520and%252For%2520EGFR-tyrosine%2520kinase%2520phosphorylation%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2552%26doi%3D10.3390%2Fijms19092552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rateb, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, S. R. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, cytotoxic evaluation and molecular docking of new fluoroquinazolinones as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1731</span>, <span class="refDoi"> DOI: 10.3390/ijms19061731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fijms19061731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWmsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1731&author=M.+F.+Zayedauthor=S.+Ahmedauthor=S.+Ihmaidauthor=H.+E.+A.+Ahmedauthor=H.+S.+Ratebauthor=S.+R.+M.+Ibrahim&title=Design%2C+synthesis%2C+cytotoxic+evaluation+and+molecular+docking+of+new+fluoroquinazolinones+as+potent+anticancer+agents+with+dual+EGFR+kinase+and+tubulin+polymerization+inhibitory+effects&doi=10.3390%2Fijms19061731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, cytotoxic evaluation and molecular docking of new fluoroquinazolinones as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span></div><div class="casAuthors">Zayed, Mohamed; Ahmed, Sahar; Ihmaid, Saleh; Ahmed, Hany; Rateb, Heba; Ibrahim, Sabrin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1731/1-1731/16</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A series of new fluoroquinazolinone 6-8 and 10a-g derivs. was designed, prepd. and screened for their in vitro cytotoxic activity against human cancer cell lines MCF-7 and MDA-MBA-231.  Compds. 6 (IC50 = 0.35 ± 0.01 μM), 10f (IC50 = 0.71 ± 0.01 μM), 10d (IC50 = 0.89 ± 0.02 μM) and 10a (IC50 = 0.95 ± 0.01 μM) displayed broad spectrum anticancer activity better than the ref. drug gefitinib (IC50 = 0.97 ± 0.02 μM) against MCF-7.  Compds. 10e (IC50 = 0.28 ± 0.02 μM), 10d (IC50 = 0.38 ± 0.01 μM), 7 (IC50 = 0.94 ± 0.07 μM) and 10c (IC50 = 1.09 ± 0.01 μM) showed better activity than the ref. gefitinib (IC50 = 1.30 ± 0.04 μM) againstMDA-MBA-231.  Moreover, EGFR and tubulin inhibition assays were performed for the highest active derivs. and showed remarkable results comparing to the ref. drugs.  In order to assess and explain their binding affinities,mol. docking simulation was studied against EGFR and tubulin binding sites.  The results obtained from mol. docking study and those obtained from cytotoxic screening were correlated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ztVlxQjMObVg90H21EOLACvtfcHk0liSXYkSJeRGTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWmsLfM&md5=47d6f49bcc9d35d59c6fb45e0936f08c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3390%2Fijms19061731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19061731%26sid%3Dliteratum%253Aachs%26aulast%3DZayed%26aufirst%3DM.%2BF.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DH.%2BE.%2BA.%26aulast%3DRateb%26aufirst%3DH.%2BS.%26aulast%3DIbrahim%26aufirst%3DS.%2BR.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520cytotoxic%2520evaluation%2520and%2520molecular%2520docking%2520of%2520new%2520fluoroquinazolinones%2520as%2520potent%2520anticancer%2520agents%2520with%2520dual%2520EGFR%2520kinase%2520and%2520tubulin%2520polymerization%2520inhibitory%2520effects%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1731%26doi%3D10.3390%2Fijms19061731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rateb, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, S. R. M.</span></span> <span> </span><span class="NLM_article-title">Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and tubulin polymerization</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1699</span>, <span class="refDoi"> DOI: 10.3390/molecules23071699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fmolecules23071699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWgt7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1699&author=M.+F.+Zayedauthor=H.+S.+Ratebauthor=S.+Ahmedauthor=O.+A.+Khaledauthor=S.+R.+M.+Ibrahim&title=Quinazolinone-amino+acid+hybrids+as+dual+inhibitors+of+EGFR+kinase+and+tubulin+polymerization&doi=10.3390%2Fmolecules23071699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and tubulin polymerization</span></div><div class="casAuthors">Zayed, Mohamed F.; Rateb, Heba S.; Ahmed, Sahar; Khaled, Osama A.; Ibrahim, Sabrin R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699/1-1699/17</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Some fluoroquinazolinones (A-H) were designed, synthesized and biol. evaluated for their antitumor activity against the two cell lines, MCF-7 and MDA-MBA-231.  New deriv. G (IC50 = 0.44 ± 0.01 μM) showed antitumor activity, better than that of the ref. drug erlotinib (IC50 = 1.14 ± 0.04 μM) against MCF-7.  New deriv. E (IC50 = 0.43 ± 0.02 μM) showed higher activity than the ref. drug erlotinib (IC50 = 2.55 ± 0.19 μM) against MDA-MBA-231.  Furthermore, the EGFR (epidermal growth factor receptor) and tubulin inhibition assays were carried out for the highest active derivs. to reveal the expected mechanism of action.  They exhibited significant results compared to the ref. drugs.  Mol. docking simulations were performed on EGFR and tubulin binding sites to rationalize the exptl. results and describe their binding modes.  The results of the mol. modeling study were correlated with that of the antitumor screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquX3CVwn1JtbVg90H21EOLACvtfcHk0liSXYkSJeRGTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWgt7rO&md5=212c5aa690adf5c4f7b3064b4a0dd4f9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23071699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23071699%26sid%3Dliteratum%253Aachs%26aulast%3DZayed%26aufirst%3DM.%2BF.%26aulast%3DRateb%26aufirst%3DH.%2BS.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DKhaled%26aufirst%3DO.%2BA.%26aulast%3DIbrahim%26aufirst%3DS.%2BR.%2BM.%26atitle%3DQuinazolinone-amino%2520acid%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520EGFR%2520kinase%2520and%2520tubulin%2520polymerization%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D1699%26doi%3D10.3390%2Fmolecules23071699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alswah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgamal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmorsy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. E. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing triazolo[4,3-<i>a</i>]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">48</span>, <span class="refDoi"> DOI: 10.3390/molecules23010048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fmolecules23010048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyhsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=48&author=M.+Alswahauthor=A.+H.+Bayoumiauthor=K.+Elgamalauthor=A.+Elmorsyauthor=S.+Ihmaidauthor=H.+E.+A.+Ahmed&title=Design%2C+synthesis+and+cytotoxic+evaluation+of+novel+chalcone+derivatives+bearing+triazolo%5B4%2C3-a%5D-quinoxaline+moieties+as+potent+anticancer+agents+with+dual+EGFR+kinase+and+tubulin+polymerization+inhibitory+effects&doi=10.3390%2Fmolecules23010048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing triazolo[4,3-a]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span></div><div class="casAuthors">Alswah, Mohamed; Bayoumi, Ashraf H.; Elgamal, Kamal; Elmorsy, Ahmed; Ihmaid, Saleh; Ahmed, Hany E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-63</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A series of hybrid of triazoloquinoxaline-chalcone derivs. 7a-k were designed, synthesized, fully characterized, and evaluated for their cytotoxic activity against three target cell lines: human breast adenocarcinoma (MCF-7), human colon carcinoma (HCT-116), and human hepatocellular carcinoma (HEPG-2).  The preliminary results showed that some of these chalcones like 7b-c, and 7e-g exhibited significant antiproliferative effects against most of the cell lines, with selective or non-selective behavior, indicated by IC50 values in the 1.65 to 34.28 μM range.  In order to investigate the mechanistic aspects of these active compds., EGFR TK and tubulin inhibitory activities were measured as further biol. assays.  The EGFR TK assay results revealed that the derivs. 7a-c, 7e, and 7g could inhibit the EGFR TK in the submicromolar range (0.093 to 0.661 μM).  Moreover, an antitubulin polymn. effect was noted for the active derivs. compared to the ref. drug colchicine, with compds. 7e and 7g displaying 14.7 and 8.4 micromolar activity, resp.  Furthermore, a mol. docking study was carried out to explain the obsd. effects and the binding modes of these chalcones with the EGFR TK and tubulin targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEB9NazeaK9rVg90H21EOLACvtfcHk0liSXYkSJeRGTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyhsL7I&md5=5e85313ba8f03cd5eda031d3f838dd09</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23010048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23010048%26sid%3Dliteratum%253Aachs%26aulast%3DAlswah%26aufirst%3DM.%26aulast%3DBayoumi%26aufirst%3DA.%2BH.%26aulast%3DElgamal%26aufirst%3DK.%26aulast%3DElmorsy%26aufirst%3DA.%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DH.%2BE.%2BA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520cytotoxic%2520evaluation%2520of%2520novel%2520chalcone%2520derivatives%2520bearing%2520triazolo%255B4%252C3-a%255D-quinoxaline%2520moieties%2520as%2520potent%2520anticancer%2520agents%2520with%2520dual%2520EGFR%2520kinase%2520and%2520tubulin%2520polymerization%2520inhibitory%2520effects%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D48%26doi%3D10.3390%2Fmolecules23010048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0lhorxRSllXdBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-alkoxycarbonyl-3-anilino benzo[<i>b</i>]thiophenes and thieno[2,3-<i>c</i>]pyridines as new potent anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2606</span>– <span class="NLM_lpage">2618</span>, <span class="refDoi"> DOI: 10.1021/jm400043d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400043d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2606-2618&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=D.+Pretiauthor=M.+A.+Tabriziauthor=M.+Bassettoauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Synthesis+and+biological+evaluation+of+2-alkoxycarbonyl-3-anilino+benzo%5Bb%5Dthiophenes+and+thieno%5B2%2C3-c%5Dpyridines+as+new+potent+anticancer+agents&doi=10.1021%2Fjm400043d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm400043d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400043d%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBassetto%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-alkoxycarbonyl-3-anilino%2520benzo%255Bb%255Dthiophenes%2520and%2520thieno%255B2%252C3-c%255Dpyridines%2520as%2520new%2520potent%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2606%26epage%3D2618%26doi%3D10.1021%2Fjm400043d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lhorxRSllXdBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosako, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okigaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">25543</span>– <span class="NLM_lpage">25549</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.36.25543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1074%2Fjbc.274.36.25543" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=25543-25549&author=H.+Gotoauthor=Y.+Tomonoauthor=K.+Ajiroauthor=H.+Kosakoauthor=M.+Fujitaauthor=M.+Sakuraiauthor=K.+Okawaauthor=A.+Iwamatsuauthor=T.+Okigakiauthor=T.+Takahashiauthor=M.+Inagaki&title=Identification+of+a+novel+phosphorylation+site+on+histone+H3+coupled+with+mitotic+chromosome+condensation&doi=10.1074%2Fjbc.274.36.25543"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.36.25543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.36.25543%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DH.%26aulast%3DTomono%26aufirst%3DY.%26aulast%3DAjiro%26aufirst%3DK.%26aulast%3DKosako%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DOkawa%26aufirst%3DK.%26aulast%3DIwamatsu%26aufirst%3DA.%26aulast%3DOkigaki%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DInagaki%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520a%2520novel%2520phosphorylation%2520site%2520on%2520histone%2520H3%2520coupled%2520with%2520mitotic%2520chromosome%2520condensation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D25543%26epage%3D25549%26doi%3D10.1074%2Fjbc.274.36.25543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">Mitochondria-mediated apoptosis in mammals</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1007/s13238-014-0089-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2Fs13238-014-0089-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25073422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KmtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=737-749&author=S.+Xiongauthor=T.+Muauthor=G.+Wangauthor=X.+Jiang&title=Mitochondria-mediated+apoptosis+in+mammals&doi=10.1007%2Fs13238-014-0089-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria-mediated apoptosis in mammals</span></div><div class="casAuthors">Xiong, Shunbin; Mu, Tianyang; Wang, Guowen; Jiang, Xuejun</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  The mitochondria-mediated caspase activation pathway is a major apoptotic pathway characterized by mitochondrial outer membrane permeabilization (MOMP) and subsequent release of cytochrome c into the cytoplasm to activate caspases.  MOMP is regulated by the Bcl-2 family of proteins.  This pathway plays important roles not only in normal development, maintenance of tissue homeostasis and the regulation of immune system, but also in human diseases such as immune disorders, neurodegeneration and cancer.  In the past decades the mol. basis of this pathway and the regulatory mechanism have been comprehensively studied, yet a great deal of new evidence indicates that cytochrome c release from mitochondria does not always lead to irreversible cell death, and that caspase activation can also have non-death functions.  Thus, many unsolved questions and new challenges are still remaining.  Furthermore, the dysfunction of this pathway involved in cancer development is obvious, and targeting the pathway as a therapeutic strategy has been extensively explored, but the efficacy of the targeted therapies is still under development.  In this review we will discuss the mitochondria-mediated apoptosis pathway and its physiol. roles and therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjf5-e940_9bVg90H21EOLACvtfcHk0ljJxE188N-gig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KmtbbK&md5=184dc962ee08b440729fda6ec65ecc10</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs13238-014-0089-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-014-0089-1%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DS.%26aulast%3DMu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DX.%26atitle%3DMitochondria-mediated%2520apoptosis%2520in%2520mammals%26jtitle%3DProtein%2520Cell%26date%3D2014%26volume%3D5%26spage%3D737%26epage%3D749%26doi%3D10.1007%2Fs13238-014-0089-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rovini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carré, M.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeted agents: when mitochondria become essential to chemotherapy</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1807</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1016/j.bbabio.2011.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bbabio.2011.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21216222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFSitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1807&publication_year=2011&pages=679-688&author=A.+Roviniauthor=A.+Savryauthor=D.+Braguerauthor=M.+Carr%C3%A9&title=Microtubule-targeted+agents%3A+when+mitochondria+become+essential+to+chemotherapy&doi=10.1016%2Fj.bbabio.2011.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeted agents: When mitochondria become essential to chemotherapy</span></div><div class="casAuthors">Rovini, A.; Savry, A.; Braguer, D.; Carre, M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1807</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-688</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Microtubule-Targeting Agents (MTAs) constitute a class of drugs largely used for cancer treatment in adults and children.  In cancer cells, they suppress microtubule dynamics, and induce cell death via the mitochondrial intrinsic pathway.  To date, links between mitochondria and microtubule network disturbance in MTAs mechanism of action are not obvious.  The aim of the present contribution is to provide elements that could answer to the question: how far are mitochondria essential to anticancer chemotherapy that targets the microtubule cytoskeleton We review the main mol. candidates to link microtubule alteration with the apoptotic mitochondrial pathway control.  Involvement of direct targeting of mitochondria in MTA efficacy is also discussed.  Furthermore, we line up current evidence and emerging concepts on the participation of both mitochondria and microtubule in MTA neurotoxic side effects.  To decipher the interconnections between the mitochondrial and the microtubule networks may help to improve cancer cell response to chemotherapy.  This article is part of a Special Issue entitled: Bioenergetics of Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHCjULnreE0rVg90H21EOLACvtfcHk0ljJxE188N-gig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFSitro%253D&md5=2afa1b9807076eaa0696d5d959f9457b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2011.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2011.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRovini%26aufirst%3DA.%26aulast%3DSavry%26aufirst%3DA.%26aulast%3DBraguer%26aufirst%3DD.%26aulast%3DCarr%25C3%25A9%26aufirst%3DM.%26atitle%3DMicrotubule-targeted%2520agents%253A%2520when%2520mitochondria%2520become%2520essential%2520to%2520chemotherapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2011%26volume%3D1807%26spage%3D679%26epage%3D688%26doi%3D10.1016%2Fj.bbabio.2011.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Policarpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenciarelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanzarella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoccia, A.</span></span> <span> </span><span class="NLM_article-title">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison combretastatin-A4</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1007/s10495-011-0619-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2Fs10495-011-0619-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21671007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=940-949&author=G.+Mendezauthor=C.+Policarpiauthor=C.+Cenciarelliauthor=C.+Tanzarellaauthor=A.+Antoccia&title=Role+of+Bim+in+apoptosis+induced+in+H460+lung+tumor+cells+by+the+spindle+poison+combretastatin-A4&doi=10.1007%2Fs10495-011-0619-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison Combretastatin-A4</span></div><div class="casAuthors">Mendez, G.; Policarpi, C.; Cenciarelli, C.; Tanzarella, C.; Antoccia, A.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-949</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The BH3-only Bcl-2 subfamily member Bim is a well known apoptosis promoting protein.  However, the mechanisms upstream of mitochondrion membrane permeability by which Bim is involved in apoptosis have been poorly investigated, particularly in response to agents capable of interfering with the cytoskeleton architecture and arresting cells in mitosis.  Based on the observation that Bim is sequestered on the microtubule-array by interaction with the light chain of dynein, we have investigated upon depolymn., whether Bim could be involved in the commitment of apoptosis.  With this purpose H460 Non Small Lung Cancer Cells (NSLC) were treated with the microtubule damaging agent combretastatin-A4 (CA-4) (7.5 nM; 8-48 h), and various parameters were investigated.  Upon treatment, cells arrested in mitosis and died through a caspase-3-dependent mitotic catastrophe.  Transient knock down of Bim drastically reduced apoptosis, indicating that this protein was involved in cell death as induced by microtubules disorganisation.  In response to increasing conditions of microtubules depolymn., we found that the protein level of Bim was strongly upregulated in a time-dependent manner at transcriptional level.  Furthermore, Bim was released from microtubule-assocd. components.  Bim was translocated to mitochondria, even in a condition of protein synthesis inhibition, where it showed a markedly increased interaction with Bcl-2.  In turn, the fraction of Bax bound to Bcl-2 decreases in response to treatment, thereby indicating that Bim possibly promotes Bax release from the pro-survival protein Bcl-2.  Overall, we demonstrated that Bim is required for the CA-4-induced cell death in the H460 lung cancer cell line via activation of the mitochondrial signalling pathway.  Defining the contribution of Bim to the mechanism of apoptosis may offer some different clues in view of developing new strategies for chemotherapy with CA-4, underlining the relevance of the cytoskeleton integrity in the apoptotic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFAXUMi6LRGLVg90H21EOLACvtfcHk0ljJxE188N-gig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF&md5=f2c8e59481098e10b8939421d59170b9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs10495-011-0619-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-011-0619-8%26sid%3Dliteratum%253Aachs%26aulast%3DMendez%26aufirst%3DG.%26aulast%3DPolicarpi%26aufirst%3DC.%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DRole%2520of%2520Bim%2520in%2520apoptosis%2520induced%2520in%2520H460%2520lung%2520tumor%2520cells%2520by%2520the%2520spindle%2520poison%2520combretastatin-A4%26jtitle%3DApoptosis%26date%3D2011%26volume%3D16%26spage%3D940%26epage%3D949%26doi%3D10.1007%2Fs10495-011-0619-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a series of 2-aryl-4-amino-5-(3′,4′,5′-trimethoxybenzoyl)thiazoles as novel anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5433</span>– <span class="NLM_lpage">5445</span>, <span class="refDoi"> DOI: 10.1021/jm300388h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300388h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvV2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5433-5445&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=D.+Pretiauthor=M.+A.+Tabriziauthor=A.+Brancaleauthor=X.-H.+Fuauthor=J.+Liauthor=S.-Z.+Zhangauthor=E.+Hamelauthor=R.+Bortolozziauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Discovery+and+optimization+of+a+series+of+2-aryl-4-amino-5-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29thiazoles+as+novel+anticancer+agents&doi=10.1021%2Fjm300388h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Salvador, Maria Kimatrai; Preti, Delia; Aghazadeh Tabrizi, Mojgan; Brancale, Andrea; Fu, Xian-Hua; Li, Jun; Zhang, Su-Zhan; Hamel, Ernest; Bortolozzi, Roberta; Porcu, Elena; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5433-5445</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of tubulin polymn. inhibitors based on the 2-aryl/heteroaryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole scaffold was synthesized and evaluated for growth inhibition activity on a panel of cancer cell lines, cell cycle effects, and in vivo potency.  Structure-activity relationships were elucidated with various substitutions at the 2-position of the thiazole skeleton.  Hydrophobic moieties, such as Ph and 3-thienyl, were well tolerated at this position, and variation of the Ph substituents had remarkable effects on potency.  The most active compd. I induced apoptosis through the mitochondrial pathway with activation of caspase-3.  We also showed that it has potential antivascular activity since it reduced in vitro endothelial cell migration and disrupted capillary-like tube formation at noncytotoxic concns.  Furthermore, compd. I significantly reduced the growth of the HT-29 xenograft in a nude mouse model, suggesting that I is a promising new antimitotic agent with clin. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrquOj-EUDFwbVg90H21EOLACvtfcHk0lgyjnOGp_OlAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvV2mtLk%253D&md5=bc98bb15015c3163a9913bd5bdc6383a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm300388h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300388h%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DX.-H.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.-Z.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520series%2520of%25202-aryl-4-amino-5-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529thiazoles%2520as%2520novel%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5433%26epage%3D5445%26doi%3D10.1021%2Fjm300388h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolasi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancellieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consolaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antimitotic and antivascular activity of 1-(3′,4′,5′-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6795</span>– <span class="NLM_lpage">6808</span>, <span class="refDoi"> DOI: 10.1021/jm5008193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5008193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6795-6808&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai+Salvadorauthor=F.+Prencipeauthor=V.+Bertolasiauthor=M.+Cancellieriauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=F.+Consolaroauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Synthesis%2C+antimitotic+and+antivascular+activity+of+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29-3-arylamino-5-amino-1%2C2%2C4-triazoles&doi=10.1021%2Fjm5008193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm5008193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5008193%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DBertolasi%26aufirst%3DV.%26aulast%3DCancellieri%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DConsolaro%26aufirst%3DF.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520antimitotic%2520and%2520antivascular%2520activity%2520of%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529-3-arylamino-5-amino-1%252C2%252C4-triazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6795%26epage%3D6808%26doi%3D10.1021%2Fjm5008193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamzami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaudin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignotte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1084/jem.182.2.367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1084%2Fjem.182.2.367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=7629499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADyaK2MXntFKhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=1995&pages=367-377&author=N.+Zamzamiauthor=P.+Marchettiauthor=M.+Castedoauthor=D.+Decaudinauthor=A.+Machoauthor=T.+Hirschauthor=S.+A.+Susinauthor=P.+X.+Petitauthor=B.+Mignotteauthor=G.+Kroemer&title=Sequential+reduction+of+mitochondrial+transmembrane+potential+and+generation+of+reactive+oxygen+species+in+early+programmed+cell+death&doi=10.1084%2Fjem.182.2.367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death</span></div><div class="casAuthors">Zamzami, Naoufal; Marchetti, Philippe; Castedo, Maria; Decaudin, Didier; Macho, Antonio; Hirsch, Tamara; Susin, Santos A.; Petit, Patrice X.; Mignotte, Bernard; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">367-77</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Programmed cell death (PCD) is a physiol. process commonly defined by alterations in nuclear morphol. (apoptosis) and/or characteristic stepwise degrdn. of chromosomal DNA occurring before cytolysis.  However, detd. characteristics of PCD such as loss in mitochondrial reductase activity or cytolysis can be induced in enucleated cells, indicating cytoplasmic PCD control.  Here we report a sequential disregulation of mitochondrial function that precedes cell shrinkage and nuclear fragmentation.  A first cyclosporin A-inhibitable step of ongoing PCD is characterized by a redn. of mitochondrial transmembrane potential as detd. by specific fluorochromes (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide; 3,3'-dihexyloxacarbocyanine iodide).  Cytofluorometrically purified cells with reduced mitochondrial transmembrane potential are initially incapable of oxidizing hydroethidine (HE) into ethidium.  Upon short-term in vitro culture, such cells acquire the capacity of HE oxidn., thus revealing a second step of PCD marked by mitochondrial generation of reactive oxygen species (ROS).  This step can be selectively inhibited by rotenone and ruthenium red yet is not affected by cyclosporin A.  Finally, cells reduce their vol., a step that is delayed by radical scavengers, indicating the implication of ROS in the apoptotic process.  This sequence of alterations, accompanying early PCD is found in very different models of apoptosis induction: glucocorticoid-induced death of lymphocytes, activation-induced PCD of T cell hybridomas, and tumor necrosis factor-induced death of U937 cells.  Transfection with the antiapoptotic protooncogene Bcl-2-simultaneously inhibits mitochondrial alterations and apoptotic cell death triggered by steroids or ceramide.  In vivo injection fo fluorochromes such as 5,5',6,6'-retrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide; 3,3'-dihexyloxacarbocyanine iodide; or HE allows for the detection of cells that are programmed for death but still lack nuclear DNA fragmentation.  In particular, assessment of mitochondrial ROS generation provides an accurate picture of PCD-mediated lymphocyte depletion.  In conclusion, alterations of mitochondrial function constitute an important feature of early PCD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNHceD860pHrVg90H21EOLACvtfcHk0lgyjnOGp_OlAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntFKhs78%253D&md5=ce8730fd7c4fc177c0002753e5f932bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1084%2Fjem.182.2.367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.182.2.367%26sid%3Dliteratum%253Aachs%26aulast%3DZamzami%26aufirst%3DN.%26aulast%3DMarchetti%26aufirst%3DP.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DDecaudin%26aufirst%3DD.%26aulast%3DMacho%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DT.%26aulast%3DSusin%26aufirst%3DS.%2BA.%26aulast%3DPetit%26aufirst%3DP.%2BX.%26aulast%3DMignotte%26aufirst%3DB.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DSequential%2520reduction%2520of%2520mitochondrial%2520transmembrane%2520potential%2520and%2520generation%2520of%2520reactive%2520oxygen%2520species%2520in%2520early%2520programmed%2520cell%2520death%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1995%26volume%3D182%26spage%3D367%26epage%3D377%26doi%3D10.1084%2Fjem.182.2.367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dueber, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maecker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span> <span> </span><span class="NLM_article-title">Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>471</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nature09779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnature09779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21368834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1Cku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2011&pages=110-114&author=I.+E.+Wertzauthor=S.+Kusamauthor=C.+Lamauthor=T.+Okamotoauthor=W.+Sandovalauthor=D.+J.+Andersonauthor=E.+Helgasonauthor=J.+A.+Ernstauthor=M.+Ebyauthor=J.+Liuauthor=L.+D.+Belmontauthor=J.+S.+Kaminkerauthor=K.+M.+O%E2%80%99Rourkeauthor=K.+Pujaraauthor=P.+B.+Kohliauthor=A.+R.+Johnsonauthor=M.+L.+Chiuauthor=J.+R.+Lillauthor=P.+K.+Jacksonauthor=W.+J.+Fairbrotherauthor=S.+Seshagiriauthor=M.+J.+Ludlamauthor=K.+G.+Leongauthor=E.+C.+Dueberauthor=H.+Maeckerauthor=D.+C.+Huangauthor=V.+M.+Dixit&title=Sensitivity+to+antitubulin+chemotherapeutics+is+regulated+by+MCL1+and+FBW7&doi=10.1038%2Fnature09779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7</span></div><div class="casAuthors">Wertz, Ingrid E.; Kusam, Saritha; Lam, Cynthia; Okamoto, Toru; Sandoval, Wendy; Anderson, Daniel J.; Helgason, Elizabeth; Ernst, James A.; Eby, Mike; Liu, Jinfeng; Belmont, Lisa D.; Kaminker, Josh S.; O'Rourke, Karen M.; Pujara, Kanan; Kohli, Pawan Bir; Johnson, Adam R.; Chiu, Mark L.; Lill, Jennie R.; Jackson, Peter K.; Fairbrother, Wayne J.; Seshagiri, Somasekar; Ludlam, Mary J. C.; Leong, Kevin G.; Dueber, Erin C.; Maecker, Heather; Huang, David C. S.; Dixit, Vishva M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">471</span>
        (<span class="NLM_cas:issue">7336</span>),
    <span class="NLM_cas:pages">110-114</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules have pivotal roles in fundamental cellular processes and are targets of antitubulin chemotherapeutics.  Microtubule-targeted agents such as Taxol and vincristine are prescribed widely for various malignancies, including ovarian and breast adenocarcinomas, non-small-cell lung cancer, leukemias and lymphomas.  These agents arrest cells in mitosis and subsequently induce cell death through poorly defined mechanisms.  The strategies that resistant tumor cells use to evade death induced by antitubulin agents are also unclear.  Here we show that the pro-survival protein MCL1 is a crucial regulator of apoptosis triggered by antitubulin chemotherapeutics.  During mitotic arrest, MCL1 protein levels decline markedly, through a post-translational mechanism, potentiating cell death.  Phosphorylation of MCL1 directs its interaction with the tumor-suppressor protein FBW7, which is the substrate-binding component of a ubiquitin ligase complex.  The polyubiquitylation of MCL1 then targets it for proteasomal degrdn.  The degrdn. of MCL1 was blocked in patient-derived tumor cells that lacked FBW7 or had loss-of-function mutations in FBW7, conferring resistance to antitubulin agents and promoting chemotherapeutic-induced polyploidy.  Addnl., primary tumor samples were enriched for FBW7 inactivation and elevated MCL1 levels, underscoring the prominent roles of these proteins in oncogenesis.  Our findings suggest that profiling the FBW7 and MCL1 status of tumors, in terms of protein levels, mRNA levels and genetic status, could be useful to predict the response of patients to antitubulin chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFiH1HCl46H7Vg90H21EOLACvtfcHk0ljZbmZcB-fJVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1Cku7g%253D&md5=9b06764b31a4b2e4597c76e9138b0a34</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature09779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09779%26sid%3Dliteratum%253Aachs%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DKusam%26aufirst%3DS.%26aulast%3DLam%26aufirst%3DC.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DHelgason%26aufirst%3DE.%26aulast%3DErnst%26aufirst%3DJ.%2BA.%26aulast%3DEby%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DK.%2BM.%26aulast%3DPujara%26aufirst%3DK.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DChiu%26aufirst%3DM.%2BL.%26aulast%3DLill%26aufirst%3DJ.%2BR.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DLeong%26aufirst%3DK.%2BG.%26aulast%3DDueber%26aufirst%3DE.%2BC.%26aulast%3DMaecker%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DD.%2BC.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26atitle%3DSensitivity%2520to%2520antitubulin%2520chemotherapeutics%2520is%2520regulated%2520by%2520MCL1%2520and%2520FBW7%26jtitle%3DNature%26date%3D2011%26volume%3D471%26spage%3D110%26epage%3D114%26doi%3D10.1038%2Fnature09779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czabotar, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. M.</span></span> <span> </span><span class="NLM_article-title">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/nrm3722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnrm3722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24355989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=49-63&author=P.+E.+Czabotarauthor=G.+Lesseneauthor=A.+Strasserauthor=J.+M.+Adams&title=Control+of+apoptosis+by+the+BCL-2+protein+family%3A+implications+for+physiology+and+therapy&doi=10.1038%2Fnrm3722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span></div><div class="casAuthors">Czabotar, Peter E.; Lessene, Guillaume; Strasser, Andreas; Adams, Jerry M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The BCL-2 protein family dets. the commitment of cells to apoptosis, an ancient cell suicide program that is essential for development, tissue homeostasis and immunity.  Too little apoptosis can promote cancer and autoimmune diseases; too much apoptosis can augment ischemic conditions and drive neurodegeneration.  We discuss the biochem., structural and genetic studies that have clarified how the interplay between members of the BCL-2 family on mitochondria sets the apoptotic threshold.  These mechanistic insights into the functions of the BCL-2 family are illuminating the physiol. control of apoptosis, the pathol. consequences of its dysregulation and the promising search for novel cancer therapies that target the BCL-2 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYVpm2heUGBbVg90H21EOLACvtfcHk0ljZbmZcB-fJVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI&md5=c18d528c2819c2df93b6798e62132372</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrm3722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3722%26sid%3Dliteratum%253Aachs%26aulast%3DCzabotar%26aufirst%3DP.%2BE.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%2BM.%26atitle%3DControl%2520of%2520apoptosis%2520by%2520the%2520BCL-2%2520protein%2520family%253A%2520implications%2520for%2520physiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D49%26epage%3D63%26doi%3D10.1038%2Fnrm3722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span> <span> </span><span class="NLM_article-title">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span>. <i>Angiogenesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1007/s10456-013-9343-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2Fs10456-013-9343-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=23456551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=647-662&author=E.+Porc%C3%B9author=G.+Violaauthor=R.+Bortolozziauthor=S.+Mitolaauthor=R.+Roncaauthor=M.+Prestaauthor=L.+Persanoauthor=R.+Romagnoliauthor=P.+G.+Baraldiauthor=G.+Basso&title=TR-644+a+novel+potent+tubulin+binding+agent+induces+impairment+of+endothelial+cells+function+and+inhibits+angiogenesis&doi=10.1007%2Fs10456-013-9343-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span></div><div class="casAuthors">Porcu, Elena; Viola, Giampietro; Bortolozzi, Roberta; Persano, Luca; Mitola, Stefania; Ronca, Roberto; Presta, Marco; Romagnoli, Romeo; Baraldi, Pier Giovanni; Basso, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-662</span>CODEN:
                <span class="NLM_cas:coden">AGIOFT</span>;
        ISSN:<span class="NLM_cas:issn">0969-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">TR-644 is a novel combretastatin A-4 (CA-4) analog endowed with potent microtubule depolymg. activity superior to that of the lead compd. and it also has high affinity to colchicines binding site of tubulin.  We tested TR-644 anti-angiogenic effects in human umbilical endothelial cells (HUVEC).  It showed no significant effects on the growth of HUVEC cells at concns. below 1,000 nM, but at much lower concns. (10-100 nM) it induced inhibition of capillary tube formation, inhibition of endothelial cell migration and affected endothelial cell morphol. as demonstrated by the disruption of the microtubule network.  TR-644 also increased permeability of HUVEC cells in a time dependent manner.  The mol. mechanism for the anti-vascular activity of TR-644 was investigated in detail.  TR-644 caused G2/M arrest in endothelial cells and this effect correlated with downregulation of the expression of Cdc25C and Cdc2Tyr15.  Moreover TR-644 inhibited VEGF-induced phosphorylation of VE-cadherin but did not prevent the VEGF-induced phosphorylation of FAK.  In chick chorioallantoic membrane in vivo assay, TR-644 (0.1-1.0 pmol/egg) efficiently counteracted the strong angiogenic response induced by FGF.  Also CA-4, used as ref. compd., caused an antagonistic effect, but in contrast, it induced per se, a remarkable angiogenic response probably due to an inflammatory reaction in the site of treatment.  In a mice allogenic tumor model, immunohistochem. staining of tumors with anti-CD31 antibody showed that TR-644 significantly reduced the no. of vessel, after 24 h from the administration of a single dose (30 mg/Kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjdcGwvsKlwbVg90H21EOLACvtfcHk0ljZbmZcB-fJVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D&md5=701845b28683c4a73edd13455485c742</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs10456-013-9343-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-013-9343-z%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DViola%26aufirst%3DG.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DPresta%26aufirst%3DM.%26aulast%3DPersano%26aufirst%3DL.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBasso%26aufirst%3DG.%26atitle%3DTR-644%2520a%2520novel%2520potent%2520tubulin%2520binding%2520agent%2520induces%2520impairment%2520of%2520endothelial%2520cells%2520function%2520and%2520inhibits%2520angiogenesis%26jtitle%3DAngiogenesis%26date%3D2013%26volume%3D16%26spage%3D647%26epage%3D662%26doi%3D10.1007%2Fs10456-013-9343-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolasi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancellieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consolaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antimitotic and antivascular activity of 1-(3′,4′,5′-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6795</span>– <span class="NLM_lpage">6808</span>, <span class="refDoi"> DOI: 10.1021/jm5008193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5008193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6795-6808&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=F.+Prencipeauthor=V.+Bertolasiauthor=M.+Cancellieriauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=F.+Consolaroauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Synthesis%2C+antimitotic+and+antivascular+activity+of+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29-3-arylamino-5-amino-1%2C2%2C4-triazoles&doi=10.1021%2Fjm5008193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm5008193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5008193%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DBertolasi%26aufirst%3DV.%26aulast%3DCancellieri%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DConsolaro%26aufirst%3DF.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520antimitotic%2520and%2520antivascular%2520activity%2520of%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529-3-arylamino-5-amino-1%252C2%252C4-triazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6795%26epage%3D6808%26doi%3D10.1021%2Fjm5008193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiaffino Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, in vitro and in vivo anticancer and antiangiogenic activity of novel 3-arylamino benzofuran derivatives targeting the colchicine site on tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3209</span>– <span class="NLM_lpage">3222</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3209-3222&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=F.+Prencipeauthor=C.+Lopez-Caraauthor=S.+Schiaffino+Ortegaauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=S.+Mitolaauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Design%2C+synthesis%2C+in+vitro+and+in+vivo+anticancer+and+antiangiogenic+activity+of+novel+3-arylamino+benzofuran+derivatives+targeting+the+colchicine+site+on+tubulin&doi=10.1021%2Facs.jmedchem.5b00155"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00155%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DLopez-Cara%26aufirst%3DC.%26aulast%3DSchiaffino%2BOrtega%26aufirst%3DS.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520and%2520antiangiogenic%2520activity%2520of%2520novel%25203-arylamino%2520benzofuran%2520derivatives%2520targeting%2520the%2520colchicine%2520site%2520on%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3209%26epage%3D3222%26doi%3D10.1021%2Facs.jmedchem.5b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">The novel antitubulin agent TR-764 strongly reduces tumor vasculature and inhibits HIF-1α activation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">27886</span> <span class="refDoi"> DOI: 10.1038/srep27886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fsrep27886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27292568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSlu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=E.+Porc%C3%B9author=L.+Persanoauthor=R.+Roncaauthor=S.+Mitolaauthor=R.+Bortolozziauthor=R.+Romagnoliauthor=P.+Olivaauthor=G.+Bassoauthor=G.+Viola&title=The+novel+antitubulin+agent+TR-764+strongly+reduces+tumor+vasculature+and+inhibits+HIF-1%CE%B1+activation&doi=10.1038%2Fsrep27886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation</span></div><div class="casAuthors">Porcu, Elena; Persano, Luca; Ronca, Roberto; Mitola, Stefania; Bortolozzi, Roberta; Romagnoli, Romeo; Oliva, Paola; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27886</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tubulin binding agents (TBAs) are commonly used in cancer therapy as antimitotics.  It has been described that TBAs, like combretastatin A-4 (CA-4), present also antivascular activity and among its derivs. we identified TR-764 as a new inhibitor of tubulin polymn., based on the 2-(alkoxycarbonyl)-3-(3',4',5'-trimethoxyanilino)benzo[b]thiophene mol. skeleton.  The antiangiogenic activity of TR-764 (1-10 nM) was tested in vitro on human umbilical endothelial cells (HUVECs), and in vivo, on the chick embryo chorioallantoic membrane (CAM) and two murine tumor models.  TR-764 binding to tubulin triggers cytoskeleton rearrangement without affecting cell cycle and viability.  It leads to capillary tube disruption, increased cell permeability, and cell motility redn.  Moreover it disrupts adherens junctions and focal adhesions, through mechanisms involving VE-cadherin/β-catenin and FAK/Src.  Importantly, TR-764 is active in hypoxic conditions significantly reducing HIF-1α.  In vivo TR-764 (1-100 pmol/egg) remarkably blocks the bFGF proangiogenic activity on CAM and shows a stronger redn. of tumor mass and microvascular d. both in murine syngeneic and xenograft tumor models, compared to the lead compd. CA-4P.  Altogether, our results indicate that TR-764 is a novel TBA with strong potential as both antivascular and antitumor mol. that could improve the common anticancer therapies, by overcoming hypoxia-induced resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmUlLSiVenbVg90H21EOLACvtfcHk0li6ug_Su06jSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSlu77I&md5=27dec7400a73d6a9c32bfeb8b26246f3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fsrep27886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27886%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DPersano%26aufirst%3DL.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DThe%2520novel%2520antitubulin%2520agent%2520TR-764%2520strongly%2520reduces%2520tumor%2520vasculature%2520and%2520inhibits%2520HIF-1%25CE%25B1%2520activation%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep27886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leali, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coltrini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarazzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribatti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presta, M.</span></span> <span> </span><span class="NLM_article-title">Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2760</span>– <span class="NLM_lpage">2771</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1158%2F1535-7163.MCT-13-0487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24130051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2760-2771&author=R.+Roncaauthor=E.+Di+Salleauthor=A.+Giacominiauthor=D.+Lealiauthor=P.+Alessiauthor=D.+Coltriniauthor=C.+Ravelliauthor=S.+Matarazzoauthor=D.+Ribattiauthor=W.+Vermiauthor=M.+Presta&title=Long+pentraxin-3+inhibits+epithelial-mesenchymal+transition+in+melanoma+cells&doi=10.1158%2F1535-7163.MCT-13-0487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Long Pentraxin-3 Inhibits Epithelial-Mesenchymal Transition in Melanoma Cells</span></div><div class="casAuthors">Ronca, Roberto; Di Salle, Emanuela; Giacomini, Arianna; Leali, Daria; Alessi, Patrizia; Coltrini, Daniela; Ravelli, Cosetta; Matarazzo, Sara; Ribatti, Domenico; Vermi, William; Presta, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2760-2771</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">During melanoma progression, malignant melanocytes are reprogrammed into mesenchymal-like cells through to an epithelial-mesenchymal transition (EMT) process assocd. with the acquisition of an invasive, prometastatic phenotype.  The fibroblast growth factor-2 (FGF2)/FGF receptor (FGFR) system plays a pivotal role in melanoma, leading to autocrine/paracrine induction of tumor cell proliferation and angiogenesis.  Long pentraxin-3 (PTX3) interacts with FGF2, and other FGF family members, inhibiting FGF-dependent neovascularization and tumor growth.  Here, PTX3 protein and the PTX3-derived acetylated pentapeptide Ac-ARPCA-NH2 inhibit FGF2-driven proliferation and downstream FGFR signaling in murine melanoma B16-F10 cells.  Moreover, human PTX3-overexpressing hPTXB16-F10 cells are characterized by the reversed transition from a mesenchymal to an epithelial-like appearance, inhibition of cell proliferation, loss of clonogenic potential, reduced motility and invasive capacity, downregulation of various mesenchymal markers, and upregulation of the epithelial marker E-cadherin.  Accordingly, PTX3 affects cell proliferation and EMT transition in human A375 and A2058 melanoma cells.  Also, hPTXB16-F10 cells showed a reduced tumorigenic and metastatic activity in syngeneic C57BL/6 mice.  In conclusion, PTX3 inhibits FGF/FGFR-driven EMT in melanoma cells, hampering their tumorigenic and metastatic potential.  These data represent the first exptl. evidence about a nonredundant role of the FGF/FGFR system in the modulation of the EMT process in melanoma and indicate that PTX3 or its derivs. may represent the basis for the design of novel therapeutic approaches in FGF/FGFR-dependent tumors, including melanoma.  Mol Cancer Ther; 12(12); 2760-71. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXU05tS8wW-7Vg90H21EOLACvtfcHk0lg7G-A9xWz7vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvM&md5=149ad1c43348bb691728ecad7f25aede</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0487%26sid%3Dliteratum%253Aachs%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DDi%2BSalle%26aufirst%3DE.%26aulast%3DGiacomini%26aufirst%3DA.%26aulast%3DLeali%26aufirst%3DD.%26aulast%3DAlessi%26aufirst%3DP.%26aulast%3DColtrini%26aufirst%3DD.%26aulast%3DRavelli%26aufirst%3DC.%26aulast%3DMatarazzo%26aufirst%3DS.%26aulast%3DRibatti%26aufirst%3DD.%26aulast%3DVermi%26aufirst%3DW.%26aulast%3DPresta%26aufirst%3DM.%26atitle%3DLong%2520pentraxin-3%2520inhibits%2520epithelial-mesenchymal%2520transition%2520in%2520melanoma%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2760%26epage%3D2771%26doi%3D10.1158%2F1535-7163.MCT-13-0487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariotto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent in vitro and in vivo anticancer agents based on 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1<i>H</i>-imidazole</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">26602</span> <span class="refDoi"> DOI: 10.1038/srep26602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fsrep26602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27216165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos12mt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=F.+Prencipeauthor=P.+Olivaauthor=P.+Olivaauthor=P.+Olivaauthor=P.+Olivaauthor=S.+Ferlaauthor=A.+Brancaleauthor=E.+Hamelauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Mariottoauthor=G.+Bassoauthor=G.+Viola&title=Design+and+synthesis+of+potent+in+vitro+and+in+vivo+anticancer+agents+based+on+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxyphenyl%29-2-aryl-1H-imidazole&doi=10.1038%2Fsrep26602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Prencipe, Filippo; Oliva, Paola; Baraldi, Stefania; Tabrizi, Mojgan Aghazadeh; Lopez-Cara, Luisa Carlota; Ferla, Salvatore; Brancale, Andrea; Hamel, Ernest; Ronca, Roberto; Bortolozzi, Roberta; Mariotto, Elena; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26602pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A novel series of tubulin polymn. inhibitors, based on the 1-(3',4',5'-trimethoxyphenyl)-2-aryl-1H-imidazole scaffold and designed as cis-restricted combretastatin A-4 analogs, compds. I [R = 4-MeC6H4, 4-EtOC6H4, 4-EtSC6H4, etc.] were synthesized with the goal of evaluating the effects of various patterns of substitution on the Ph at the 2-position of the imidazole ring on biol. activity.  Compd. I [R = 4-EtO-3-Cl-C6H4] produced the most active compd. in the series, with IC50 values of 0.4-3.8 nM against a panel of seven cancer cell lines.  Except in HL-60 cells, compd. I [R = 4-EtO-3-Cl-C4-EtO-3-Cl-C6H4] had greater antiproliferative than CA-4, indicating that the 3'-chloro-4'-ethoxyphenyl moiety was a good surrogate for the CA-4 B-ring.  Expts. carried out in a mouse syngenic model demonstrated high antitumor activity of compd. I [R = 4-EtO-3-Cl-4-EtO-3-Cl-C6H4], which significantly reduced the tumor mass at a dose thirty times lower than that required for CA-4P, which was used as a ref. compd.  Altogether, thr findings suggeste that compd. I [R = 4-EtO-3-Cl-4-EtO-3-Cl-C6H4] is a promising anticancer drug candidate that warrants further preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAjNLSZc2QC7Vg90H21EOLACvtfcHk0lg7G-A9xWz7vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos12mt7w%253D&md5=6ffe29f76796aed8d9b44e966a8eace1</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsrep26602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26602%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DFerla%26aufirst%3DS.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DMariotto%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520agents%2520based%2520on%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxyphenyl%2529-2-aryl-1H-imidazole%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep26602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qingjun Ma, Q.</span></span> <span> </span><span class="NLM_article-title">Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">91</span>, <span class="refDoi"> DOI: 10.1186/1472-6750-10-91</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1186%2F1472-6750-10-91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21176167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=91&author=Q.+Xuauthor=X.+Zhangauthor=J.+Yueauthor=C.+Liuauthor=C.+Caoauthor=H.+Zhongauthor=Q.+Qingjun+Ma&title=Human+TGFalpha-derived+peptide+TGFalphaL3+fused+with+superantigen+for+immunotherapy+of+EGFR-expressing+tumours&doi=10.1186%2F1472-6750-10-91"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumors</span></div><div class="casAuthors">Xu, Quanbin; Zhang, Xiaojuan; Yue, Junjie; Liu, Chuanxuan; Cao, Cheng; Zhong, Hui; Ma, Qingjun</div><div class="citationInfo"><span class="NLM_cas:title">BMC Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91</span>CODEN:
                <span class="NLM_cas:coden">BBMIE6</span>;
        ISSN:<span class="NLM_cas:issn">1472-6750</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Monoclonal antibodies have been employed as targeting mols. of superantigen for the preclin. treatment of a variety of tumors.  However, other targeting mols., such as tumor-related ligands or peptides, are less exploited.  Here, we tested other targeting mols. by genetically fusing the third loop of transforming growth factor alpha (TGFalphaL3) to mutant staphylococcal enterotoxin A (SEAD227A).  Results: The resultant fusion proteins were expressed in E.coli and purified to homogeneity through a Ni-NTA affinity column.  Fusion protein TGFalphaL3SEAD227A can promote splenocyte proliferation to a level comparable to recombinant SEA (rSEA) and bind to EGFR-expressing tumor cells in an EGFR-dependent way.  Consistent with these observations, TGFalphaL3SEAD227A exerted an inhibitory effect on the growth of EGFR-expressing tumor cells both in vitro and in vivo.  Notably, significant infiltrations of CD8+ and CD4+ T cells were detected in the tumor tissues of these C57BL/6 mice treated with TGFalphaL3SEAD227A, suggesting the involvement of T cells in this tumor-inhibitory process.  Conclusions: The data here showed that TGFαL3 is capable of targeting superantigen to tumors and exerting an inhibitory effect on tumor growth, which enables TGFαL3SEAD227A to be an attractive candidate for the immunotherapy of EGFR-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbMw-zSyfLDrVg90H21EOLACvtfcHk0lg7G-A9xWz7vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFSkuw%253D%253D&md5=146cbe440e733b995c5aa06988364fb2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1186%2F1472-6750-10-91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6750-10-91%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DQingjun%2BMa%26aufirst%3DQ.%26atitle%3DHuman%2520TGFalpha-derived%2520peptide%2520TGFalphaL3%2520fused%2520with%2520superantigen%2520for%2520immunotherapy%2520of%2520EGFR-expressing%2520tumours%26jtitle%3DBMC%2520Biotechnol.%26date%3D2010%26volume%3D10%26spage%3D91%26doi%3D10.1186%2F1472-6750-10-91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span>. <i>Cell Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1385/CBB:38:1:1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1385%2FCBB%3A38%3A1%3A1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=12663938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1-21&author=E.+Hamel&title=Evaluation+of+antimitotic+agents+by+quantitative+comparisons+of+their+effects+on+the+polymerization+of+purified+tubulin&doi=10.1385%2FCBB%3A38%3A1%3A1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53aR"><div class="casContent"><span class="casTitleNuber">53a</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span></div><div class="casAuthors">Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Most antimitotic compds. have highly specific interactions with tubulin, the major protein component of microtubules.  It is, therefore, often desirable to characterize interactions of these agents with tubulin.  In particular, quant. comparisons between new and old ("std.") agents, between different classes of agent, and between structural analogs (e.g., for a structure-activity relationship study) are important.  Because antimitotic drugs have a variety of effects on tubulin and bind at multiple distinct sites on the protein, the tubulin assembly reaction is probably the only universally applicable reaction that can be analyzed.  In my lab., we use the assembly of purified tubulin induced by higher concns. of monosodium glutamate as our basic assay system.  This report presents a detailed description of our current routine assay, including the effects of a variety of reaction components on the reaction.  In addn., the variety of effects that reaction components can have on the quant. results obtained with drugs, using the colchicine site drug combretastatin A-4 as a model compd., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvDICXLUiYbVg90H21EOLACvtfcHk0lgKf3JMneiXsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D&md5=c37c365cc707e237f43feffca64d706b</span></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=10.1385%2FCBB%3A38%3A1%3A1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCBB%253A38%253A1%253A1%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DEvaluation%2520of%2520antimitotic%2520agents%2520by%2520quantitative%2520comparisons%2520of%2520their%2520effects%2520on%2520the%2520polymerization%2520of%2520purified%2520tubulin%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2003%26volume%3D38%26spage%3D1%26epage%3D21%26doi%3D10.1385%2FCBB%3A38%3A1%3A1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit53b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Verdier-Pinard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falck, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1124/mol.53.1.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1124%2Fmol.53.1.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=62-67&author=P.+Verdier-Pinardauthor=J.-Y.+Laiauthor=H.-D.+Yooauthor=J.+Yuauthor=B.+Marquezauthor=D.+G.+Nagleauthor=M.+Nambuauthor=J.+D.+Whiteauthor=J.+R.+Falckauthor=W.+H.+Gerwickauthor=B.+W.+Dayauthor=E.+Hamel&title=Structure-activity+analysis+of+the+interaction+of+curacin+A%2C+the+potent+colchicine+site+antimitotic+agent%2C+with+tubulin+and+effects+of+analogs+on+the+growth+of+MCF-7+breast+cancer+cells&doi=10.1124%2Fmol.53.1.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=10.1124%2Fmol.53.1.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.53.1.62%26sid%3Dliteratum%253Aachs%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DJ.-Y.%26aulast%3DYoo%26aufirst%3DH.-D.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMarquez%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DD.%2BG.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DFalck%26aufirst%3DJ.%2BR.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure-activity%2520analysis%2520of%2520the%2520interaction%2520of%2520curacin%2520A%252C%2520the%2520potent%2520colchicine%2520site%2520antimitotic%2520agent%252C%2520with%2520tubulin%2520and%2520effects%2520of%2520analogs%2520on%2520the%2520growth%2520of%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26spage%3D62%26epage%3D67%26doi%3D10.1124%2Fmol.53.1.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span> <i>Molecular Operating
Environment (MOE 2015.10)</i>; <span class="NLM_publisher-name">Chemical Computing
Group, Inc.</span>: <span class="NLM_publisher-loc">Montreal, Quebec, Canada</span>, <span class="NLM_year">2015</span>. <a href="http://www.chemcomp.com" class="extLink">http://www.chemcomp.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating%0AEnvironment+%28MOE+2015.10%29%3B+Chemical+Computing%0AGroup%2C+Inc.%3A+Montreal%2C+Quebec%2C+Canada%2C+2015.+http%3A%2F%2Fwww.chemcomp.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Operating%250AEnvironment%2520%2528MOE%25202015.10%2529%26pub%3DChemical%2520Computing%250AGroup%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span> <i>Schrödinger Release 2017-1: Maestro</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Schr%C3%B6dinger+Release+2017-1%3A+Maestro%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C%0ANY%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSchr%25C3%25B6dinger%2520Release%25202017-1%253A%2520Maestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20a','cit20b','cit20c','cit20d'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53a','cit53b'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wen Shuai, Guan Wang, Yiwen Zhang, Faqian Bu, Sicheng Zhang, Duane D. Miller, Wei Li, Liang Ouyang, <span class="NLM_string-name hlFld-ContribAuthor">Yuxi Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7963-7990. <a href="https://doi.org/10.1021/acs.jmedchem.1c00100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00100%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bon%252BTubulin%252BInhibitors%252Bwith%252BDual%252BTargeting%252BCapabilities%252Bfor%252BCancer%252BTherapy%26aulast%3DShuai%26aufirst%3DWen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19012021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D7963%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mudasir Nabi Peerzada, Parvez Khan, Nashrah Sharif Khan, Fernando Avecilla, Shadab Miyan Siddiqui, Md. Imtaiyaz Hassan, <span class="NLM_string-name hlFld-ContribAuthor">Amir Azam</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (36)
                                     , 22759-22771. <a href="https://doi.org/10.1021/acsomega.0c01703" title="DOI URL">https://doi.org/10.1021/acsomega.0c01703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c01703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c01703%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDesign%252Band%252BDevelopment%252Bof%252BSmall-Molecule%252BArylaldoxime%25252F5-Nitroimidazole%252BHybrids%252Bas%252BPotent%252BInhibitors%252Bof%252BMARK4%25253A%252BA%252BPromising%252BApproach%252Bfor%252BTarget-Based%252BCancer%252BTherapy%26aulast%3DPeerzada%26aufirst%3DMudasir%2BNabi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14042020%26date%3D17072020%26date%3D01092020%26volume%3D5%26issue%3D36%26spage%3D22759%26epage%3D22771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peng Chen, Kaixiu Luo, Xianglin Yu, Xu Yuan, Xiaoyu Liu, Jun Lin, <span class="NLM_string-name hlFld-ContribAuthor">Yi Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Cu-Catalyzed Direct Amination of Cyclic Amides via C–OH Bond Activation Using DMF. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (16)
                                     , 6547-6551. <a href="https://doi.org/10.1021/acs.orglett.0c02320" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02320</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02320%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCu-Catalyzed%252BDirect%252BAmination%252Bof%252BCyclic%252BAmides%252Bvia%252BC%2525E2%252580%252593OH%252BBond%252BActivation%252BUsing%252BDMF%26aulast%3DChen%26aufirst%3DPeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12072020%26date%3D11082020%26volume%3D22%26issue%3D16%26spage%3D6547%26epage%3D6551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113523. <a href="https://doi.org/10.1016/j.ejmech.2021.113523" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113523%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-based%252BEGFR%252BTK%252Binhibitors%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2021%26volume%3D221%26spage%3D113523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seohyeon  Ahn</span>, <span class="hlFld-ContribAuthor ">Moon-Kook  Jeon</span>. </span><span class="cited-content_cbyCitation_article-title">Solid-phase synthetic method for N-alkyl-4-alkylamino-6-arylthieno[3,2-d]pyrimidine-2-carboxamide derivatives. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>91 </em>, 132247. <a href="https://doi.org/10.1016/j.tet.2021.132247" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132247%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSolid-phase%252Bsynthetic%252Bmethod%252Bfor%252BN-alkyl-4-alkylamino-6-arylthieno%25255B3%25252C2-d%25255Dpyrimidine-2-carboxamide%252Bderivatives%26aulast%3DAhn%26aufirst%3DSeohyeon%26date%3D2021%26volume%3D91%26spage%3D132247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zukela  Ruzi</span>, <span class="hlFld-ContribAuthor ">Lifei  Nie</span>, <span class="hlFld-ContribAuthor ">Khurshed  Bozorov</span>, <span class="hlFld-ContribAuthor ">Jiangyu  Zhao</span>, <span class="hlFld-ContribAuthor ">Haji A.  Aisa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anticancer activity of ethyl 5‐amino‐1‐
              N
              ‐substituted‐imidazole‐4‐carboxylate building blocks. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>68 </em><a href="https://doi.org/10.1002/ardp.202000470" title="DOI URL">https://doi.org/10.1002/ardp.202000470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000470%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%252Band%252Banticancer%252Bactivity%252Bof%252Bethyl%252B5%2525E2%252580%252590amino%2525E2%252580%2525901%2525E2%252580%252590%252BN%252B%2525E2%252580%252590substituted%2525E2%252580%252590imidazole%2525E2%252580%2525904%2525E2%252580%252590carboxylate%252Bbuilding%252Bblocks%26aulast%3DRuzi%26aufirst%3DZukela%26date%3D2021%26date%3D2021%26volume%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenjing  Liu</span>, <span class="hlFld-ContribAuthor ">Guangcheng  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiyun  Peng</span>, <span class="hlFld-ContribAuthor ">Yongjun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel 4-(4-Methoxynaphthalen-1-yl)-5-arylpyrimidin-2-amines as Tubulin Polymerization Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2020,</strong> <em>68 </em>
                                    (12)
                                     , 1184-1192. <a href="https://doi.org/10.1248/cpb.c20-00575" title="DOI URL">https://doi.org/10.1248/cpb.c20-00575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c20-00575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c20-00575%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B4-%2525284-Methoxynaphthalen-1-yl%252529-5-arylpyrimidin-2-amines%252Bas%252BTubulin%252BPolymerization%252BInhibitors%26aulast%3DLiu%26aufirst%3DWenjing%26date%3D2020%26volume%3D68%26issue%3D12%26spage%3D1184%26epage%3D1192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eun Sun  Noh</span>, <span class="hlFld-ContribAuthor ">Sung Min  Kim</span>, <span class="hlFld-ContribAuthor ">Yang-Heon  Song</span>. </span><span class="cited-content_cbyCitation_article-title">4-(3-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)thieno[3,2-d]pyrimidine. </span><span class="cited-content_cbyCitation_journal-name">Molbank</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (2)
                                     , M1136. <a href="https://doi.org/10.3390/M1136" title="DOI URL">https://doi.org/10.3390/M1136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/M1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2FM1136%26sid%3Dliteratum%253Aachs%26jtitle%3DMolbank%26atitle%3D4-%2525283-Phenyl-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529thieno%25255B3%25252C2-d%25255Dpyrimidine%26aulast%3DNoh%26aufirst%3DEun%2BSun%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D2%26spage%3DM1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maneesh Kumar Reddy  Singam</span>, <span class="hlFld-ContribAuthor ">Attunuri  Nagireddy</span>, <span class="hlFld-ContribAuthor ">Sridhar Reddy  Maddi</span>. </span><span class="cited-content_cbyCitation_article-title">Base-mediated benzannulation of α-cyanocrotonates with ynones: facile synthesis of benzonitriles and fluorenes. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (8)
                                     , 2370-2374. <a href="https://doi.org/10.1039/D0GC00608D" title="DOI URL">https://doi.org/10.1039/D0GC00608D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0GC00608D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0GC00608D%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DBase-mediated%252Bbenzannulation%252Bof%252B%2525CE%2525B1-cyanocrotonates%252Bwith%252Bynones%25253A%252Bfacile%252Bsynthesis%252Bof%252Bbenzonitriles%252Band%252Bfluorenes%26aulast%3DSingam%26aufirst%3DManeesh%2BKumar%2BReddy%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D8%26spage%3D2370%26epage%3D2374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Filippo  Prencipe</span>, <span class="hlFld-ContribAuthor ">Paola  Oliva</span>, <span class="hlFld-ContribAuthor ">Barbara  Cacciari</span>, <span class="hlFld-ContribAuthor ">Jan  Balzarini</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ferla</span>, <span class="hlFld-ContribAuthor ">Stefano  Manfredini</span>, <span class="hlFld-ContribAuthor ">Matteo  Zurlo</span>, <span class="hlFld-ContribAuthor ">Alessia  Finotti</span>, <span class="hlFld-ContribAuthor ">Roberto  Gambari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of New Antitubulin Agents Containing 2-(3′,4′,5′-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (7)
                                     , 1690. <a href="https://doi.org/10.3390/molecules25071690" title="DOI URL">https://doi.org/10.3390/molecules25071690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25071690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25071690%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNew%252BAntitubulin%252BAgents%252BContaining%252B2-%2525283%2525E2%252580%2525B2%25252C4%2525E2%252580%2525B2%25252C5%2525E2%252580%2525B2-trimethoxyanilino%252529-3%25252C6-disubstituted-4%25252C5%25252C6%25252C7-tetrahydrothieno%25255B2%25252C3-c%25255Dpyridine%252BScaffold%26aulast%3DRomagnoli%26aufirst%3DRomeo%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D7%26spage%3D1690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sviatoslav  Batsyts</span>, <span class="hlFld-ContribAuthor ">Maksym  Shehedyn</span>, <span class="hlFld-ContribAuthor ">Evgeny A.  Goreshnik</span>, <span class="hlFld-ContribAuthor ">Mykola D.  Obushak</span>, <span class="hlFld-ContribAuthor ">Andreas  Schmidt</span>, <span class="hlFld-ContribAuthor ">Yurii V.  Ostapiuk</span>. </span><span class="cited-content_cbyCitation_article-title">2‐Bromo‐2‐chloro‐3‐arylpropanenitriles as C‐3 Synthons for the Synthesis of Functionalized 3‐Aminothiophenes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (48)
                                     , 7842-7856. <a href="https://doi.org/10.1002/ejoc.201901512" title="DOI URL">https://doi.org/10.1002/ejoc.201901512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901512%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3D2%2525E2%252580%252590Bromo%2525E2%252580%2525902%2525E2%252580%252590chloro%2525E2%252580%2525903%2525E2%252580%252590arylpropanenitriles%252Bas%252BC%2525E2%252580%2525903%252BSynthons%252Bfor%252Bthe%252BSynthesis%252Bof%252BFunctionalized%252B3%2525E2%252580%252590Aminothiophenes%26aulast%3DBatsyts%26aufirst%3DSviatoslav%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D48%26spage%3D7842%26epage%3D7856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of tubulin-depolymerizing agents CA-4 and CA-4P and selected epidermal growth factor receptor (EGFR) (<b>2a</b>–<b>d</b>) and vascular endothelial growth factor receptor-2 (VEGFR-2) (<b>2e</b>) tyrosine kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of representative thieno[3,2-<i>d</i>]pyrimidines and thiazolo[4,5-<i>d</i>]pyrimidines as known tubulin polymerization (<b>4</b>) and EGFR kinase (<b>3</b> and <b>5</b>) inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy for thieno[3,2-<i>d</i>]pyrimidines <b>6a</b>–<b>j</b>. Target compounds containing the thiazolo[4,5-<i>d</i>]pyrimidine (<b>7a</b>–<b>d</b>) and thieno[2,3-<i>d</i>]pyrimidine (<b>8a</b>–<b>l</b>) scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0013.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Thieno[3,2-<i>d</i>]pyrimidines <b>6a</b>–<b>j</b> and Thiazolo[4,5-<i>d</i>]pyrimidines <b>7a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) HCONH<sub>2</sub>, 180 °C; (b) POCl<sub>3</sub>, 110 °C; (c) 3,4,5-trimethoxyaniline, isopropanol, reflux.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0014.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Thieno[2,3-<i>d</i>]pyrimidines (<b>8a</b>–<b>l</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) HCONH<sub>2</sub>, 180 °C; (b) POCl<sub>3</sub>, 110 °C; (c) 3,4,5-trimethoxyaniline, isopropanol, reflux.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of <b>6g</b> on EGFR signaling in HeLa cells. Cells were treated with the indicated concentrations of <b>6g</b> for 6 h and then stimulated by EGF (30 ng/mL) for 15 min. Cells were harvested for Western blot analysis for both EGFR and its phosphorylation at Y1068. Erlotinib (Erl) was used as the reference compound. We established that each gel lane had similar quantities of protein by determining their β-actin content.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proposed binding modes for compounds <b>6b</b> (A), <b>6e</b> (B), and <b>6g</b> (C) in comparison with DAMA-colchicine at the colchicine site (Protein Data Bank (PDB) ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0">1SA0</a>). Carbons are shown in green for the cocrystallized DAMA-colchicine, in purple for compound <b>6b</b>, in orange for compound <b>6e</b>, and in turquoise for compound <b>6g</b>. The residues from the α-tubulin chain are shown in salmon, whereas residues from β-tubulin are colored in teal. The subpocket is highlighted with a red surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed binding modes for compounds <b>6b</b> (A) and <b>6e</b> (B) in comparison with those for the inhibitor AEE788 in the crystal structure of the EGFR kinase domain (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M">2J6M</a>). The carbons are shown in green for cocrystallized AEE788, in purple for compound <b>6b</b>, and in orange for compound <b>6e</b>. The phenyl ring of <b>6e</b> and the thiophene of <b>6b</b> are not involved in any interaction with the surrounding residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle effects caused by <b>6g</b>: (A) HeLa cells treated with varying concentrations of <b>6g</b>, stained with PI, and examined by flow cytometry. (B) Jurkat cells treated with varying concentrations of <b>6g</b>, stained with PI, and examined by flow cytometry. G1 cells are indicated by the symbol ■, G2/M cells, by the symbol ●, and S cells, by the symbol ▲. Three independent experiments were performed, and the standard error of the mean (SEM) values are indicated. (C) Typical flow cytometric patterns of mitotic HeLa cells immunofluorescently stained with an antibody to <i>p</i>-histone H3, following treatment with 0 (left-hand pattern), 50 (middle pattern), or 100 (right-hand pattern) nM <b>6g</b>. (D) Histogram presentation of the data from (C) (two experiments, with SEM values indicated).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Apoptotic effects caused by <b>6g</b>: (A) Apoptosis examined by flow cytometry after treatment of HeLa cells for 24 h with <b>6g</b>, as indicated. (B) Apoptosis examined by flow cytometry after treatment of HeLa cells for 48 h with <b>6g</b>, as indicated. (C) Apoptosis examined by flow cytometry after treatment of Jurkat cells for 24 h with <b>6g</b>, as indicated. (D) Apoptosis examined by flow cytometry after treatment of Jurkat cells for 48 h with <b>6g</b>, as indicated. In all cases, cells were stained with annexin V linked to fluorescene and with PI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Flow cytometric measurement of Δψ<sub>mt</sub> and ROS following treatment of HeLa cells with <b>6g</b>. Treatment times and <b>6g</b> concentrations are indicated: (A) Measurement of Δψ<sub>mt</sub> by JC-1 fluorescence. (B) Measurement of ROS by fluorescence of 2,7-dichlorodihydrofluorescein diacetate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Western blot demonstrating PARP, Bcl-2, and Mcl-1 levels. HeLa cells were treated with <b>6g</b> as indicated. Equivalent protein loading was confirmed by evaluating anti-β-actin levels in the gel slots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Antivascular effects of <b>6g</b> treatment on HUVECs. (A) Typical images after 1 h of growth on Matrigel of untreated cells (left-hand image), of cells treated with 10 nM <b>6g</b> (middle image), and of cells treated with 100 nM <b>6g</b> (right-hand image). (B–G) Quantitative evaluation of <b>6g</b> on standard parameters of HUVEC tubule formation, as indicated, at the indicated <b>6g</b> concentrations. Mean ± SEM, three experiments. ** <i>p</i> < 0.01; *** <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/medium/jm-2018-01391c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0012.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. In vivo activity of <b>6g</b> in the treatment of murine B16 melanoma in an allograft model. (A) Each male C57BL/6 mouse was injected subcutaneously (s.c.) in its dorsum with 2.5 × 10<sup>5</sup> murine melanoma cells. On the days indicated by the arrows, mice were administered intraperitoneally (i.p.) with either vehicle 3.0 mg/kg <b>6g</b>, 7.5 mg/kg <b>6g</b>, or 30 mg/kg CA-4P. (B) Body weight variation after treatment with compound <b>6g</b> or CA-4P as described above. The data are plotted as mean ± SEM of tumor volume at each time point for five animals per group, * <i>p</i> < 0.05; *** <i>p</i> < 0.001 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-3/acs.jmedchem.8b01391/20190211/images/large/jm-2018-01391c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01391&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Control of microtubule organization and dynamics: two ends in the limelight</span>. <i>Nat. Rev. Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1038/nrm4084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnrm4084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=26562752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=711-726&author=A.+Akhmanovaauthor=M.+O.+Steinmetz&title=Control+of+microtubule+organization+and+dynamics%3A+two+ends+in+the+limelight&doi=10.1038%2Fnrm4084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Control of microtubule organization and dynamics: two ends in the limelight</span></div><div class="casAuthors">Akhmanova, Anna; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">711-726</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules have fundamental roles in many essential biol. processes, including cell division and intracellular transport.  They assemble and disassemble from their two ends, denoted the plus end and the minus end.  Significant advances have been made in our understanding of microtubule plus-end-tracking proteins (+TIPs) such as end-binding protein 1 (EB1), XMAP215, selected kinesins and dynein.  By contrast, information on microtubule minus-end-targeting proteins (-TIPs), such as the calmodulin-regulated spectrin-assocd. proteins (CAMSAPs) and Patronin, has only recently started to emerge.  Here, we review our current knowledge of factors, including microtubule-targeting agents, that assoc. with microtubule ends to control the dynamics and function of microtubules during the cell cycle and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps4xzvh0o6PbVg90H21EOLACvtfcHk0lh60Snc4pSRRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI&md5=7c941bcce8d5d51aef6a8deb140356d3</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrm4084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm4084%26sid%3Dliteratum%253Aachs%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DControl%2520of%2520microtubule%2520organization%2520and%2520dynamics%253A%2520two%2520ends%2520in%2520the%2520limelight%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D711%26epage%3D726%26doi%3D10.1038%2Fnrm4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brouhard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. M.</span></span> <span> </span><span class="NLM_article-title">The contribution of αβ-tubulin curvature to microtubule dynamics</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1083/jcb.201407095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1083%2Fjcb.201407095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25385183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2014&pages=323-334&author=G.+J.+Brouhardauthor=L.+M.+Rice&title=The+contribution+of+%CE%B1%CE%B2-tubulin+curvature+to+microtubule+dynamics&doi=10.1083%2Fjcb.201407095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The contribution of αβ-tubulin curvature to microtubule dynamics</span></div><div class="casAuthors">Brouhard, Gary J.; Rice, Luke M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-334</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic polymers of αβ-tubulin that form diverse cellular structures, such as the mitotic spindle for cell division, the backbone of neurons, and axonemes.  To control the architecture of microtubule networks, microtubule-assocd. proteins (MAPs) and motor proteins regulate microtubule growth, shrinkage, and the transitions between these states.  Recent evidence shows that many MAPs exert their effects by selectively binding to distinct conformations of polymd. or unpolymd. αβ-tubulin.  The ability of αβ-tubulin to adopt distinct conformations contributes to the intrinsic polymn. dynamics of microtubules.  αβ-Tubulin conformation is a fundamental property that MAPs monitor and control to build proper microtubule networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGyoU-iIkFELVg90H21EOLACvtfcHk0li7i5GbBJqIsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE&md5=5ff241f0a021843f7678daec3f7476f1</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201407095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201407095%26sid%3Dliteratum%253Aachs%26aulast%3DBrouhard%26aufirst%3DG.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DThe%2520contribution%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520curvature%2520to%2520microtubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D207%26spage%3D323%26epage%3D334%26doi%3D10.1083%2Fjcb.201407095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vindya, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethiraj, K. R.</span></span> <span> </span><span class="NLM_article-title">Tubulins-the target for anticancer therapy</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150112115805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1568026615666150112115805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25579568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=73-82&author=N.+G.+Vindyaauthor=N.+Sharmaauthor=M.+Yadavauthor=K.+R.+Ethiraj&title=Tubulins-the+target+for+anticancer+therapy&doi=10.2174%2F1568026615666150112115805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulins - The Target for Anticancer Therapy</span></div><div class="casAuthors">Vindya, N. G.; Sharma, Nishant; Yadav, Mukesh; Ethiraj, K. R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tubulin has picked up great focus as a major target in drug discovery and consequently, tubulin inhibitors have pulling in a considerable attention as anticancer agents.  Numerable naturally occurring agents have focused on tubulin system act as an imperative target of cancer chemotherapy.  Substantial no. of tubulin inhibitors has been discovered so far and these agents are classified as indicated by their interaction.  They are colchicine site binder, vinca- alkaloid related drugs and those interacting with the Taxol binding site and functioning as stabilizing agents.  We review the recent advances in the advancement of tubulin interfering agents and will render the current trend in the improvement of tubulin inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tIyc1PffELVg90H21EOLACvtfcHk0li7i5GbBJqIsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKgsbo%253D&md5=8805a32e1f038693336ceb464c67193d</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150112115805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150112115805%26sid%3Dliteratum%253Aachs%26aulast%3DVindya%26aufirst%3DN.%2BG.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DYadav%26aufirst%3DM.%26aulast%3DEthiraj%26aufirst%3DK.%2BR.%26atitle%3DTubulins-the%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D73%26epage%3D82%26doi%3D10.2174%2F1568026615666150112115805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nitika, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapil, K.</span></span> <span> </span><span class="NLM_article-title">Microtubule targeting agents: a benchmark in cancer therapy</span>. <i>Curr. Drug Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.2174/15748855113086660011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F15748855113086660011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=189-196&author=V.+Nitikaauthor=K.+Kapil&title=Microtubule+targeting+agents%3A+a+benchmark+in+cancer+therapy&doi=10.2174%2F15748855113086660011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F15748855113086660011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748855113086660011%26sid%3Dliteratum%253Aachs%26aulast%3DNitika%26aufirst%3DV.%26aulast%3DKapil%26aufirst%3DK.%26atitle%3DMicrotubule%2520targeting%2520agents%253A%2520a%2520benchmark%2520in%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D189%26epage%3D196%26doi%3D10.2174%2F15748855113086660011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naphade, S. S.</span></span> <span> </span><span class="NLM_article-title">Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.2174/1871520615666150526141259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1871520615666150526141259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=955-969&author=P.+O.+Patilauthor=A.+G.+Patilauthor=R.+A.+Raneauthor=P.+C.+Patilauthor=P.+K.+Deshmukhauthor=S.+B.+Bariauthor=D.+A.+Patilauthor=S.+S.+Naphade&title=Recent+advancement+in+discovery+and+development+of+natural+product+combretastatin-inspired+anticancer+agents&doi=10.2174%2F1871520615666150526141259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150526141259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150526141259%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DPatil%26aufirst%3DA.%2BG.%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DPatil%26aufirst%3DP.%2BC.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26aulast%3DNaphade%26aufirst%3DS.%2BS.%26atitle%3DRecent%2520advancement%2520in%2520discovery%2520and%2520development%2520of%2520natural%2520product%2520combretastatin-inspired%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D955%26epage%3D969%26doi%3D10.2174%2F1871520615666150526141259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0liZF5i3WxsghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.MCT-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Recent advances in vascular disrupting agents in cancer therapy</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.4155%2Ffmc.14.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25365233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1485-1498&author=E.+Porc%C3%B9author=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Recent+advances+in+vascular+disrupting+agents+in+cancer+therapy&doi=10.4155%2Ffmc.14.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in vascular disrupting agents in cancer therapy</span></div><div class="casAuthors">Porcu, Elena; Bortolozzi, Roberta; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1485-1498</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are an important class of compds. that exhibit selective activity against pre-existing tumor vasculature, causing rapid shutdown of the tumor blood flow and consequent necrosis of the tumor mass.  The VDAs can be divided into flavonoid compds., which are related to flavone acetic acid, and tubulin-binding agents.  Tubulin-binding agents represent the largest group of VDAs and are characterized by different chem. structures, although most of them are derivs. of the lead compd. combretastatin (CA-4).  They demonstrated clin. activity, although recent findings have established that they have insufficient activity as single agents.  Several resistance mechanisms occur, such as the resistance of the tumor rim cells, while promising results have been described in combination with other chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG_xRqLIL1wrVg90H21EOLACvtfcHk0liZF5i3WxsghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN&md5=daf2387ad5729d02e889bf0301dac807</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.104%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DRecent%2520advances%2520in%2520vascular%2520disrupting%2520agents%2520in%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1485%26epage%3D1498%26doi%3D10.4155%2Ffmc.14.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargsyan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, M.</span></span> <span> </span><span class="NLM_article-title">Vascular disrupting agents in oncology</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1517/13543784.2013.759557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1517%2F13543784.2013.759557" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=317-328&author=M.+M.+Mitaauthor=L.+Sargsyanauthor=A.+C.+Mitaauthor=M.+Spear&title=Vascular+disrupting+agents+in+oncology&doi=10.1517%2F13543784.2013.759557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.759557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.759557%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DSargsyan%26aufirst%3DL.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DSpear%26aufirst%3DM.%26atitle%3DVascular%2520disrupting%2520agents%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D317%26epage%3D328%26doi%3D10.1517%2F13543784.2013.759557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Kendall, D.</span></span> <span> </span><span class="NLM_article-title">Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4</span>. <i>Experientia</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1007/BF01954881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2FBF01954881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=2920809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADyaL1MXktVShtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1989&pages=209-211&author=G.+R.+Pettitauthor=S.+B.+Singhauthor=E.+Hamelauthor=C.+M.+Linauthor=D.+S.+Albertsauthor=D.+Garcia-Kendall&title=Isolation+and+structure+of+the+strong+cell+growth+and+tubulin+inhibitor+combretastatin+A-4&doi=10.1007%2FBF01954881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4</span></div><div class="casAuthors">Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D.</div><div class="citationInfo"><span class="NLM_cas:title">Experientia</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-11</span>CODEN:
                <span class="NLM_cas:coden">EXPEAM</span>;
        ISSN:<span class="NLM_cas:issn">0014-4754</span>.
    </div><div class="casAbstract">From Combretum caffrum were isolated combretastatin A-4 (I, R1 = R2 = Me, R3 = H), combretastatin A-5 (I, R1 = H, R2 = R3 = Me), and combretastatin A-6 (II, R1 = H and R3 = Me) (the latter as the silyl ether).  The structures of these compds. detd. by spectroscopic methods were confirmed by total syntheses.  Combretastatins A-4, A-5 and A-6 were significantly active against murine L1210 and P388 lymphocytic leukemia cell lines with esp., combretastatin A-4 competing with combretastatin A-1 as the most inhibitor of colchicine binding to tubulin yet described.  Combretastatin A-4 was an inhibitor of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt_PDOS8sCIrVg90H21EOLACvtfcHk0liZF5i3WxsghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXktVShtbg%253D&md5=5f9cda9322b202960705a92aa1a751ff</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1007%2FBF01954881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01954881%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DAlberts%26aufirst%3DD.%2BS.%26aulast%3DGarcia-Kendall%26aufirst%3DD.%26atitle%3DIsolation%2520and%2520structure%2520of%2520the%2520strong%2520cell%2520growth%2520and%2520tubulin%2520inhibitor%2520combretastatin%2520A-4%26jtitle%3DExperientia%26date%3D1989%26volume%3D45%26spage%3D209%26epage%3D211%26doi%3D10.1007%2FBF01954881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragg, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herald, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohavanijaya, P.</span></span> <span> </span><span class="NLM_article-title">Isolation and structure of combretastatin</span>. <i>Can. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1376</span>, <span class="refDoi"> DOI: 10.1139/v82-202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1139%2Fv82-202" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1982&pages=1374-1376&author=G.+R.+Pettitauthor=G.+M.+Craggauthor=D.+L.+Heraldauthor=J.+M.+Schmidtauthor=P.+Lohavanijaya&title=Isolation+and+structure+of+combretastatin&doi=10.1139%2Fv82-202"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1139%2Fv82-202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fv82-202%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DLohavanijaya%26aufirst%3DP.%26atitle%3DIsolation%2520and%2520structure%2520of%2520combretastatin%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1982%26volume%3D60%26spage%3D1374%26epage%3D1376%26doi%3D10.1139%2Fv82-202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">6984</span>– <span class="NLM_lpage">6991</span>, <span class="refDoi"> DOI: 10.1021/bi00443a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00443a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=6984-6991&author=C.+M.+Linauthor=H.+H.+Hoauthor=G.+R.+Pettitauthor=E.+Hamel&title=Antimitotic+natural+products+combretastatin+A-4+and+combretastatin+A-2%3A+studies+on+the+mechanism+of+their+inhibition+of+the+binding+of+colchicine+to+tubulin&doi=10.1021%2Fbi00443a031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antimitotic natural products combretastatin A-4 and combretastatin A-2:  studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span></div><div class="casAuthors">Lin, Chii M.; Ho, Holly H.; Pettit, George R.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6984-91</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The mechanism of the binding of combretastatin A-4 (CS-A4) and combretastatin A-2 (CS-A2), isolated from Combretum caffrum, to tubulin was examd. indirectly by evaluating their effects on the binding of radiolabeled colchicine to the protein.  There was rapid binding of both compds. to tubulin even at 0° (binding was complete at the earliest times examd.), in contrast to the relatively slow and temp.-dependent binding of colchicine.  Although the binding of the C. caffrum compds. to tubulin was quite tight, permitting ready isolation of near-stoichiometric amts. of drug-tubulin complex even in the absence of free drug, both CS-A4 and CS-A2 dissocd. rapidly from tubulin in the presence of high concns. of radiolabeled colchicine.  Apparent rate consts. for drug dissocn. from tubulin at 37° were 3.2 × 10-3/s for CS-A4, 4.8 × 10-3/s for CS-A2, and 2.9 × 10-5/s for colchicine (half-lives of 3.6, 2.4, and 405 min, resp.).  Thus, the effectiveness of the C. caffrum compds. as antimitotic agents appears to derive primarily from the rapidity of their binding to tubulin.  A new model for the colchicine binding site on tubulin is proposed which envisages A-ring and C-ring subsites in homologous locations on the 2 tubulin subunits, with Ph rings binding as well as or better than the tropolone ring of colchicine in the C-ring subsite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVM6YQr13WbVg90H21EOLACvtfcHk0lijqlEGuzHBZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D&md5=4fc9bd899f65be38961729d7c51a6b16</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fbi00443a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00443a031%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHo%26aufirst%3DH.%2BH.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DAntimitotic%2520natural%2520products%2520combretastatin%2520A-4%2520and%2520combretastatin%2520A-2%253A%2520studies%2520on%2520the%2520mechanism%2520of%2520their%2520inhibition%2520of%2520the%2520binding%2520of%2520colchicine%2520to%2520tubulin%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D6984%26epage%3D6991%26doi%3D10.1021%2Fbi00443a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1097%2FCAD.0000000000000070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24500030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=462-471&author=P.+Liuauthor=Y.+Qinauthor=L.+Wuauthor=S.+Yangauthor=N.+Liauthor=H.+Wangauthor=H.+Xuauthor=K.+Sunauthor=S.+Zhangauthor=X.+Hanauthor=Y.+Sunauthor=Y.+Shi&title=A+phase+I+clinical+trial+assessing+the+safety+and+tolerability+of+combretastatin+A4+phosphate+injections&doi=10.1097%2FCAD.0000000000000070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections</span></div><div class="casAuthors">Liu, Peng; Qin, Yan; Wu, Lingying; Yang, Sheng; Li, Nan; Wang, Haijun; Xu, Haiyan; Sun, Kelin; Zhang, Shuxiang; Han, Xiaohong; Sun, Yan; Shi, Yuankai</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-471</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clin. trials.  The aims of this single-center, open label, phase I clin. trial were to investigate the safety and tolerability of CA4P administered i.v. to patients aged 18-65 years with advanced solid tumors.  Using a dose-escalation protocol, patients were assigned to five groups that received injections with 20 (n=3), 33 (n=3), 50 (n=11), 65 (n=6), or 85 (n=2) mg/m CA4P.  Patients in the 20 and 85 mg/m groups received a single dose and the other groups received multiple doses.  Adverse events (AE), cardiovascular parameters, and biochem. investigations were studied, and the max. tolerated dose was detd.  Of twenty-five patients enrolled, eight were withdrawn/excluded (not because of AE).  There were no deaths.  A total of 394 AE occurred in the 25 patients, with 89.3% considered related/possibly related to the drug.  AE included headache and dizziness (19.8%), tumor-induced pain (14.2%), vascular vagal excitation (10.7%), and vomiting (9.4%).  Ninety-five percent of AE were mild (grades 0-II), with only 5% being grade III-IV.  Drug administration was assocd. with biphasic changes in heart rate and blood pressure, and only limited abnormalities in the lab. investigations performed.  The max. tolerated dose was 65 mg/m.  We conclude that CA4P is generally well tolerated, with the vast majority of AE that occurred being of mild severity.  Further studies will establish the role of CA4P in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvmdFO81FLLVg90H21EOLACvtfcHk0lijqlEGuzHBZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1SksLg%253D&md5=1573e6f13d625ddc78fdac4ffff13181</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000070%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520assessing%2520the%2520safety%2520and%2520tolerability%2520of%2520combretastatin%2520A4%2520phosphate%2520injections%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D462%26epage%3D471%26doi%3D10.1097%2FCAD.0000000000000070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naphade, S. S.</span></span> <span> </span><span class="NLM_article-title">Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.2174/1871520615666150526141259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1871520615666150526141259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=955-969&author=P.+O.+Patilauthor=A.+G.+Patilauthor=R.+A.+Raneauthor=P.+C.+Patilauthor=P.+K.+Deshmukhauthor=S.+B.+Bariauthor=D.+A.+Patilauthor=S.+S.+Naphade&title=Recent+advancement+in+discovery+and+development+of+natural+product+combretastatin-inspired+anticancer+agents&doi=10.2174%2F1871520615666150526141259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150526141259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150526141259%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DPatil%26aufirst%3DA.%2BG.%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DPatil%26aufirst%3DP.%2BC.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26aulast%3DNaphade%26aufirst%3DS.%2BS.%26atitle%3DRecent%2520advancement%2520in%2520discovery%2520and%2520development%2520of%2520natural%2520product%2520combretastatin-inspired%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D955%26epage%3D969%26doi%3D10.2174%2F1871520615666150526141259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rajak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewangan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerasamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, A.</span></span> <span> </span><span class="NLM_article-title">design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1923</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.2174/1381612811319100013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1381612811319100013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=23237054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1923-1955&author=H.+Rajakauthor=P.+K.+Dewanganauthor=V.+Patelauthor=D.+K.+Jainauthor=A.+Singhauthor=R.+Veerasamyauthor=P.+C.+Sharmaauthor=A.+Dixit&title=design+of+combretastatin+A-4+analogs+as+tubulin+targeted+vascular+disrupting+agent+with+special+emphasis+on+their+cis-restricted+isomers&doi=10.2174%2F1381612811319100013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span></div><div class="casAuthors">Rajak, Harish; Dewangan, Pramod Kumar; Patel, Vijay; Jain, Deepak Kumar; Singh, Avineesh; Veerasamy, Ravichandran; Sharma, Prabodh Chander; Dixit, Anshuman</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1923-1955</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is a highly imperative and feasible goal for anticancer drug discovery.  Hundreds of naturally occurring, semi synthetic and synthetic antitubulin agents have been reported till now.  Among these, Combretastatin A - 4 (CA - 4) is effective antimitotic agent possessing potent cytotoxicity against a panel of cancer cells, including multi-drug resistant cancer cell lines.  The inadequate water soly. and inactivation of these analogs during storage limit their use as clin. anticancer agents.  To overcome these short-comings, numerous water sol. amino analogs, amino acid deriv., phosphate prodrug (CA - 4P) and cis-locked CA - 4 have been developed with distinctive attributes of antitubulin and antivascular properties in a wide variety of preclin. tumor models.  Subsequently, several heterocycle based cis restricted CA - 4 analogs are being reported for antitumor activity against collection of cancer cell lines.  This review recapitulates the rational design, structure activity relationship, pharmacokinetic and pharmacodynamic profile of synthesized cis restricted CA - 4 analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVkQxS7xaDPLVg90H21EOLACvtfcHk0lidvQJywAe_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D&md5=4aaa3f776e46ef2c0e4b18e8a163dee2</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.2174%2F1381612811319100013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319100013%26sid%3Dliteratum%253Aachs%26aulast%3DRajak%26aufirst%3DH.%26aulast%3DDewangan%26aufirst%3DP.%2BK.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DD.%2BK.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DVeerasamy%26aufirst%3DR.%26aulast%3DSharma%26aufirst%3DP.%2BC.%26aulast%3DDixit%26aufirst%3DA.%26atitle%3Ddesign%2520of%2520combretastatin%2520A-4%2520analogs%2520as%2520tubulin%2520targeted%2520vascular%2520disrupting%2520agent%2520with%2520special%2520emphasis%2520on%2520their%2520cis-restricted%2520isomers%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D1923%26epage%3D1955%26doi%3D10.2174%2F1381612811319100013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span> <span> </span><span class="NLM_article-title">Combretastatins: more than just vascular targeting agents?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.226225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1124%2Fjpet.115.226225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=26354991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=212-227&author=L.+M.+Greeneauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatins%3A+more+than+just+vascular+targeting+agents%3F&doi=10.1124%2Fjpet.115.226225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatins: more than just vascular targeting agents?</span></div><div class="casAuthors">Greene, Lisa M.; Meegan, Mary J.; Zisterer, Daniela M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-227</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several prodrugs of the naturally occurring combretastatins have undergone extensive clin. evaluation as vascular targeting agents (VTAs).  Their increased selectivity toward endothelial cells together with their innate ability to rapidly induce vascular shutdown and inhibit tumor growth at doses up to 10-fold less than the max. tolerated dose led to the clin. evaluation of combretastatins as VTAs.  Tubulin is well established as the mol. target of the combretastatins and the vast majority of its synthetic derivs.  Furthermore, tubulin is a highly validated mol. target of many direct anticancer agents routinely used as front-line chemotherapeutics.  The unique vascular targeting properties of the combretastatins have somewhat overshadowed their development as direct anticancer agents and the delineation of the various cell death pathways and anticancer properties assocd. with such chemotherapeutics.  Moreover, the ongoing clin. trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclin. evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins.  In this review, we discuss the development of the combretastatins from nature to the clinic.  The various mechanisms underlying combretastatin-induced cell cycle arrest, mitotic catastrophe, cell death, and survival are also reviewed in an attempt to further enhance the clin. prospects of this unique class of VTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKpiV5x3vPLVg90H21EOLACvtfcHk0lidvQJywAe_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D&md5=7e965d3cd51715cec3f84fde9cd6e88e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226225%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatins%253A%2520more%2520than%2520just%2520vascular%2520targeting%2520agents%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D212%26epage%3D227%26doi%3D10.1124%2Fjpet.115.226225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakkanthara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. H.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5050</span>– <span class="NLM_lpage">5059</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2014.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24650703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5050-5059&author=J.+J.+Fieldauthor=A.+Kanakkantharaauthor=J.+H.+Miller&title=Microtubule-targeting+agents+are+clinically+successful+due+to+both+mitotic+and+interphase+impairment+of+microtubule+function&doi=10.1016%2Fj.bmc.2014.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span></div><div class="casAuthors">Field, Jessica J.; Kanakkanthara, Arun; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5050-5059</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microtubules undergo continual dynamic changes in mitotic cells as the mitotic spindle forms and is broken down and in interphase cells where they play a central role in intracellular trafficking, cell signaling, cell migration, and angiogenesis.  Compds. that target the microtubule have been hugely successful in the clinic as chemotherapeutics, and this success is likely due to their ability to target cells regardless of their cell cycle stage.  Addnl., new generation antibody-conjugated microtubule-targeting agents are improving the targeting of these drugs to tumors.  Microtubule-targeting agents have been shown to have anti-angiogenic and vascular-disrupting properties as well as effects on cellular migration, intracellular trafficking, and cell secretion.  There are a no. of these compds. in development that target the vasculature, and different formulations of clin. used drugs are being developed to take advantage of these anti-angiogenic properties.  Microtubule-targeting agents have also been shown to have the potential to treat neurodegenerative diseases, such as Alzheimer's disease.  Thus, drugs that target the microtubule will continue to have a major impact in oncol. not only as anti-mitotics but also as potent inhibitors of interphase functions, and in future may also prove to be effective in reducing the consequences of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d-DR0ciixrVg90H21EOLACvtfcHk0lidvQJywAe_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D&md5=e3ec8c5c15dfe25d1c527cecaec20d2f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DKanakkanthara%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520are%2520clinically%2520successful%2520due%2520to%2520both%2520mitotic%2520and%2520interphase%2520impairment%2520of%2520microtubule%2520function%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5050%26epage%3D5059%26doi%3D10.1016%2Fj.bmc.2014.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goffin, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbuk, K.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor: pathway, therapies, and pipeline</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1282</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2013.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.clinthera.2013.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24054705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyltbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=1282-1303&author=J.+R.+Goffinauthor=K.+Zbuk&title=Epidermal+growth+factor+receptor%3A+pathway%2C+therapies%2C+and+pipeline&doi=10.1016%2Fj.clinthera.2013.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline</span></div><div class="casAuthors">Goffin, John R.; Zbuk, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1282-1303</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) pathway is important in tumor growth, survival, and metastasis and is now the target of several therapeutic agents.  This paper seeks to review the EGFR pathway, the study and use of EGFR-directed agents in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC), and related new drug development.  PubMed was searched for English-language articles by MeSH and title terms of EGFR published from 2006 to 2013, using the limits of clin. trials as well as reviews.  Ref. lists were assessed for relevant articles, and guidelines were searched.  Clinicaltrials.gov and meeting abstrs. were queried for investigational agents.  Eligible papers included those concerning EGFR biol., NSCLC or CRC studies involving EGFR-directed agents, and/or investigational drugs targeting EGFR and/or assocd. pathways.  The activity of oral tyrosine kinase inhibitors (TKIs) against EGFR has improved survival in NSCLC, and these agents particularly effective in cancers with an EGFR mutation.  Resistance to TKIs is most commonly related to a second, T790M, mutation, or to MET amplification, with newer agents directed against these mechanisms.  Conversely, in CRC, TKIs have been ineffective, whereas monoclonal antibodies have improved survival.  Both primary and secondary KRAS mutations in CRC abrogate mAb effectiveness.  Several targets, including MET, BRAF, and PI3K, may serve useful in combination with anti-EGFR drugs.  Exploitation of EGFR-directed therapies has offered improvement in survival and quality of life in NSCLC and CRC.  New therapies directed at EGFR may offer further improvements.  However, resistance mechanisms suggest that combination therapies or multitargeted agents will be crucial in making significant future advances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6LWzUjeEPfbVg90H21EOLACvtfcHk0lidvQJywAe_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyltbrJ&md5=25b4b4240668193a3238c85121d2968d</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2013.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2013.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoffin%26aufirst%3DJ.%2BR.%26aulast%3DZbuk%26aufirst%3DK.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%253A%2520pathway%252C%2520therapies%252C%2520and%2520pipeline%26jtitle%3DClin.%2520Ther.%26date%3D2013%26volume%3D35%26spage%3D1282%26epage%3D1303%26doi%3D10.1016%2Fj.clinthera.2013.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinghoff, I. K.</span></span> <span> </span><span class="NLM_article-title">Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">viii7</span>– <span class="NLM_lpage">viii13</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nou232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1093%2Fneuonc%2Fnou232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25342602" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=viii7-viii13&author=D.+A.+Reardonauthor=P.+Y.+Wenauthor=I.+K.+Mellinghoff&title=Targeted+molecular+therapies+against+epidermal+growth+factor+receptor%3A+past+experiences+and+challenges&doi=10.1093%2Fneuonc%2Fnou232"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnou232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnou232%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26atitle%3DTargeted%2520molecular%2520therapies%2520against%2520epidermal%2520growth%2520factor%2520receptor%253A%2520past%2520experiences%2520and%2520challenges%26jtitle%3DNeuro%2520Oncol.%26date%3D2014%26volume%3D16%26spage%3Dviii7%26epage%3Dviii13%26doi%3D10.1093%2Fneuonc%2Fnou232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olayioye, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badache, A.</span></span> <span> </span><span class="NLM_article-title">The ErbB receptor tyrosine family as signal integrators</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0080151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1677%2Ferc.0.0080151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=151-159&author=N.+E.+Hynesauthor=K.+Horschauthor=M.+A.+Olayioyeauthor=A.+Badache&title=The+ErbB+receptor+tyrosine+family+as+signal+integrators&doi=10.1677%2Ferc.0.0080151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0080151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0080151%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DHorsch%26aufirst%3DK.%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DBadache%26aufirst%3DA.%26atitle%3DThe%2520ErbB%2520receptor%2520tyrosine%2520family%2520as%2520signal%2520integrators%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2001%26volume%3D8%26spage%3D151%26epage%3D159%26doi%3D10.1677%2Ferc.0.0080151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lgHfSRZ75Pp7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor dependence in human tumors: more than just expression?</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.7-suppl_4-31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1634%2Ftheoncologist.7-suppl_4-31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=12202786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFOiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=31-39&author=C.+L.+Arteaga&title=Epidermal+growth+factor+receptor+dependence+in+human+tumors%3A+more+than+just+expression%3F&doi=10.1634%2Ftheoncologist.7-suppl_4-31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor dependence in human tumors: more than just expression?</span></div><div class="casAuthors">Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a rational target for antitumor strategies.  EGFR signaling causes increased proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis.  The EGFR is expressed or highly expressed in a variety of human tumors of epithelial origin.  ZD1839 (Iressa) is an orally active, selective EGFR tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells.  The lack of a consistent method of evaluating levels of EGFR has caused a disparity in reports of the EGFR as a prognostic factor; however, for some tumors, EGFR is a strong prognostic indicator assocd. with more aggressive disease and reduced survival.  So far, no clear assocn. between EGFR levels and response to EGFR-targeted agents has been found.  Preclin. studies with ZD1839 have noted a relationship between the two in some cases, but not others.  EGFR signaling may be increased by a no. of mechanisms in addn. to high expression levels of EGFR, including receptor mutations, heterodimerization with other members of this receptor family such as HER2 (erbB2), increased expression of (autocrine/paracrine) ligands, and alterations in mols. that control receptor signaling output.  Each of these components could be assessed to give an indication of the magnitude of EGFR signal amplification.  Evaluation of signaling components downstream from EGFR should provide information on the activation of the EGFR pathway.  Until EGFR-based assays predictive of a response to receptor-targeted therapies are available, there is no clear justification for stratifying patients by EGFR status or excluding patients with low EGFR levels from trials with ZD1839 or other EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq11PFZoC2MDLVg90H21EOLACvtfcHk0lgHfSRZ75Pp7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFOiurg%253D&md5=624685036112bb7925cbc5870744c9fc</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.7-suppl_4-31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.7-suppl_4-31%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520dependence%2520in%2520human%2520tumors%253A%2520more%2520than%2520just%2520expression%253F%26jtitle%3DOncologist%26date%3D2002%26volume%3D7%26spage%3D31%26epage%3D39%26doi%3D10.1634%2Ftheoncologist.7-suppl_4-31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olayioye, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span> <span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3159</span>– <span class="NLM_lpage">3167</span>, <span class="refDoi"> DOI: 10.1093/emboj/19.13.3159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+N.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer&doi=10.1093%2Femboj%2F19.13.3159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0lgHfSRZ75Pp7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%2BN.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167%26doi%3D10.1093%2Femboj%2F19.13.3159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3867</span>– <span class="NLM_lpage">3872</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S119162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2147%2FDDDT.S119162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27920501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyis7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=3867-3872&author=H.+Zhang&title=Three+generations+of+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+developed+to+revolutionize+the+therapy+of+lung+cancer&doi=10.2147%2FDDDT.S119162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer</span></div><div class="casAuthors">Zhang, Haijun</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3867-3872</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Lung cancer, ∼80%-85% of which is non-small-cell lung cancer (NSCLC), is the leading cause of cancer-related mortality worldwide.  Sensitizing mutations in epidermal growth factor receptor (EGFR) gene (EGFRm♂), such as exon 19 deletions and exon 21 L858R point mutations, are the most important drivers in NSCLC patients.  In this respect, small-mol. EGFR tyrosine kinase inhibitors (TKIs) have been designed and developed, which launched the era of targeted, personalized and precise medicine for lung cancer.  Patients with EGFRm♂ could achieve good responses to the treatment with the first-generation EGFR TKIs, such as erlotinib and gefitinib.  However, most patients develop acquired drug resistance mostly driven by the T790M mutation occurring within exon 20.  Although the second-generation EGFR TKIs, such as afatinib, dacomitinib and neratinib, demonstrated promising activity against T790M in preclin. models, they have failed to overcome resistance in patients due to dose-limiting toxicity.  Recently, the third-generation EGFR TKIs have shown to be effective against cell lines and murine models harboring T790M mutations while sparing wild-type EGFR, which represents a promising breakthrough approach in overcoming T790M-mediated resistance in NSCLC patients.  This article provides a comprehensive review of the therapy revolution for NSCLC with three generations of EGFR TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF_iaNrFGZHLVg90H21EOLACvtfcHk0lgNeQWfEkSHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyis7rI&md5=c50ca45f94b1babed9350c8759284235</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S119162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S119162%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThree%2520generations%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520developed%2520to%2520revolutionize%2520the%2520therapy%2520of%2520lung%2520cancer%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D3867%26epage%3D3872%26doi%3D10.2147%2FDDDT.S119162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hossam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A.</span></span> <span> </span><span class="NLM_article-title">Covalent EGFR inhibitors: binding mechanisms, synthetic approaches, and clinical profiles</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1002/ardp.201600063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1002%2Fardp.201600063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27258393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVGmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2016&pages=573-593&author=M.+Hossamauthor=D.+S.+Lasheenauthor=K.+A.+Abouzid&title=Covalent+EGFR+inhibitors%3A+binding+mechanisms%2C+synthetic+approaches%2C+and+clinical+profiles&doi=10.1002%2Fardp.201600063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles</span></div><div class="casAuthors">Hossam, Monia; Lasheen, Deena S.; Abouzid, Khaled A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-593</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Being overexpressed in several types of cancer, the epidermal growth factor receptor (EGFR) is considered one of the key therapeutic targets in oncol.  Although many first-generation EGFR inhibitors had been FDA approved for the treatment of certain types of cancer, patients soon developed resistance to these reversible ATP competitive inhibitors via mutations in the kinase domain of EGFR.  A new trend was adopted to design covalent irreversible inhibitors, i.e., second- and third-generation inhibitors.  Second-generation inhibitors can inhibit the mutant forms but, unfortunately, they had dose limiting side effects due to wild-type EGFR inhibition.  Third-generation inhibitors emerged shortly, which were capable of inhibiting the mutant forms exclusively while sparing the wild type.  Many other strategies have also been developed to reduce the risk of covalent interactions with off-targets, thus improving the pharmacokinetic and/or pharmacodynamic profile of the antiproliferative agents.  In this review, the authors focused mainly on second- and third-generation EGFR inhibitors, their binding mechanisms (either docking studies or co-crystd. structures), their synthetic approaches, clin. profiles, and limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo81VTxrg7O67Vg90H21EOLACvtfcHk0lgNeQWfEkSHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVGmsbY%253D&md5=cf777cc2bd1891fd4cc039e4dcb3d5c2</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1002%2Fardp.201600063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201600063%26sid%3Dliteratum%253Aachs%26aulast%3DHossam%26aufirst%3DM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%26atitle%3DCovalent%2520EGFR%2520inhibitors%253A%2520binding%2520mechanisms%252C%2520synthetic%2520approaches%252C%2520and%2520clinical%2520profiles%26jtitle%3DArch.%2520Pharm.%26date%3D2016%26volume%3D349%26spage%3D573%26epage%3D593%26doi%3D10.1002%2Fardp.201600063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">4-Anilinoquinazoline derivatives with epidermal growth factor receptor inhibitor activity</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1652</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.2174/1871520616666160404113141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.2174%2F1871520616666160404113141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27039919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOhu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1652-1664&author=F.+Liuauthor=B.+Tangauthor=H.+Liuauthor=L.+Liauthor=G.+Liuauthor=Y.+Chengauthor=Y.+Xuauthor=W.+Chenauthor=Y.+Huang&title=4-Anilinoquinazoline+derivatives+with+epidermal+growth+factor+receptor+inhibitor+activity&doi=10.2174%2F1871520616666160404113141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity</span></div><div class="casAuthors">Liu, Fang; Tang, Baoding; Liu, Hao; Li, Leina; Liu, Gang; Cheng, Yun; Xu, Yan; Chen, Wenwen; Huang, Yinjiu</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1652-1664</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline derivs. possess high anti-cancer activities.  Many of them are highly selective tyrosine kinase inhibitors (TKI), particularly against epidermal growth factor receptor (EGFR).  EGFRs are overexpressed or mutated in most carcinomas and are required for tumor progression.  The efficacy of EGFR-targeted anti-tumor drugs is impaired by drug-induced acquired resistance.  Therefore, there is urgency to find better anti-cancer agents with novel effects on EGFR.  4-Anilinoquinazolines are small mol. EGFR inhibitors that have been synthesized and assessed for their anti-tumor bioactivity.  In this paper, we review the 4-anilinoquinazoline derivs. with EGFR inhibitor activity reported in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnNzV0P4o42LVg90H21EOLACvtfcHk0lgNeQWfEkSHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOhu7rN&md5=85f6a1219aee1b23639bb854cfbc3239</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.2174%2F1871520616666160404113141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520616666160404113141%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26atitle%3D4-Anilinoquinazoline%2520derivatives%2520with%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520activity%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1652%26epage%3D1664%26doi%3D10.2174%2F1871520616666160404113141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, S. M.</span></span> <span> </span><span class="NLM_article-title">Lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1380</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0802714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1056%2FNEJMra0802714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=18815398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1367-1380&author=R.+S.+Herbstauthor=J.+V.+Heymachauthor=S.+M.+Lippman&title=Lung+cancer&doi=10.1056%2FNEJMra0802714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular origins of cancer: lung cancer</span></div><div class="casAuthors">Herbst, Roy S.; Heymach, John V.; Lippman, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1367-1380</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The altered mol. genetics of non-small-cell lung cancer is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxvIgLl4BT2LVg90H21EOLACvtfcHk0lgjfucMNfunog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM&md5=a5968124ab5b0807e9a1b89e5e2dad51</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0802714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0802714%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26atitle%3DLung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1367%26epage%3D1380%26doi%3D10.1056%2FNEJMra0802714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normanno, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span> <span> </span><span class="NLM_article-title">Trying to compose the puzzle with all the pieces: epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1002/jcp.20402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1002%2Fjcp.20402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=15895392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Shtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2005&pages=355-363&author=M.+Di+Maioauthor=C.+Gridelliauthor=N.+Normannoauthor=F.+Perroneauthor=F.+Ciardiello&title=Trying+to+compose+the+puzzle+with+all+the+pieces%3A+epidermal+growth+factor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer&doi=10.1002%2Fjcp.20402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Di Maio, Massimo; Gridelli, Cesare; Normanno, Nicola; Perrone, Francesco; Ciardiello, Fortunato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Small mol. epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown promising activity in patients with non-small cell lung cancer (NSCLC).  Gefitinib has been the first of these drugs to be licensed for third-line treatment of advanced NSCLC patients.  More recently, erlotinib has been shown to be more effective than placebo in increasing overall survival (OAS) and has been approved for NSCLC patients after failure of chemotherapy.  However, a large body of clin. and exptl. evidence suggests that the benefit from these drugs is limited to a subgroup of patients.  The availability of clin. or mol. criteria for predicting sensitivity to EGFR-TKIs is the most relevant issue for their correct use and for planning future research.  Detn. of EGFR expression is not sufficient to predict sensitivity to EGFR-TKIs.  However, several clin. features (female gender, adenocarcinoma/bronchioloalveolar histotype, never-smoking status, Oriental Asian origin) are assocd. with major clin. responses.  The identification of somatic mutations in the tyrosine kinase domain of the EGFR gene represents the most important mol. marker of sensitivity to EGFR-TKIs.  These "activating" mutations can be found in a high proportion of gefitinib- or erlotinib-responding patients.  However, clin. effectiveness might not be limited to patients carrying EGFR mutations, in which the objective response is probably the detectable effect of apoptosis induction in cancer cells.  In fact, clin. efficacy with gefitinib or erlotinib is also obsd. in another subgroup of patients, in which a tumor growth delay, detd. by a block in cancer cell proliferation, could induce a prolonged and clin. relevant disease stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_n0iYGK5fULVg90H21EOLACvtfcHk0lgjfucMNfunog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Shtr7K&md5=5454676bceaedb2d8a7e6a1c6534f34c</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20402%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMaio%26aufirst%3DM.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DCiardiello%26aufirst%3DF.%26atitle%3DTrying%2520to%2520compose%2520the%2520puzzle%2520with%2520all%2520the%2520pieces%253A%2520epidermal%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D205%26spage%3D355%26epage%3D363%26doi%3D10.1002%2Fjcp.20402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Soler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1056/NEJMct0807960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1056%2FNEJMct0807960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21388312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=947-955&author=V.+D.+Cataldoauthor=D.+L.+Gibbonsauthor=R.+Perez-Solerauthor=A.+Quintas-Cardama&title=Treatment+of+non-small-cell+lung+cancer+with+erlotinib+or+gefitinib&doi=10.1056%2FNEJMct0807960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span></div><div class="casAuthors">Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintas-Cardama, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDIxHbNbHr7Vg90H21EOLACvtfcHk0lgjfucMNfunog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D&md5=5030feb97e5b6b09e3e11d6946cde577</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0807960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0807960%26sid%3Dliteratum%253Aachs%26aulast%3DCataldo%26aufirst%3DV.%2BD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DPerez-Soler%26aufirst%3DR.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520non-small-cell%2520lung%2520cancer%2520with%2520erlotinib%2520or%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D947%26epage%3D955%26doi%3D10.1056%2FNEJMct0807960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liqnsHt8-s8fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Trusolino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertotti, A.</span></span> <span> </span><span class="NLM_article-title">Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1158%2F2159-8290.CD-12-0400" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=876-880&author=L.+Trusolinoauthor=A.+Bertotti&title=Compensatory+pathways+in+oncogenic+kinase+signaling+and+resistance+to+targeted+therapies%3A+six+degrees+of+separation&doi=10.1158%2F2159-8290.CD-12-0400"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0400%26sid%3Dliteratum%253Aachs%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DBertotti%26aufirst%3DA.%26atitle%3DCompensatory%2520pathways%2520in%2520oncogenic%2520kinase%2520signaling%2520and%2520resistance%2520to%2520targeted%2520therapies%253A%2520six%2520degrees%2520of%2520separation%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D876%26epage%3D880%26doi%3D10.1158%2F2159-8290.CD-12-0400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>The identification numbers in <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a> websites are: NCT02326285, NCT00720304, NCT00049283, NCT02319577,
NCT00083057, NCT01405079, NCT01755923, NCT00532441, NCT01749072, NCT01050322,
NCT00446225, and NCT00553358 (accessed Oct 25, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+identification+numbers+in+https%3A%2F%2Fclinicaltrials.gov+websites+are%3A+NCT02326285%2C+NCT00720304%2C+NCT00049283%2C+NCT02319577%2C%0ANCT00083057%2C+NCT01405079%2C+NCT01755923%2C+NCT00532441%2C+NCT01749072%2C+NCT01050322%2C%0ANCT00446225%2C+and+NCT00553358+%28accessed+Oct+25%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Litvinov, V. P.</span></span> <span> </span><span class="NLM_article-title">The chemistry of thienopyrimidines</span>. <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2006&pages=83-143&author=V.+P.+Litvinov&title=The+chemistry+of+thienopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLitvinov%26aufirst%3DV.%2BP.%26atitle%3DThe%2520chemistry%2520of%2520thienopyrimidines%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D2006%26volume%3D92%26spage%3D83%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ansary, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ghorafi, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 4-anilinoquinazoline bioisosteres as potential anti-breast cancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2014.08.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=202-210&author=A.+K.+El-Ansaryauthor=A.+M.+Kamalauthor=M.+A.+Al-Ghorafi&title=Synthesis+and+evaluation+of+4-anilinoquinazoline+bioisosteres+as+potential+anti-breast+cancer+agents&doi=10.1016%2Fj.ejmech.2014.08.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ansary%26aufirst%3DA.%2BK.%26aulast%3DKamal%26aufirst%3DA.%2BM.%26aulast%3DAl-Ghorafi%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25204-anilinoquinazoline%2520bioisosteres%2520as%2520potential%2520anti-breast%2520cancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D202%26epage%3D210%26doi%3D10.1016%2Fj.ejmech.2014.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel thieno[3,2-<i>d</i>]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2014.10.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=782-799&author=Z.+Liuauthor=S.+Wuauthor=Y.+Wangauthor=R.+Liauthor=J.+Wangauthor=L.+Wangauthor=Y.+Zhaoauthor=P.+Gong&title=Design%2C+synthesis+and+biological+evaluation+of+novel+thieno%5B3%2C2-d%5Dpyrimidine+derivatives+possessing+diaryl+semicarbazone+scaffolds+as+potent+antitumor+agents&doi=10.1016%2Fj.ejmech.2014.10.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520thieno%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520possessing%2520diaryl%2520semicarbazone%2520scaffolds%2520as%2520potent%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D782%26epage%3D799%26doi%3D10.1016%2Fj.ejmech.2014.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bugge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspersen, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonstad, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjørkøy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, B. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2014.01.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24556149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1Ojs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2014&pages=354-374&author=S.+Buggeauthor=S.+J.+Kaspersenauthor=S.+Larsenauthor=U.+Nonstadauthor=G.+Bj%C3%B8rk%C3%B8yauthor=E.+Sundbyauthor=B.+H.+Hoff&title=Structure-activity+study+leading+to+identification+of+a+highly+active+thienopyrimidine+based+EGFR+inhibitor&doi=10.1016%2Fj.ejmech.2014.01.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor</span></div><div class="casAuthors">Bugge, Steffen; Kaspersen, Svein Jacob; Larsen, Synne; Nonstad, Unni; Bjoerkoey, Geir; Sundby, Eirik; Hoff, Baard Helge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354-374</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Based on the thieno[2,3-d]pyrimidine scaffold, a series of new 4-amino-6-aryl thienopyrimidines have been prepd. and evaluated as EGFR tyrosine kinase inhibitors.  The in vitro activity was found to depend strongly on the substitution pattern in the 6-aryl ring, the stereochem., and the basicity at the secondary 4-amino group.  A stepwise optimization by combination of active fragments led to the discovery of three structures with EGFR IC50 < 1 nM.  The most potent drug candidate had an IC50 of 0.3 nM towards EGFR and its mutants L858R and L861Q.  Studies using human cancer cell lines and an EGFR-L858R reporter cell system revealed good cellular potency, verifying the identified thienopyrimidines as promising lead structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqIJzK2_3fLVg90H21EOLACvtfcHk0ljN20LXhpStEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1Ojs7s%253D&md5=1a639bc8b6ea6b5996db573099bb5d6a</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.042%26sid%3Dliteratum%253Aachs%26aulast%3DBugge%26aufirst%3DS.%26aulast%3DKaspersen%26aufirst%3DS.%2BJ.%26aulast%3DLarsen%26aufirst%3DS.%26aulast%3DNonstad%26aufirst%3DU.%26aulast%3DBj%25C3%25B8rk%25C3%25B8y%26aufirst%3DG.%26aulast%3DSundby%26aufirst%3DE.%26aulast%3DHoff%26aufirst%3DB.%2BH.%26atitle%3DStructure-activity%2520study%2520leading%2520to%2520identification%2520of%2520a%2520highly%2520active%2520thienopyrimidine%2520based%2520EGFR%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D75%26spage%3D354%26epage%3D374%26doi%3D10.1016%2Fj.ejmech.2014.01.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rheault, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caferro, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spehar, G. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2008.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=817-820&author=T.+R.+Rheaultauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=K.+H.+Donaldsonauthor=M.+D.+Gaulauthor=A.+S.+Goetzauthor=R.+J.+Mullinauthor=O.+B.+McDonaldauthor=K.+G.+Petrovauthor=D.+W.+Rusnakauthor=L.+M.+Shewchukauthor=G.+H.+M.+Speharauthor=A.+T.+Truesdaleauthor=D.+E.+Vanderwallauthor=E.+R.+Woodauthor=D.+E.+Uehling&title=Thienopyrimidine-based+dual+EGFR%2FErbB-2+inhibitors&doi=10.1016%2Fj.bmcl.2008.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%2BD.%26aulast%3DGoetz%26aufirst%3DA.%2BS.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DSpehar%26aufirst%3DG.%2BH.%2BM.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DThienopyrimidine-based%2520dual%2520EGFR%252FErbB-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D817%26epage%3D820%26doi%3D10.1016%2Fj.bmcl.2008.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaechtele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totzke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krumbach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span> <span> </span><span class="NLM_article-title">Novel inhibitors of epidermal growth factor receptor: (4-(arylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-yl)(1<i>H</i>-indol-2-yl)methanones and (1<i>H</i>-indol-2-yl)(4-(phenylamino) thieno[2,3-<i>d</i>]pyrimidin-6-yl)methanones</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2011.11.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=125-136&author=T.+Beckersauthor=A.+Sellmerauthor=E.+Eichhornauthor=H.+Pongratzauthor=C.+Schaechteleauthor=F.+Totzkeauthor=G.+Kelterauthor=R.+Krumbachauthor=H.+H.+Fiebigauthor=F.+D.+Boehmerauthor=S.+Mahboobi&title=Novel+inhibitors+of+epidermal+growth+factor+receptor%3A+%284-%28arylamino%29-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-6-yl%29%281H-indol-2-yl%29methanones+and+%281H-indol-2-yl%29%284-%28phenylamino%29+thieno%5B2%2C3-d%5Dpyrimidin-6-yl%29methanones&doi=10.1016%2Fj.bmc.2011.11.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DBeckers%26aufirst%3DT.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DSchaechtele%26aufirst%3DC.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DKrumbach%26aufirst%3DR.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DBoehmer%26aufirst%3DF.%2BD.%26aulast%3DMahboobi%26aufirst%3DS.%26atitle%3DNovel%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%253A%2520%25284-%2528arylamino%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-6-yl%2529%25281H-indol-2-yl%2529methanones%2520and%2520%25281H-indol-2-yl%2529%25284-%2528phenylamino%2529%2520thieno%255B2%252C3-d%255Dpyrimidin-6-yl%2529methanones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D125%26epage%3D136%26doi%3D10.1016%2Fj.bmc.2011.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Milik, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serya, R. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-<i>d</i>]pyrimidine-based dual EGFR/HER2 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2018.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=29902719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFemsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=316-336&author=S.+N.+Milikauthor=A.+K.+Abdel-Azizauthor=D.+S.+Lasheenauthor=R.+A.+T.+Seryaauthor=S.+Minucciauthor=K.+A.+M.+Abouzid&title=Surmounting+the+resistance+against+EGFR+inhibitors+through+the+development+of+thieno%5B2%2C3-d%5Dpyrimidine-based+dual+EGFR%2FHER2+inhibitors&doi=10.1016%2Fj.ejmech.2018.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors</span></div><div class="casAuthors">Milik, Sandra N.; Abdel-Aziz, Amal Kamal; Lasheen, Deena S.; Serya, Rabah A. T.; Minucci, Saverio; Abouzid, Khaled A. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">316-336</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In light of the emergence of resistance against the currently available EGFR inhibitors, our study focuses on tackling this problem through the development of dual EGFR/HER2 inhibitors with improved enzymic affinities.  Guided by the binding mode of the marketed dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors based on the 6-phenylthieno[2,3-d]pyrimidine as a core scaffold and hinge binder.  After two cycles of screening aiming to identify the optimum aniline headgroup and solubilizing group, we eventually identified 27b as a dual EGFR/HER2 inhibitor with IC50 values of 91.7 nM and 1.2 μM, resp.  Notably, 27b dramatically reduced the viability of various patient-derived cancer cells preferentially overexpressing EGFR/HER2 (A431, MDA-MBA-361 and SKBr3 with IC50 values of 1.45, 3.5 and 4.83 μM, resp.).  Addnl., 27b efficiently thwarted the proliferation of lapatinib-resistant human non-small lung carcinoma (NCI-H1975) cells, harboring T790 M mutation, with IC50 of 4.2 μM.  Consistently, 27b significantly blocked EGF-induced EGFR activation and inactivated its downstream AKT/mTOR/S6 signalling pathway triggering apoptotic cell death in NCI-H1975 cells.  The present study presents a promising candidate for further design and development of novel EGFR/HER2 inhibitors capable of overcoming EGFR TKIs resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR7DEfVDfa_rVg90H21EOLACvtfcHk0ljN20LXhpStEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFemsbzK&md5=d4c6b29330f43b8ca3f7f3f6e2e85f8c</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DMilik%26aufirst%3DS.%2BN.%26aulast%3DAbdel-Aziz%26aufirst%3DA.%2BK.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DSerya%26aufirst%3DR.%2BA.%2BT.%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DSurmounting%2520the%2520resistance%2520against%2520EGFR%2520inhibitors%2520through%2520the%2520development%2520of%2520thieno%255B2%252C3-d%255Dpyrimidine-based%2520dual%2520EGFR%252FHER2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D316%26epage%3D336%26doi%3D10.1016%2Fj.ejmech.2018.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higdon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillerman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderstrom, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauth, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolov, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2003.10.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=21-24&author=M.+J.+Munchhofauthor=J.+S.+Beebeauthor=J.+M.+Casavantauthor=B.+A.+Cooperauthor=J.+L.+Dotyauthor=R.+C.+Higdonauthor=S.+M.+Hillermanauthor=C.+I.+Soderstromauthor=E.+A.+Knauthauthor=M.+A.+Marxauthor=A.+M.+Rossiauthor=S.+B.+Sobolovauthor=J.+Sun&title=Design+and+SAR+of+thienopyrimidine+and+thienopyridine+inhibitors+of+VEGFR-2+kinase+activity&doi=10.1016%2Fj.bmcl.2003.10.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DHigdon%26aufirst%3DR.%2BC.%26aulast%3DHillerman%26aufirst%3DS.%2BM.%26aulast%3DSoderstrom%26aufirst%3DC.%2BI.%26aulast%3DKnauth%26aufirst%3DE.%2BA.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DSobolov%26aufirst%3DS.%2BB.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520SAR%2520of%2520thienopyrimidine%2520and%2520thienopyridine%2520inhibitors%2520of%2520VEGFR-2%2520kinase%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D21%26epage%3D24%26doi%3D10.1016%2Fj.bmcl.2003.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kemnitzer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisoma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S. X.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-anilino-<i>N</i>-methylthieno[3,2-<i>d</i>]pyrimidines and 4-anilino-<i>N</i>-methylthieno[2,3-<i>d</i>]pyrimidines as potent apoptosis inducers</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3536</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2009.04.145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3536-3540&author=W.+Kemnitzerauthor=N.+Sirisomaauthor=C.+Mayauthor=B.+Tsengauthor=J.+Dreweauthor=S.+X.+Cai&title=Discovery+of+4-anilino-N-methylthieno%5B3%2C2-d%5Dpyrimidines+and+4-anilino-N-methylthieno%5B2%2C3-d%5Dpyrimidines+as+potent+apoptosis+inducers&doi=10.1016%2Fj.bmcl.2009.04.145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.145%26sid%3Dliteratum%253Aachs%26aulast%3DKemnitzer%26aufirst%3DW.%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DMay%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DDiscovery%2520of%25204-anilino-N-methylthieno%255B3%252C2-d%255Dpyrimidines%2520and%25204-anilino-N-methylthieno%255B2%252C3-d%255Dpyrimidines%2520as%2520potent%2520apoptosis%2520inducers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3536%26epage%3D3540%26doi%3D10.1016%2Fj.bmcl.2009.04.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bugge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buene, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurisch-Yaksi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moen, I. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skjønsfjell, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, B. H.</span></span> <span> </span><span class="NLM_article-title">Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ejmech.2015.11.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=255-274&author=S.+Buggeauthor=A.+F.+Bueneauthor=N.+Jurisch-Yaksiauthor=I.+U.+Moenauthor=E.+M.+Skj%C3%B8nsfjellauthor=E.+Sundbyauthor=B.+H.+Hoff&title=Extended+structure-activity+study+of+thienopyrimidine-based+EGFR+inhibitors+with+evaluation+of+drug-like+properties&doi=10.1016%2Fj.ejmech.2015.11.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DBugge%26aufirst%3DS.%26aulast%3DBuene%26aufirst%3DA.%2BF.%26aulast%3DJurisch-Yaksi%26aufirst%3DN.%26aulast%3DMoen%26aufirst%3DI.%2BU.%26aulast%3DSkj%25C3%25B8nsfjell%26aufirst%3DE.%2BM.%26aulast%3DSundby%26aufirst%3DE.%26aulast%3DHoff%26aufirst%3DB.%2BH.%26atitle%3DExtended%2520structure-activity%2520study%2520of%2520thienopyrimidine-based%2520EGFR%2520inhibitors%2520with%2520evaluation%2520of%2520drug-like%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D107%26spage%3D255%26epage%3D274%26doi%3D10.1016%2Fj.ejmech.2015.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetter, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binnun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Mazza, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes-Pesquera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, S. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-<i>d</i>]pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2333</span>– <span class="NLM_lpage">2337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2009.02.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2333-2337&author=R.+Linauthor=S.+G.+Johnsonauthor=P.+J.+Connollyauthor=S.+K.+Wetterauthor=E.+Binnunauthor=T.+V.+Hughesauthor=W.+V.+Murrayauthor=N.+B.+Pandeyauthor=S.+J.+Moreno-Mazzaauthor=M.+Adamsauthor=A.+R.+Fuentes-Pesqueraauthor=S.+A.+Middleton&title=Synthesis+and+evaluation+of+2%2C7-diamino-thiazolo%5B4%2C5-d%5Dpyrimidine+analogues+as+anti-tumor+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2009.02.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.067%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DS.%2BG.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DWetter%26aufirst%3DS.%2BK.%26aulast%3DBinnun%26aufirst%3DE.%26aulast%3DHughes%26aufirst%3DT.%2BV.%26aulast%3DMurray%26aufirst%3DW.%2BV.%26aulast%3DPandey%26aufirst%3DN.%2BB.%26aulast%3DMoreno-Mazza%26aufirst%3DS.%2BJ.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25202%252C7-diamino-thiazolo%255B4%252C5-d%255Dpyrimidine%2520analogues%2520as%2520anti-tumor%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2333%26epage%3D2337%26doi%3D10.1016%2Fj.bmcl.2009.02.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of analogues of (<i>Z</i>)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2293</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1021/jm00090a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00090a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2293-2306&author=M.+Cushmanauthor=D.+Nagarathnamauthor=D.+Gopalauthor=H.-M.+Heauthor=C.+M.+Linauthor=E.+Hamel&title=Synthesis+and+evaluation+of+analogues+of+%28Z%29-1-%284-methoxyphenyl%29-2-%283%2C4%2C5-trimethoxyphenyl%29ethene+as+potential+cytotoxic+and+antimitotic+agents&doi=10.1021%2Fjm00090a021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Fjm00090a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00090a021%26sid%3Dliteratum%253Aachs%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DGopal%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.-M.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520analogues%2520of%2520%2528Z%2529-1-%25284-methoxyphenyl%2529-2-%25283%252C4%252C5-trimethoxyphenyl%2529ethene%2520as%2520potential%2520cytotoxic%2520and%2520antimitotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2293%26epage%3D2306%26doi%3D10.1021%2Fjm00090a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nihei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span> <span> </span><span class="NLM_article-title">Novel B-ring modified combretastatin analogues: synthesis and antineoplastic activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3371</span>– <span class="NLM_lpage">3374</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00622-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2FS0960-894X%2898%2900622-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3371-3374&author=T.+Hatanakaauthor=K.+Fujitaauthor=K.+Ohsumiauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=Y.+Niheiauthor=Y.+Sugaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Novel+B-ring+modified+combretastatin+analogues%3A+synthesis+and+antineoplastic+activity&doi=10.1016%2FS0960-894X%2898%2900622-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900622-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900622-2%26sid%3Dliteratum%253Aachs%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DNovel%2520B-ring%2520modified%2520combretastatin%2520analogues%253A%2520synthesis%2520and%2520antineoplastic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3371%26epage%3D3374%26doi%3D10.1016%2FS0960-894X%2898%2900622-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luqman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konwar, R.</span></span> <span> </span><span class="NLM_article-title">Natural antitubulin agents: Importance of 3,4,5-trimethoxyphenyl fragment</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2014.12.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=373-389&author=A.+S.+Negiauthor=Y.+Gautamauthor=S.+Alamauthor=D.+Chandaauthor=S.+Luqmanauthor=J.+Sarkarauthor=F.+Khanauthor=R.+Konwar&title=Natural+antitubulin+agents%3A+Importance+of+3%2C4%2C5-trimethoxyphenyl+fragment&doi=10.1016%2Fj.bmc.2014.12.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.027%26sid%3Dliteratum%253Aachs%26aulast%3DNegi%26aufirst%3DA.%2BS.%26aulast%3DGautam%26aufirst%3DY.%26aulast%3DAlam%26aufirst%3DS.%26aulast%3DChanda%26aufirst%3DD.%26aulast%3DLuqman%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DF.%26aulast%3DKonwar%26aufirst%3DR.%26atitle%3DNatural%2520antitubulin%2520agents%253A%2520Importance%2520of%25203%252C4%252C5-trimethoxyphenyl%2520fragment%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D373%26epage%3D389%26doi%3D10.1016%2Fj.bmc.2014.12.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devambatla, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and preclinical evaluation of 5-methyl-N<sup>4</sup>-aryl-furo[2,3-<i>d</i>]pyrimidines as single agents with combination chemotherapy potential</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3085</span>– <span class="NLM_lpage">3093</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmcl.2018.07.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3085-3093&author=R.+K.+V.+Devambatlaauthor=S.+Choudharyauthor=M.+Ihnatauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=Design%2C+synthesis+and+preclinical+evaluation+of+5-methyl-N4-aryl-furo%5B2%2C3-d%5Dpyrimidines+as+single+agents+with+combination+chemotherapy+potential&doi=10.1016%2Fj.bmcl.2018.07.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DDevambatla%26aufirst%3DR.%2BK.%2BV.%26aulast%3DChoudhary%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520preclinical%2520evaluation%2520of%25205-methyl-N4-aryl-furo%255B2%252C3-d%255Dpyrimidines%2520as%2520single%2520agents%2520with%2520combination%2520chemotherapy%2520potential%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3085%26epage%3D3093%26doi%3D10.1016%2Fj.bmcl.2018.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavana, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical evaluation of 7-benzyl-<i>N</i>-(substituted)-pyrrolo[3,2-<i>d</i>]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2016.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27894589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=545-556&author=R.+K.+Pavanaauthor=S.+Choudharyauthor=A.+Bastianauthor=M.+A.+Ihnatauthor=R.+Baiauthor=E.+Hamelauthor=A.+Gangjee&title=Discovery+and+preclinical+evaluation+of+7-benzyl-N-%28substituted%29-pyrrolo%5B3%2C2-d%5Dpyrimidin-4-amines+as+single+agents+with+microtubule+targeting+effects+along+with+triple-acting+angiokinase+inhibition+as+antitumor+agents&doi=10.1016%2Fj.bmc.2016.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span></div><div class="casAuthors">Pavana, Roheeth Kumar; Choudhary, Shruti; Bastian, Anja; Ihnat, Michael A.; Bai, Ruoli; Hamel, Ernest; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The utility of cytostatic antiangiogenic agents (AA) in cancer chemotherapy lies in their combination with cytotoxic chemotherapeutic agents.  Clin. combinations of AA with microtubule targeting agents (MTAs) have been particularly successful.  The discovery, synthesis and biol. evaluations of a series of 7-benzyl-N-substituted-pyrrolo[3,2-d]pyrimidin-4-amines are reported.  Novel compds. which inhibit proangiogenic receptor tyrosine kinases (RTKs) including vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β) and epidermal growth factor receptor (EGFR), along with microtubule targeting in single mols. are described.  These compds. also inhibited blood vessel formation in the chicken chorioallantoic membrane (CAM) assay, and some potently inhibited tubulin assembly (with activity comparable to that of combretastatin A-4 (CA)).  In addn., some of the analogs circumvent the most clin. relevant tumor resistance mechanisms (P-glycoprotein and β-III tubulin expression) to microtubule targeting agents (MTA).  These MTAs bind at the colchicine site on tubulin.  Two analogs displayed two to three digit nanomolar GIC50 values across the entire NCI 60 tumor cell panel and one of these, compd. 7, freely water sol. as its HCl salt, afforded excellent in vivo antitumor activity against an orthotopic triple neg. 4T1 breast cancer model and was superior to doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwGOvmBOf0h7Vg90H21EOLACvtfcHk0lj74FEMWwYOsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM&md5=9fd3c0008bda8c9222761f9d344610e6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DPavana%26aufirst%3DR.%2BK.%26aulast%3DChoudhary%26aufirst%3DS.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520preclinical%2520evaluation%2520of%25207-benzyl-N-%2528substituted%2529-pyrrolo%255B3%252C2-d%255Dpyrimidin-4-amines%2520as%2520single%2520agents%2520with%2520microtubule%2520targeting%2520effects%2520along%2520with%2520triple-acting%2520angiokinase%2520inhibition%2520as%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D545%26epage%3D556%26doi%3D10.1016%2Fj.bmc.2016.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-<i>d</i>]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bmc.2015.03.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25882519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2408-2423&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=E.+Hamelauthor=C.+Zammielloauthor=A.+Bastianauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design%2C+synthesis+and+biological+evaluation+of+conformationally+restricted+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multi-targeted+receptor+tyrosine+kinase+and+microtubule+inhibitors+as+potential+antitumor+agents&doi=10.1016%2Fj.bmc.2015.03.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Hamel, Ernest; Zammiello, Cynthia; Bastian, Anja; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2423</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of eleven conformationally restricted, 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines was designed to explore the bioactive conformation required for dual inhibition of microtubule assembly and receptor tyrosine kinases (RTKs), and their biol. activities are reported.  All three rotatable single bonds in the lead compd. were sequentially restricted to address the role of each in SAR for microtubule and RTK inhibitory effects.  Several compds. showed microtubule depolymg. activity comparable to or better than the lead compd., some with nanomolar EC50 values.  One compd. had no effect on microtubules, others showed potent RTK inhibition with nanomolar IC50s.  These compds. confirm that the bioactive conformation for RTK inhibition is different from that for tubulin inhibition.  A tetrahydroquinoline analog showed the most potent dual tubulin inhibitors (i.e., tubulin polymn. inhibitors, microtubule-disrupting agents) and RTK inhibitory activities [i.e., low nanomolar inhibition of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFR-β)].  The tetrahydroquinoline analog has highly potent activity against many NCI cancer cell lines, including several chemo-resistant cell lines, and could serve as a lead for further preclin. studies.  The synthesis of the target compds. was achieved by a reaction of 4-chloro-2,6-dimethylfuro[2,3-d]pyrimidine with amine derivs., such as benzenamine derivs., benzofuranamine derivs., tetrahydroquinoline derivs., indole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3IUVQLu9YarVg90H21EOLACvtfcHk0lj74FEMWwYOsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D&md5=4a6d65424606155db3ab4ec5751ad213</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DZammiello%26aufirst%3DC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multi-targeted%2520receptor%2520tyrosine%2520kinase%2520and%2520microtubule%2520inhibitors%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2408%26epage%3D2423%26doi%3D10.1016%2Fj.bmc.2015.03.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, M. F.</span></span> <span> </span><span class="NLM_article-title">The design and development of potent small molecules as anticancer agents targeting EGFR TK and tubulin polymerization</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">408</span>, <span class="refDoi"> DOI: 10.3390/ijms19020408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fijms19020408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=408&author=S.+Ihmaidauthor=H.+E.+A.+Ahmedauthor=M.+F.+Zayed&title=The+design+and+development+of+potent+small+molecules+as+anticancer+agents+targeting+EGFR+TK+and+tubulin+polymerization&doi=10.3390%2Fijms19020408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The design and development of potent small molecules as anticancer agents targeting EGFR TK and tubulin polymerization</span></div><div class="casAuthors">Ihmaid, Saleh; Ahmed, Hany E. A.; Zayed, Mohamed F.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">408/1-408/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Some novel anthranilate diamides derivs. 4a-e, 6a-c and 9a-d were designed and synthesized to be evaluated for their in vitro anticancer activity.  Structures of all newly synthesized compds. were confirmed by infra-red (IR), high-resoln. mass (HR-MS) spectra, 1H NMR (NMR) and 13C NMR (NMR) analyses.  Cytotoxic screening was performed according to (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium (MTT) assay method using erlotinib as a ref. drug against two different types of breast cancer cells.  The mol. docking study was performed for representative compds. against two targets, epidermal growth factor receptor (EGFR) and tubulin in colchicine binding site to assess their binding affinities in order to rationalize their anticancer activity in a qual. way.  The data obtained from the mol. modeling was correlated with that obtained from the biol. screening.  These data showed considerable anticancer activity for these newly synthesized compds.  Biol. data for most of the anthranilate diamide showed excellent activity with nanomolar or sub nanomolar half maximal inhibitory concn. (IC50) values against tumor cells.  EGFR tyrosine kinase (TK) inhibition assay, tubulin inhibition assay and apoptosis anal. were performed for selected compds. to get more details about their mechanism of action.  Extensive structure activity relationship (SAR) analyses were also carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Hwp1J1XowrVg90H21EOLACvtfcHk0lhduC5bCb7kDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7bJ&md5=c1eb543d1cac9d6f6a39d8ec807ac70d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3390%2Fijms19020408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19020408%26sid%3Dliteratum%253Aachs%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DH.%2BE.%2BA.%26aulast%3DZayed%26aufirst%3DM.%2BF.%26atitle%3DThe%2520design%2520and%2520development%2520of%2520potent%2520small%2520molecules%2520as%2520anticancer%2520agents%2520targeting%2520EGFR%2520TK%2520and%2520tubulin%2520polymerization%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D408%26doi%3D10.3390%2Fijms19020408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mphahlele, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maluleka, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parbhoo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malindisa, S. T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, evaluation for cytotoxicity and molecular docking studies of benzo[<i>c</i>]furan-chalcones for potential to inhibit tubulin polymerization and/or EGFR-tyrosine kinase phosphorylation</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2552</span>, <span class="refDoi"> DOI: 10.3390/ijms19092552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fijms19092552" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2552&author=M.+J.+Mphahleleauthor=M.+M.+Malulekaauthor=N.+Parbhooauthor=S.+T.+Malindisa&title=Synthesis%2C+evaluation+for+cytotoxicity+and+molecular+docking+studies+of+benzo%5Bc%5Dfuran-chalcones+for+potential+to+inhibit+tubulin+polymerization+and%2For+EGFR-tyrosine+kinase+phosphorylation&doi=10.3390%2Fijms19092552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3390%2Fijms19092552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19092552%26sid%3Dliteratum%253Aachs%26aulast%3DMphahlele%26aufirst%3DM.%2BJ.%26aulast%3DMaluleka%26aufirst%3DM.%2BM.%26aulast%3DParbhoo%26aufirst%3DN.%26aulast%3DMalindisa%26aufirst%3DS.%2BT.%26atitle%3DSynthesis%252C%2520evaluation%2520for%2520cytotoxicity%2520and%2520molecular%2520docking%2520studies%2520of%2520benzo%255Bc%255Dfuran-chalcones%2520for%2520potential%2520to%2520inhibit%2520tubulin%2520polymerization%2520and%252For%2520EGFR-tyrosine%2520kinase%2520phosphorylation%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2552%26doi%3D10.3390%2Fijms19092552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rateb, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, S. R. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, cytotoxic evaluation and molecular docking of new fluoroquinazolinones as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1731</span>, <span class="refDoi"> DOI: 10.3390/ijms19061731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fijms19061731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWmsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1731&author=M.+F.+Zayedauthor=S.+Ahmedauthor=S.+Ihmaidauthor=H.+E.+A.+Ahmedauthor=H.+S.+Ratebauthor=S.+R.+M.+Ibrahim&title=Design%2C+synthesis%2C+cytotoxic+evaluation+and+molecular+docking+of+new+fluoroquinazolinones+as+potent+anticancer+agents+with+dual+EGFR+kinase+and+tubulin+polymerization+inhibitory+effects&doi=10.3390%2Fijms19061731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, cytotoxic evaluation and molecular docking of new fluoroquinazolinones as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span></div><div class="casAuthors">Zayed, Mohamed; Ahmed, Sahar; Ihmaid, Saleh; Ahmed, Hany; Rateb, Heba; Ibrahim, Sabrin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1731/1-1731/16</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A series of new fluoroquinazolinone 6-8 and 10a-g derivs. was designed, prepd. and screened for their in vitro cytotoxic activity against human cancer cell lines MCF-7 and MDA-MBA-231.  Compds. 6 (IC50 = 0.35 ± 0.01 μM), 10f (IC50 = 0.71 ± 0.01 μM), 10d (IC50 = 0.89 ± 0.02 μM) and 10a (IC50 = 0.95 ± 0.01 μM) displayed broad spectrum anticancer activity better than the ref. drug gefitinib (IC50 = 0.97 ± 0.02 μM) against MCF-7.  Compds. 10e (IC50 = 0.28 ± 0.02 μM), 10d (IC50 = 0.38 ± 0.01 μM), 7 (IC50 = 0.94 ± 0.07 μM) and 10c (IC50 = 1.09 ± 0.01 μM) showed better activity than the ref. gefitinib (IC50 = 1.30 ± 0.04 μM) againstMDA-MBA-231.  Moreover, EGFR and tubulin inhibition assays were performed for the highest active derivs. and showed remarkable results comparing to the ref. drugs.  In order to assess and explain their binding affinities,mol. docking simulation was studied against EGFR and tubulin binding sites.  The results obtained from mol. docking study and those obtained from cytotoxic screening were correlated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ztVlxQjMObVg90H21EOLACvtfcHk0lhduC5bCb7kDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWmsLfM&md5=47d6f49bcc9d35d59c6fb45e0936f08c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3390%2Fijms19061731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19061731%26sid%3Dliteratum%253Aachs%26aulast%3DZayed%26aufirst%3DM.%2BF.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DH.%2BE.%2BA.%26aulast%3DRateb%26aufirst%3DH.%2BS.%26aulast%3DIbrahim%26aufirst%3DS.%2BR.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520cytotoxic%2520evaluation%2520and%2520molecular%2520docking%2520of%2520new%2520fluoroquinazolinones%2520as%2520potent%2520anticancer%2520agents%2520with%2520dual%2520EGFR%2520kinase%2520and%2520tubulin%2520polymerization%2520inhibitory%2520effects%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1731%26doi%3D10.3390%2Fijms19061731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rateb, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, S. R. M.</span></span> <span> </span><span class="NLM_article-title">Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and tubulin polymerization</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1699</span>, <span class="refDoi"> DOI: 10.3390/molecules23071699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fmolecules23071699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWgt7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1699&author=M.+F.+Zayedauthor=H.+S.+Ratebauthor=S.+Ahmedauthor=O.+A.+Khaledauthor=S.+R.+M.+Ibrahim&title=Quinazolinone-amino+acid+hybrids+as+dual+inhibitors+of+EGFR+kinase+and+tubulin+polymerization&doi=10.3390%2Fmolecules23071699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and tubulin polymerization</span></div><div class="casAuthors">Zayed, Mohamed F.; Rateb, Heba S.; Ahmed, Sahar; Khaled, Osama A.; Ibrahim, Sabrin R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699/1-1699/17</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Some fluoroquinazolinones (A-H) were designed, synthesized and biol. evaluated for their antitumor activity against the two cell lines, MCF-7 and MDA-MBA-231.  New deriv. G (IC50 = 0.44 ± 0.01 μM) showed antitumor activity, better than that of the ref. drug erlotinib (IC50 = 1.14 ± 0.04 μM) against MCF-7.  New deriv. E (IC50 = 0.43 ± 0.02 μM) showed higher activity than the ref. drug erlotinib (IC50 = 2.55 ± 0.19 μM) against MDA-MBA-231.  Furthermore, the EGFR (epidermal growth factor receptor) and tubulin inhibition assays were carried out for the highest active derivs. to reveal the expected mechanism of action.  They exhibited significant results compared to the ref. drugs.  Mol. docking simulations were performed on EGFR and tubulin binding sites to rationalize the exptl. results and describe their binding modes.  The results of the mol. modeling study were correlated with that of the antitumor screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquX3CVwn1JtbVg90H21EOLACvtfcHk0lhduC5bCb7kDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWgt7rO&md5=212c5aa690adf5c4f7b3064b4a0dd4f9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23071699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23071699%26sid%3Dliteratum%253Aachs%26aulast%3DZayed%26aufirst%3DM.%2BF.%26aulast%3DRateb%26aufirst%3DH.%2BS.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DKhaled%26aufirst%3DO.%2BA.%26aulast%3DIbrahim%26aufirst%3DS.%2BR.%2BM.%26atitle%3DQuinazolinone-amino%2520acid%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520EGFR%2520kinase%2520and%2520tubulin%2520polymerization%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D1699%26doi%3D10.3390%2Fmolecules23071699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alswah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgamal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmorsy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. E. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing triazolo[4,3-<i>a</i>]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">48</span>, <span class="refDoi"> DOI: 10.3390/molecules23010048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.3390%2Fmolecules23010048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyhsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=48&author=M.+Alswahauthor=A.+H.+Bayoumiauthor=K.+Elgamalauthor=A.+Elmorsyauthor=S.+Ihmaidauthor=H.+E.+A.+Ahmed&title=Design%2C+synthesis+and+cytotoxic+evaluation+of+novel+chalcone+derivatives+bearing+triazolo%5B4%2C3-a%5D-quinoxaline+moieties+as+potent+anticancer+agents+with+dual+EGFR+kinase+and+tubulin+polymerization+inhibitory+effects&doi=10.3390%2Fmolecules23010048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing triazolo[4,3-a]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects</span></div><div class="casAuthors">Alswah, Mohamed; Bayoumi, Ashraf H.; Elgamal, Kamal; Elmorsy, Ahmed; Ihmaid, Saleh; Ahmed, Hany E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-63</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A series of hybrid of triazoloquinoxaline-chalcone derivs. 7a-k were designed, synthesized, fully characterized, and evaluated for their cytotoxic activity against three target cell lines: human breast adenocarcinoma (MCF-7), human colon carcinoma (HCT-116), and human hepatocellular carcinoma (HEPG-2).  The preliminary results showed that some of these chalcones like 7b-c, and 7e-g exhibited significant antiproliferative effects against most of the cell lines, with selective or non-selective behavior, indicated by IC50 values in the 1.65 to 34.28 μM range.  In order to investigate the mechanistic aspects of these active compds., EGFR TK and tubulin inhibitory activities were measured as further biol. assays.  The EGFR TK assay results revealed that the derivs. 7a-c, 7e, and 7g could inhibit the EGFR TK in the submicromolar range (0.093 to 0.661 μM).  Moreover, an antitubulin polymn. effect was noted for the active derivs. compared to the ref. drug colchicine, with compds. 7e and 7g displaying 14.7 and 8.4 micromolar activity, resp.  Furthermore, a mol. docking study was carried out to explain the obsd. effects and the binding modes of these chalcones with the EGFR TK and tubulin targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEB9NazeaK9rVg90H21EOLACvtfcHk0ljo3a_wb5BnXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyhsL7I&md5=5e85313ba8f03cd5eda031d3f838dd09</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23010048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23010048%26sid%3Dliteratum%253Aachs%26aulast%3DAlswah%26aufirst%3DM.%26aulast%3DBayoumi%26aufirst%3DA.%2BH.%26aulast%3DElgamal%26aufirst%3DK.%26aulast%3DElmorsy%26aufirst%3DA.%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DH.%2BE.%2BA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520cytotoxic%2520evaluation%2520of%2520novel%2520chalcone%2520derivatives%2520bearing%2520triazolo%255B4%252C3-a%255D-quinoxaline%2520moieties%2520as%2520potent%2520anticancer%2520agents%2520with%2520dual%2520EGFR%2520kinase%2520and%2520tubulin%2520polymerization%2520inhibitory%2520effects%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D48%26doi%3D10.3390%2Fmolecules23010048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0ljo3a_wb5BnXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-alkoxycarbonyl-3-anilino benzo[<i>b</i>]thiophenes and thieno[2,3-<i>c</i>]pyridines as new potent anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2606</span>– <span class="NLM_lpage">2618</span>, <span class="refDoi"> DOI: 10.1021/jm400043d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400043d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2606-2618&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=D.+Pretiauthor=M.+A.+Tabriziauthor=M.+Bassettoauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Synthesis+and+biological+evaluation+of+2-alkoxycarbonyl-3-anilino+benzo%5Bb%5Dthiophenes+and+thieno%5B2%2C3-c%5Dpyridines+as+new+potent+anticancer+agents&doi=10.1021%2Fjm400043d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm400043d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400043d%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBassetto%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-alkoxycarbonyl-3-anilino%2520benzo%255Bb%255Dthiophenes%2520and%2520thieno%255B2%252C3-c%255Dpyridines%2520as%2520new%2520potent%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2606%26epage%3D2618%26doi%3D10.1021%2Fjm400043d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lijgtlMw-sW0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosako, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okigaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">25543</span>– <span class="NLM_lpage">25549</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.36.25543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1074%2Fjbc.274.36.25543" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=25543-25549&author=H.+Gotoauthor=Y.+Tomonoauthor=K.+Ajiroauthor=H.+Kosakoauthor=M.+Fujitaauthor=M.+Sakuraiauthor=K.+Okawaauthor=A.+Iwamatsuauthor=T.+Okigakiauthor=T.+Takahashiauthor=M.+Inagaki&title=Identification+of+a+novel+phosphorylation+site+on+histone+H3+coupled+with+mitotic+chromosome+condensation&doi=10.1074%2Fjbc.274.36.25543"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.36.25543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.36.25543%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DH.%26aulast%3DTomono%26aufirst%3DY.%26aulast%3DAjiro%26aufirst%3DK.%26aulast%3DKosako%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DOkawa%26aufirst%3DK.%26aulast%3DIwamatsu%26aufirst%3DA.%26aulast%3DOkigaki%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DInagaki%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520a%2520novel%2520phosphorylation%2520site%2520on%2520histone%2520H3%2520coupled%2520with%2520mitotic%2520chromosome%2520condensation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D25543%26epage%3D25549%26doi%3D10.1074%2Fjbc.274.36.25543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">Mitochondria-mediated apoptosis in mammals</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1007/s13238-014-0089-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2Fs13238-014-0089-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=25073422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KmtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=737-749&author=S.+Xiongauthor=T.+Muauthor=G.+Wangauthor=X.+Jiang&title=Mitochondria-mediated+apoptosis+in+mammals&doi=10.1007%2Fs13238-014-0089-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria-mediated apoptosis in mammals</span></div><div class="casAuthors">Xiong, Shunbin; Mu, Tianyang; Wang, Guowen; Jiang, Xuejun</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  The mitochondria-mediated caspase activation pathway is a major apoptotic pathway characterized by mitochondrial outer membrane permeabilization (MOMP) and subsequent release of cytochrome c into the cytoplasm to activate caspases.  MOMP is regulated by the Bcl-2 family of proteins.  This pathway plays important roles not only in normal development, maintenance of tissue homeostasis and the regulation of immune system, but also in human diseases such as immune disorders, neurodegeneration and cancer.  In the past decades the mol. basis of this pathway and the regulatory mechanism have been comprehensively studied, yet a great deal of new evidence indicates that cytochrome c release from mitochondria does not always lead to irreversible cell death, and that caspase activation can also have non-death functions.  Thus, many unsolved questions and new challenges are still remaining.  Furthermore, the dysfunction of this pathway involved in cancer development is obvious, and targeting the pathway as a therapeutic strategy has been extensively explored, but the efficacy of the targeted therapies is still under development.  In this review we will discuss the mitochondria-mediated apoptosis pathway and its physiol. roles and therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjf5-e940_9bVg90H21EOLACvtfcHk0lijgtlMw-sW0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KmtbbK&md5=184dc962ee08b440729fda6ec65ecc10</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs13238-014-0089-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-014-0089-1%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DS.%26aulast%3DMu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DX.%26atitle%3DMitochondria-mediated%2520apoptosis%2520in%2520mammals%26jtitle%3DProtein%2520Cell%26date%3D2014%26volume%3D5%26spage%3D737%26epage%3D749%26doi%3D10.1007%2Fs13238-014-0089-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rovini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braguer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carré, M.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeted agents: when mitochondria become essential to chemotherapy</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1807</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1016/j.bbabio.2011.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1016%2Fj.bbabio.2011.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21216222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFSitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1807&publication_year=2011&pages=679-688&author=A.+Roviniauthor=A.+Savryauthor=D.+Braguerauthor=M.+Carr%C3%A9&title=Microtubule-targeted+agents%3A+when+mitochondria+become+essential+to+chemotherapy&doi=10.1016%2Fj.bbabio.2011.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeted agents: When mitochondria become essential to chemotherapy</span></div><div class="casAuthors">Rovini, A.; Savry, A.; Braguer, D.; Carre, M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1807</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-688</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Microtubule-Targeting Agents (MTAs) constitute a class of drugs largely used for cancer treatment in adults and children.  In cancer cells, they suppress microtubule dynamics, and induce cell death via the mitochondrial intrinsic pathway.  To date, links between mitochondria and microtubule network disturbance in MTAs mechanism of action are not obvious.  The aim of the present contribution is to provide elements that could answer to the question: how far are mitochondria essential to anticancer chemotherapy that targets the microtubule cytoskeleton We review the main mol. candidates to link microtubule alteration with the apoptotic mitochondrial pathway control.  Involvement of direct targeting of mitochondria in MTA efficacy is also discussed.  Furthermore, we line up current evidence and emerging concepts on the participation of both mitochondria and microtubule in MTA neurotoxic side effects.  To decipher the interconnections between the mitochondrial and the microtubule networks may help to improve cancer cell response to chemotherapy.  This article is part of a Special Issue entitled: Bioenergetics of Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHCjULnreE0rVg90H21EOLACvtfcHk0lijgtlMw-sW0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFSitro%253D&md5=2afa1b9807076eaa0696d5d959f9457b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2011.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2011.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRovini%26aufirst%3DA.%26aulast%3DSavry%26aufirst%3DA.%26aulast%3DBraguer%26aufirst%3DD.%26aulast%3DCarr%25C3%25A9%26aufirst%3DM.%26atitle%3DMicrotubule-targeted%2520agents%253A%2520when%2520mitochondria%2520become%2520essential%2520to%2520chemotherapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2011%26volume%3D1807%26spage%3D679%26epage%3D688%26doi%3D10.1016%2Fj.bbabio.2011.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Policarpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenciarelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanzarella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoccia, A.</span></span> <span> </span><span class="NLM_article-title">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison combretastatin-A4</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1007/s10495-011-0619-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2Fs10495-011-0619-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21671007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=940-949&author=G.+Mendezauthor=C.+Policarpiauthor=C.+Cenciarelliauthor=C.+Tanzarellaauthor=A.+Antoccia&title=Role+of+Bim+in+apoptosis+induced+in+H460+lung+tumor+cells+by+the+spindle+poison+combretastatin-A4&doi=10.1007%2Fs10495-011-0619-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison Combretastatin-A4</span></div><div class="casAuthors">Mendez, G.; Policarpi, C.; Cenciarelli, C.; Tanzarella, C.; Antoccia, A.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-949</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The BH3-only Bcl-2 subfamily member Bim is a well known apoptosis promoting protein.  However, the mechanisms upstream of mitochondrion membrane permeability by which Bim is involved in apoptosis have been poorly investigated, particularly in response to agents capable of interfering with the cytoskeleton architecture and arresting cells in mitosis.  Based on the observation that Bim is sequestered on the microtubule-array by interaction with the light chain of dynein, we have investigated upon depolymn., whether Bim could be involved in the commitment of apoptosis.  With this purpose H460 Non Small Lung Cancer Cells (NSLC) were treated with the microtubule damaging agent combretastatin-A4 (CA-4) (7.5 nM; 8-48 h), and various parameters were investigated.  Upon treatment, cells arrested in mitosis and died through a caspase-3-dependent mitotic catastrophe.  Transient knock down of Bim drastically reduced apoptosis, indicating that this protein was involved in cell death as induced by microtubules disorganisation.  In response to increasing conditions of microtubules depolymn., we found that the protein level of Bim was strongly upregulated in a time-dependent manner at transcriptional level.  Furthermore, Bim was released from microtubule-assocd. components.  Bim was translocated to mitochondria, even in a condition of protein synthesis inhibition, where it showed a markedly increased interaction with Bcl-2.  In turn, the fraction of Bax bound to Bcl-2 decreases in response to treatment, thereby indicating that Bim possibly promotes Bax release from the pro-survival protein Bcl-2.  Overall, we demonstrated that Bim is required for the CA-4-induced cell death in the H460 lung cancer cell line via activation of the mitochondrial signalling pathway.  Defining the contribution of Bim to the mechanism of apoptosis may offer some different clues in view of developing new strategies for chemotherapy with CA-4, underlining the relevance of the cytoskeleton integrity in the apoptotic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFAXUMi6LRGLVg90H21EOLACvtfcHk0lhQxhNa_Dbu2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF&md5=f2c8e59481098e10b8939421d59170b9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs10495-011-0619-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-011-0619-8%26sid%3Dliteratum%253Aachs%26aulast%3DMendez%26aufirst%3DG.%26aulast%3DPolicarpi%26aufirst%3DC.%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DRole%2520of%2520Bim%2520in%2520apoptosis%2520induced%2520in%2520H460%2520lung%2520tumor%2520cells%2520by%2520the%2520spindle%2520poison%2520combretastatin-A4%26jtitle%3DApoptosis%26date%3D2011%26volume%3D16%26spage%3D940%26epage%3D949%26doi%3D10.1007%2Fs10495-011-0619-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a series of 2-aryl-4-amino-5-(3′,4′,5′-trimethoxybenzoyl)thiazoles as novel anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5433</span>– <span class="NLM_lpage">5445</span>, <span class="refDoi"> DOI: 10.1021/jm300388h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300388h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvV2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5433-5445&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=D.+Pretiauthor=M.+A.+Tabriziauthor=A.+Brancaleauthor=X.-H.+Fuauthor=J.+Liauthor=S.-Z.+Zhangauthor=E.+Hamelauthor=R.+Bortolozziauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Discovery+and+optimization+of+a+series+of+2-aryl-4-amino-5-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29thiazoles+as+novel+anticancer+agents&doi=10.1021%2Fjm300388h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Salvador, Maria Kimatrai; Preti, Delia; Aghazadeh Tabrizi, Mojgan; Brancale, Andrea; Fu, Xian-Hua; Li, Jun; Zhang, Su-Zhan; Hamel, Ernest; Bortolozzi, Roberta; Porcu, Elena; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5433-5445</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of tubulin polymn. inhibitors based on the 2-aryl/heteroaryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole scaffold was synthesized and evaluated for growth inhibition activity on a panel of cancer cell lines, cell cycle effects, and in vivo potency.  Structure-activity relationships were elucidated with various substitutions at the 2-position of the thiazole skeleton.  Hydrophobic moieties, such as Ph and 3-thienyl, were well tolerated at this position, and variation of the Ph substituents had remarkable effects on potency.  The most active compd. I induced apoptosis through the mitochondrial pathway with activation of caspase-3.  We also showed that it has potential antivascular activity since it reduced in vitro endothelial cell migration and disrupted capillary-like tube formation at noncytotoxic concns.  Furthermore, compd. I significantly reduced the growth of the HT-29 xenograft in a nude mouse model, suggesting that I is a promising new antimitotic agent with clin. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrquOj-EUDFwbVg90H21EOLACvtfcHk0lhQxhNa_Dbu2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvV2mtLk%253D&md5=bc98bb15015c3163a9913bd5bdc6383a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm300388h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300388h%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DX.-H.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.-Z.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520series%2520of%25202-aryl-4-amino-5-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529thiazoles%2520as%2520novel%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5433%26epage%3D5445%26doi%3D10.1021%2Fjm300388h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolasi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancellieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consolaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antimitotic and antivascular activity of 1-(3′,4′,5′-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6795</span>– <span class="NLM_lpage">6808</span>, <span class="refDoi"> DOI: 10.1021/jm5008193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5008193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6795-6808&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai+Salvadorauthor=F.+Prencipeauthor=V.+Bertolasiauthor=M.+Cancellieriauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=F.+Consolaroauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Synthesis%2C+antimitotic+and+antivascular+activity+of+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29-3-arylamino-5-amino-1%2C2%2C4-triazoles&doi=10.1021%2Fjm5008193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm5008193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5008193%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DBertolasi%26aufirst%3DV.%26aulast%3DCancellieri%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DConsolaro%26aufirst%3DF.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520antimitotic%2520and%2520antivascular%2520activity%2520of%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529-3-arylamino-5-amino-1%252C2%252C4-triazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6795%26epage%3D6808%26doi%3D10.1021%2Fjm5008193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamzami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaudin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignotte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1084/jem.182.2.367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1084%2Fjem.182.2.367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=7629499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADyaK2MXntFKhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=1995&pages=367-377&author=N.+Zamzamiauthor=P.+Marchettiauthor=M.+Castedoauthor=D.+Decaudinauthor=A.+Machoauthor=T.+Hirschauthor=S.+A.+Susinauthor=P.+X.+Petitauthor=B.+Mignotteauthor=G.+Kroemer&title=Sequential+reduction+of+mitochondrial+transmembrane+potential+and+generation+of+reactive+oxygen+species+in+early+programmed+cell+death&doi=10.1084%2Fjem.182.2.367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death</span></div><div class="casAuthors">Zamzami, Naoufal; Marchetti, Philippe; Castedo, Maria; Decaudin, Didier; Macho, Antonio; Hirsch, Tamara; Susin, Santos A.; Petit, Patrice X.; Mignotte, Bernard; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">367-77</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Programmed cell death (PCD) is a physiol. process commonly defined by alterations in nuclear morphol. (apoptosis) and/or characteristic stepwise degrdn. of chromosomal DNA occurring before cytolysis.  However, detd. characteristics of PCD such as loss in mitochondrial reductase activity or cytolysis can be induced in enucleated cells, indicating cytoplasmic PCD control.  Here we report a sequential disregulation of mitochondrial function that precedes cell shrinkage and nuclear fragmentation.  A first cyclosporin A-inhibitable step of ongoing PCD is characterized by a redn. of mitochondrial transmembrane potential as detd. by specific fluorochromes (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide; 3,3'-dihexyloxacarbocyanine iodide).  Cytofluorometrically purified cells with reduced mitochondrial transmembrane potential are initially incapable of oxidizing hydroethidine (HE) into ethidium.  Upon short-term in vitro culture, such cells acquire the capacity of HE oxidn., thus revealing a second step of PCD marked by mitochondrial generation of reactive oxygen species (ROS).  This step can be selectively inhibited by rotenone and ruthenium red yet is not affected by cyclosporin A.  Finally, cells reduce their vol., a step that is delayed by radical scavengers, indicating the implication of ROS in the apoptotic process.  This sequence of alterations, accompanying early PCD is found in very different models of apoptosis induction: glucocorticoid-induced death of lymphocytes, activation-induced PCD of T cell hybridomas, and tumor necrosis factor-induced death of U937 cells.  Transfection with the antiapoptotic protooncogene Bcl-2-simultaneously inhibits mitochondrial alterations and apoptotic cell death triggered by steroids or ceramide.  In vivo injection fo fluorochromes such as 5,5',6,6'-retrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide; 3,3'-dihexyloxacarbocyanine iodide; or HE allows for the detection of cells that are programmed for death but still lack nuclear DNA fragmentation.  In particular, assessment of mitochondrial ROS generation provides an accurate picture of PCD-mediated lymphocyte depletion.  In conclusion, alterations of mitochondrial function constitute an important feature of early PCD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNHceD860pHrVg90H21EOLACvtfcHk0liFNNESvFpK2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntFKhs78%253D&md5=ce8730fd7c4fc177c0002753e5f932bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1084%2Fjem.182.2.367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.182.2.367%26sid%3Dliteratum%253Aachs%26aulast%3DZamzami%26aufirst%3DN.%26aulast%3DMarchetti%26aufirst%3DP.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DDecaudin%26aufirst%3DD.%26aulast%3DMacho%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DT.%26aulast%3DSusin%26aufirst%3DS.%2BA.%26aulast%3DPetit%26aufirst%3DP.%2BX.%26aulast%3DMignotte%26aufirst%3DB.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DSequential%2520reduction%2520of%2520mitochondrial%2520transmembrane%2520potential%2520and%2520generation%2520of%2520reactive%2520oxygen%2520species%2520in%2520early%2520programmed%2520cell%2520death%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1995%26volume%3D182%26spage%3D367%26epage%3D377%26doi%3D10.1084%2Fjem.182.2.367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dueber, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maecker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span> <span> </span><span class="NLM_article-title">Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>471</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nature09779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnature09779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21368834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1Cku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2011&pages=110-114&author=I.+E.+Wertzauthor=S.+Kusamauthor=C.+Lamauthor=T.+Okamotoauthor=W.+Sandovalauthor=D.+J.+Andersonauthor=E.+Helgasonauthor=J.+A.+Ernstauthor=M.+Ebyauthor=J.+Liuauthor=L.+D.+Belmontauthor=J.+S.+Kaminkerauthor=K.+M.+O%E2%80%99Rourkeauthor=K.+Pujaraauthor=P.+B.+Kohliauthor=A.+R.+Johnsonauthor=M.+L.+Chiuauthor=J.+R.+Lillauthor=P.+K.+Jacksonauthor=W.+J.+Fairbrotherauthor=S.+Seshagiriauthor=M.+J.+Ludlamauthor=K.+G.+Leongauthor=E.+C.+Dueberauthor=H.+Maeckerauthor=D.+C.+Huangauthor=V.+M.+Dixit&title=Sensitivity+to+antitubulin+chemotherapeutics+is+regulated+by+MCL1+and+FBW7&doi=10.1038%2Fnature09779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7</span></div><div class="casAuthors">Wertz, Ingrid E.; Kusam, Saritha; Lam, Cynthia; Okamoto, Toru; Sandoval, Wendy; Anderson, Daniel J.; Helgason, Elizabeth; Ernst, James A.; Eby, Mike; Liu, Jinfeng; Belmont, Lisa D.; Kaminker, Josh S.; O'Rourke, Karen M.; Pujara, Kanan; Kohli, Pawan Bir; Johnson, Adam R.; Chiu, Mark L.; Lill, Jennie R.; Jackson, Peter K.; Fairbrother, Wayne J.; Seshagiri, Somasekar; Ludlam, Mary J. C.; Leong, Kevin G.; Dueber, Erin C.; Maecker, Heather; Huang, David C. S.; Dixit, Vishva M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">471</span>
        (<span class="NLM_cas:issue">7336</span>),
    <span class="NLM_cas:pages">110-114</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules have pivotal roles in fundamental cellular processes and are targets of antitubulin chemotherapeutics.  Microtubule-targeted agents such as Taxol and vincristine are prescribed widely for various malignancies, including ovarian and breast adenocarcinomas, non-small-cell lung cancer, leukemias and lymphomas.  These agents arrest cells in mitosis and subsequently induce cell death through poorly defined mechanisms.  The strategies that resistant tumor cells use to evade death induced by antitubulin agents are also unclear.  Here we show that the pro-survival protein MCL1 is a crucial regulator of apoptosis triggered by antitubulin chemotherapeutics.  During mitotic arrest, MCL1 protein levels decline markedly, through a post-translational mechanism, potentiating cell death.  Phosphorylation of MCL1 directs its interaction with the tumor-suppressor protein FBW7, which is the substrate-binding component of a ubiquitin ligase complex.  The polyubiquitylation of MCL1 then targets it for proteasomal degrdn.  The degrdn. of MCL1 was blocked in patient-derived tumor cells that lacked FBW7 or had loss-of-function mutations in FBW7, conferring resistance to antitubulin agents and promoting chemotherapeutic-induced polyploidy.  Addnl., primary tumor samples were enriched for FBW7 inactivation and elevated MCL1 levels, underscoring the prominent roles of these proteins in oncogenesis.  Our findings suggest that profiling the FBW7 and MCL1 status of tumors, in terms of protein levels, mRNA levels and genetic status, could be useful to predict the response of patients to antitubulin chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFiH1HCl46H7Vg90H21EOLACvtfcHk0liFNNESvFpK2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1Cku7g%253D&md5=9b06764b31a4b2e4597c76e9138b0a34</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature09779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09779%26sid%3Dliteratum%253Aachs%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DKusam%26aufirst%3DS.%26aulast%3DLam%26aufirst%3DC.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DHelgason%26aufirst%3DE.%26aulast%3DErnst%26aufirst%3DJ.%2BA.%26aulast%3DEby%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DK.%2BM.%26aulast%3DPujara%26aufirst%3DK.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DChiu%26aufirst%3DM.%2BL.%26aulast%3DLill%26aufirst%3DJ.%2BR.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DLeong%26aufirst%3DK.%2BG.%26aulast%3DDueber%26aufirst%3DE.%2BC.%26aulast%3DMaecker%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DD.%2BC.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26atitle%3DSensitivity%2520to%2520antitubulin%2520chemotherapeutics%2520is%2520regulated%2520by%2520MCL1%2520and%2520FBW7%26jtitle%3DNature%26date%3D2011%26volume%3D471%26spage%3D110%26epage%3D114%26doi%3D10.1038%2Fnature09779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czabotar, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. M.</span></span> <span> </span><span class="NLM_article-title">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/nrm3722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fnrm3722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24355989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=49-63&author=P.+E.+Czabotarauthor=G.+Lesseneauthor=A.+Strasserauthor=J.+M.+Adams&title=Control+of+apoptosis+by+the+BCL-2+protein+family%3A+implications+for+physiology+and+therapy&doi=10.1038%2Fnrm3722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span></div><div class="casAuthors">Czabotar, Peter E.; Lessene, Guillaume; Strasser, Andreas; Adams, Jerry M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The BCL-2 protein family dets. the commitment of cells to apoptosis, an ancient cell suicide program that is essential for development, tissue homeostasis and immunity.  Too little apoptosis can promote cancer and autoimmune diseases; too much apoptosis can augment ischemic conditions and drive neurodegeneration.  We discuss the biochem., structural and genetic studies that have clarified how the interplay between members of the BCL-2 family on mitochondria sets the apoptotic threshold.  These mechanistic insights into the functions of the BCL-2 family are illuminating the physiol. control of apoptosis, the pathol. consequences of its dysregulation and the promising search for novel cancer therapies that target the BCL-2 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYVpm2heUGBbVg90H21EOLACvtfcHk0liFNNESvFpK2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI&md5=c18d528c2819c2df93b6798e62132372</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrm3722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3722%26sid%3Dliteratum%253Aachs%26aulast%3DCzabotar%26aufirst%3DP.%2BE.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%2BM.%26atitle%3DControl%2520of%2520apoptosis%2520by%2520the%2520BCL-2%2520protein%2520family%253A%2520implications%2520for%2520physiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D49%26epage%3D63%26doi%3D10.1038%2Fnrm3722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span> <span> </span><span class="NLM_article-title">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span>. <i>Angiogenesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1007/s10456-013-9343-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1007%2Fs10456-013-9343-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=23456551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=647-662&author=E.+Porc%C3%B9author=G.+Violaauthor=R.+Bortolozziauthor=S.+Mitolaauthor=R.+Roncaauthor=M.+Prestaauthor=L.+Persanoauthor=R.+Romagnoliauthor=P.+G.+Baraldiauthor=G.+Basso&title=TR-644+a+novel+potent+tubulin+binding+agent+induces+impairment+of+endothelial+cells+function+and+inhibits+angiogenesis&doi=10.1007%2Fs10456-013-9343-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span></div><div class="casAuthors">Porcu, Elena; Viola, Giampietro; Bortolozzi, Roberta; Persano, Luca; Mitola, Stefania; Ronca, Roberto; Presta, Marco; Romagnoli, Romeo; Baraldi, Pier Giovanni; Basso, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-662</span>CODEN:
                <span class="NLM_cas:coden">AGIOFT</span>;
        ISSN:<span class="NLM_cas:issn">0969-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">TR-644 is a novel combretastatin A-4 (CA-4) analog endowed with potent microtubule depolymg. activity superior to that of the lead compd. and it also has high affinity to colchicines binding site of tubulin.  We tested TR-644 anti-angiogenic effects in human umbilical endothelial cells (HUVEC).  It showed no significant effects on the growth of HUVEC cells at concns. below 1,000 nM, but at much lower concns. (10-100 nM) it induced inhibition of capillary tube formation, inhibition of endothelial cell migration and affected endothelial cell morphol. as demonstrated by the disruption of the microtubule network.  TR-644 also increased permeability of HUVEC cells in a time dependent manner.  The mol. mechanism for the anti-vascular activity of TR-644 was investigated in detail.  TR-644 caused G2/M arrest in endothelial cells and this effect correlated with downregulation of the expression of Cdc25C and Cdc2Tyr15.  Moreover TR-644 inhibited VEGF-induced phosphorylation of VE-cadherin but did not prevent the VEGF-induced phosphorylation of FAK.  In chick chorioallantoic membrane in vivo assay, TR-644 (0.1-1.0 pmol/egg) efficiently counteracted the strong angiogenic response induced by FGF.  Also CA-4, used as ref. compd., caused an antagonistic effect, but in contrast, it induced per se, a remarkable angiogenic response probably due to an inflammatory reaction in the site of treatment.  In a mice allogenic tumor model, immunohistochem. staining of tumors with anti-CD31 antibody showed that TR-644 significantly reduced the no. of vessel, after 24 h from the administration of a single dose (30 mg/Kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjdcGwvsKlwbVg90H21EOLACvtfcHk0ljHJAM-fdy2FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D&md5=701845b28683c4a73edd13455485c742</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs10456-013-9343-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-013-9343-z%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DViola%26aufirst%3DG.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DPresta%26aufirst%3DM.%26aulast%3DPersano%26aufirst%3DL.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBasso%26aufirst%3DG.%26atitle%3DTR-644%2520a%2520novel%2520potent%2520tubulin%2520binding%2520agent%2520induces%2520impairment%2520of%2520endothelial%2520cells%2520function%2520and%2520inhibits%2520angiogenesis%26jtitle%3DAngiogenesis%26date%3D2013%26volume%3D16%26spage%3D647%26epage%3D662%26doi%3D10.1007%2Fs10456-013-9343-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolasi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancellieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consolaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antimitotic and antivascular activity of 1-(3′,4′,5′-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6795</span>– <span class="NLM_lpage">6808</span>, <span class="refDoi"> DOI: 10.1021/jm5008193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5008193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6795-6808&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=F.+Prencipeauthor=V.+Bertolasiauthor=M.+Cancellieriauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=F.+Consolaroauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Synthesis%2C+antimitotic+and+antivascular+activity+of+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29-3-arylamino-5-amino-1%2C2%2C4-triazoles&doi=10.1021%2Fjm5008193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm5008193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5008193%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DBertolasi%26aufirst%3DV.%26aulast%3DCancellieri%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DConsolaro%26aufirst%3DF.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520antimitotic%2520and%2520antivascular%2520activity%2520of%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529-3-arylamino-5-amino-1%252C2%252C4-triazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6795%26epage%3D6808%26doi%3D10.1021%2Fjm5008193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai
Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiaffino Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagliuolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, in vitro and in vivo anticancer and antiangiogenic activity of novel 3-arylamino benzofuran derivatives targeting the colchicine site on tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3209</span>– <span class="NLM_lpage">3222</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3209-3222&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+Kimatrai%0ASalvadorauthor=F.+Prencipeauthor=C.+Lopez-Caraauthor=S.+Schiaffino+Ortegaauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=S.+Mitolaauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Design%2C+synthesis%2C+in+vitro+and+in+vivo+anticancer+and+antiangiogenic+activity+of+novel+3-arylamino+benzofuran+derivatives+targeting+the+colchicine+site+on+tubulin&doi=10.1021%2Facs.jmedchem.5b00155"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00155%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DLopez-Cara%26aufirst%3DC.%26aulast%3DSchiaffino%2BOrtega%26aufirst%3DS.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520and%2520antiangiogenic%2520activity%2520of%2520novel%25203-arylamino%2520benzofuran%2520derivatives%2520targeting%2520the%2520colchicine%2520site%2520on%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3209%26epage%3D3222%26doi%3D10.1021%2Facs.jmedchem.5b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porcù, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">The novel antitubulin agent TR-764 strongly reduces tumor vasculature and inhibits HIF-1α activation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">27886</span> <span class="refDoi"> DOI: 10.1038/srep27886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fsrep27886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27292568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSlu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=E.+Porc%C3%B9author=L.+Persanoauthor=R.+Roncaauthor=S.+Mitolaauthor=R.+Bortolozziauthor=R.+Romagnoliauthor=P.+Olivaauthor=G.+Bassoauthor=G.+Viola&title=The+novel+antitubulin+agent+TR-764+strongly+reduces+tumor+vasculature+and+inhibits+HIF-1%CE%B1+activation&doi=10.1038%2Fsrep27886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation</span></div><div class="casAuthors">Porcu, Elena; Persano, Luca; Ronca, Roberto; Mitola, Stefania; Bortolozzi, Roberta; Romagnoli, Romeo; Oliva, Paola; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27886</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tubulin binding agents (TBAs) are commonly used in cancer therapy as antimitotics.  It has been described that TBAs, like combretastatin A-4 (CA-4), present also antivascular activity and among its derivs. we identified TR-764 as a new inhibitor of tubulin polymn., based on the 2-(alkoxycarbonyl)-3-(3',4',5'-trimethoxyanilino)benzo[b]thiophene mol. skeleton.  The antiangiogenic activity of TR-764 (1-10 nM) was tested in vitro on human umbilical endothelial cells (HUVECs), and in vivo, on the chick embryo chorioallantoic membrane (CAM) and two murine tumor models.  TR-764 binding to tubulin triggers cytoskeleton rearrangement without affecting cell cycle and viability.  It leads to capillary tube disruption, increased cell permeability, and cell motility redn.  Moreover it disrupts adherens junctions and focal adhesions, through mechanisms involving VE-cadherin/β-catenin and FAK/Src.  Importantly, TR-764 is active in hypoxic conditions significantly reducing HIF-1α.  In vivo TR-764 (1-100 pmol/egg) remarkably blocks the bFGF proangiogenic activity on CAM and shows a stronger redn. of tumor mass and microvascular d. both in murine syngeneic and xenograft tumor models, compared to the lead compd. CA-4P.  Altogether, our results indicate that TR-764 is a novel TBA with strong potential as both antivascular and antitumor mol. that could improve the common anticancer therapies, by overcoming hypoxia-induced resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmUlLSiVenbVg90H21EOLACvtfcHk0ljHJAM-fdy2FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSlu77I&md5=27dec7400a73d6a9c32bfeb8b26246f3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fsrep27886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27886%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DPersano%26aufirst%3DL.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DThe%2520novel%2520antitubulin%2520agent%2520TR-764%2520strongly%2520reduces%2520tumor%2520vasculature%2520and%2520inhibits%2520HIF-1%25CE%25B1%2520activation%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep27886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leali, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coltrini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarazzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribatti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presta, M.</span></span> <span> </span><span class="NLM_article-title">Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2760</span>– <span class="NLM_lpage">2771</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1158%2F1535-7163.MCT-13-0487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=24130051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2760-2771&author=R.+Roncaauthor=E.+Di+Salleauthor=A.+Giacominiauthor=D.+Lealiauthor=P.+Alessiauthor=D.+Coltriniauthor=C.+Ravelliauthor=S.+Matarazzoauthor=D.+Ribattiauthor=W.+Vermiauthor=M.+Presta&title=Long+pentraxin-3+inhibits+epithelial-mesenchymal+transition+in+melanoma+cells&doi=10.1158%2F1535-7163.MCT-13-0487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Long Pentraxin-3 Inhibits Epithelial-Mesenchymal Transition in Melanoma Cells</span></div><div class="casAuthors">Ronca, Roberto; Di Salle, Emanuela; Giacomini, Arianna; Leali, Daria; Alessi, Patrizia; Coltrini, Daniela; Ravelli, Cosetta; Matarazzo, Sara; Ribatti, Domenico; Vermi, William; Presta, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2760-2771</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">During melanoma progression, malignant melanocytes are reprogrammed into mesenchymal-like cells through to an epithelial-mesenchymal transition (EMT) process assocd. with the acquisition of an invasive, prometastatic phenotype.  The fibroblast growth factor-2 (FGF2)/FGF receptor (FGFR) system plays a pivotal role in melanoma, leading to autocrine/paracrine induction of tumor cell proliferation and angiogenesis.  Long pentraxin-3 (PTX3) interacts with FGF2, and other FGF family members, inhibiting FGF-dependent neovascularization and tumor growth.  Here, PTX3 protein and the PTX3-derived acetylated pentapeptide Ac-ARPCA-NH2 inhibit FGF2-driven proliferation and downstream FGFR signaling in murine melanoma B16-F10 cells.  Moreover, human PTX3-overexpressing hPTXB16-F10 cells are characterized by the reversed transition from a mesenchymal to an epithelial-like appearance, inhibition of cell proliferation, loss of clonogenic potential, reduced motility and invasive capacity, downregulation of various mesenchymal markers, and upregulation of the epithelial marker E-cadherin.  Accordingly, PTX3 affects cell proliferation and EMT transition in human A375 and A2058 melanoma cells.  Also, hPTXB16-F10 cells showed a reduced tumorigenic and metastatic activity in syngeneic C57BL/6 mice.  In conclusion, PTX3 inhibits FGF/FGFR-driven EMT in melanoma cells, hampering their tumorigenic and metastatic potential.  These data represent the first exptl. evidence about a nonredundant role of the FGF/FGFR system in the modulation of the EMT process in melanoma and indicate that PTX3 or its derivs. may represent the basis for the design of novel therapeutic approaches in FGF/FGFR-dependent tumors, including melanoma.  Mol Cancer Ther; 12(12); 2760-71. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXU05tS8wW-7Vg90H21EOLACvtfcHk0liOYZtluEYGEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyqsrvM&md5=149ad1c43348bb691728ecad7f25aede</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0487%26sid%3Dliteratum%253Aachs%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DDi%2BSalle%26aufirst%3DE.%26aulast%3DGiacomini%26aufirst%3DA.%26aulast%3DLeali%26aufirst%3DD.%26aulast%3DAlessi%26aufirst%3DP.%26aulast%3DColtrini%26aufirst%3DD.%26aulast%3DRavelli%26aufirst%3DC.%26aulast%3DMatarazzo%26aufirst%3DS.%26aulast%3DRibatti%26aufirst%3DD.%26aulast%3DVermi%26aufirst%3DW.%26aulast%3DPresta%26aufirst%3DM.%26atitle%3DLong%2520pentraxin-3%2520inhibits%2520epithelial-mesenchymal%2520transition%2520in%2520melanoma%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2760%26epage%3D2771%26doi%3D10.1158%2F1535-7163.MCT-13-0487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariotto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent in vitro and in vivo anticancer agents based on 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1<i>H</i>-imidazole</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">26602</span> <span class="refDoi"> DOI: 10.1038/srep26602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1038%2Fsrep26602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=27216165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos12mt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=F.+Prencipeauthor=P.+Olivaauthor=P.+Olivaauthor=P.+Olivaauthor=P.+Olivaauthor=S.+Ferlaauthor=A.+Brancaleauthor=E.+Hamelauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Mariottoauthor=G.+Bassoauthor=G.+Viola&title=Design+and+synthesis+of+potent+in+vitro+and+in+vivo+anticancer+agents+based+on+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxyphenyl%29-2-aryl-1H-imidazole&doi=10.1038%2Fsrep26602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Prencipe, Filippo; Oliva, Paola; Baraldi, Stefania; Tabrizi, Mojgan Aghazadeh; Lopez-Cara, Luisa Carlota; Ferla, Salvatore; Brancale, Andrea; Hamel, Ernest; Ronca, Roberto; Bortolozzi, Roberta; Mariotto, Elena; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26602pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A novel series of tubulin polymn. inhibitors, based on the 1-(3',4',5'-trimethoxyphenyl)-2-aryl-1H-imidazole scaffold and designed as cis-restricted combretastatin A-4 analogs, compds. I [R = 4-MeC6H4, 4-EtOC6H4, 4-EtSC6H4, etc.] were synthesized with the goal of evaluating the effects of various patterns of substitution on the Ph at the 2-position of the imidazole ring on biol. activity.  Compd. I [R = 4-EtO-3-Cl-C6H4] produced the most active compd. in the series, with IC50 values of 0.4-3.8 nM against a panel of seven cancer cell lines.  Except in HL-60 cells, compd. I [R = 4-EtO-3-Cl-C4-EtO-3-Cl-C6H4] had greater antiproliferative than CA-4, indicating that the 3'-chloro-4'-ethoxyphenyl moiety was a good surrogate for the CA-4 B-ring.  Expts. carried out in a mouse syngenic model demonstrated high antitumor activity of compd. I [R = 4-EtO-3-Cl-4-EtO-3-Cl-C6H4], which significantly reduced the tumor mass at a dose thirty times lower than that required for CA-4P, which was used as a ref. compd.  Altogether, thr findings suggeste that compd. I [R = 4-EtO-3-Cl-4-EtO-3-Cl-C6H4] is a promising anticancer drug candidate that warrants further preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAjNLSZc2QC7Vg90H21EOLACvtfcHk0liOYZtluEYGEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos12mt7w%253D&md5=6ffe29f76796aed8d9b44e966a8eace1</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsrep26602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26602%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DFerla%26aufirst%3DS.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DMariotto%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520agents%2520based%2520on%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxyphenyl%2529-2-aryl-1H-imidazole%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep26602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qingjun Ma, Q.</span></span> <span> </span><span class="NLM_article-title">Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">91</span>, <span class="refDoi"> DOI: 10.1186/1472-6750-10-91</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1186%2F1472-6750-10-91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=21176167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=91&author=Q.+Xuauthor=X.+Zhangauthor=J.+Yueauthor=C.+Liuauthor=C.+Caoauthor=H.+Zhongauthor=Q.+Qingjun+Ma&title=Human+TGFalpha-derived+peptide+TGFalphaL3+fused+with+superantigen+for+immunotherapy+of+EGFR-expressing+tumours&doi=10.1186%2F1472-6750-10-91"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumors</span></div><div class="casAuthors">Xu, Quanbin; Zhang, Xiaojuan; Yue, Junjie; Liu, Chuanxuan; Cao, Cheng; Zhong, Hui; Ma, Qingjun</div><div class="citationInfo"><span class="NLM_cas:title">BMC Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91</span>CODEN:
                <span class="NLM_cas:coden">BBMIE6</span>;
        ISSN:<span class="NLM_cas:issn">1472-6750</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Monoclonal antibodies have been employed as targeting mols. of superantigen for the preclin. treatment of a variety of tumors.  However, other targeting mols., such as tumor-related ligands or peptides, are less exploited.  Here, we tested other targeting mols. by genetically fusing the third loop of transforming growth factor alpha (TGFalphaL3) to mutant staphylococcal enterotoxin A (SEAD227A).  Results: The resultant fusion proteins were expressed in E.coli and purified to homogeneity through a Ni-NTA affinity column.  Fusion protein TGFalphaL3SEAD227A can promote splenocyte proliferation to a level comparable to recombinant SEA (rSEA) and bind to EGFR-expressing tumor cells in an EGFR-dependent way.  Consistent with these observations, TGFalphaL3SEAD227A exerted an inhibitory effect on the growth of EGFR-expressing tumor cells both in vitro and in vivo.  Notably, significant infiltrations of CD8+ and CD4+ T cells were detected in the tumor tissues of these C57BL/6 mice treated with TGFalphaL3SEAD227A, suggesting the involvement of T cells in this tumor-inhibitory process.  Conclusions: The data here showed that TGFαL3 is capable of targeting superantigen to tumors and exerting an inhibitory effect on tumor growth, which enables TGFαL3SEAD227A to be an attractive candidate for the immunotherapy of EGFR-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbMw-zSyfLDrVg90H21EOLACvtfcHk0liOYZtluEYGEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFSkuw%253D%253D&md5=146cbe440e733b995c5aa06988364fb2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1186%2F1472-6750-10-91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6750-10-91%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DQingjun%2BMa%26aufirst%3DQ.%26atitle%3DHuman%2520TGFalpha-derived%2520peptide%2520TGFalphaL3%2520fused%2520with%2520superantigen%2520for%2520immunotherapy%2520of%2520EGFR-expressing%2520tumours%26jtitle%3DBMC%2520Biotechnol.%26date%3D2010%26volume%3D10%26spage%3D91%26doi%3D10.1186%2F1472-6750-10-91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span>. <i>Cell Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1385/CBB:38:1:1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1385%2FCBB%3A38%3A1%3A1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=12663938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=1-21&author=E.+Hamel&title=Evaluation+of+antimitotic+agents+by+quantitative+comparisons+of+their+effects+on+the+polymerization+of+purified+tubulin&doi=10.1385%2FCBB%3A38%3A1%3A1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53aR"><div class="casContent"><span class="casTitleNuber">53a</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin</span></div><div class="casAuthors">Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Most antimitotic compds. have highly specific interactions with tubulin, the major protein component of microtubules.  It is, therefore, often desirable to characterize interactions of these agents with tubulin.  In particular, quant. comparisons between new and old ("std.") agents, between different classes of agent, and between structural analogs (e.g., for a structure-activity relationship study) are important.  Because antimitotic drugs have a variety of effects on tubulin and bind at multiple distinct sites on the protein, the tubulin assembly reaction is probably the only universally applicable reaction that can be analyzed.  In my lab., we use the assembly of purified tubulin induced by higher concns. of monosodium glutamate as our basic assay system.  This report presents a detailed description of our current routine assay, including the effects of a variety of reaction components on the reaction.  In addn., the variety of effects that reaction components can have on the quant. results obtained with drugs, using the colchicine site drug combretastatin A-4 as a model compd., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvDICXLUiYbVg90H21EOLACvtfcHk0li68gs4xqLWNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVaisLY%253D&md5=c37c365cc707e237f43feffca64d706b</span></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=10.1385%2FCBB%3A38%3A1%3A1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCBB%253A38%253A1%253A1%26sid%3Dliteratum%253Aachs%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DEvaluation%2520of%2520antimitotic%2520agents%2520by%2520quantitative%2520comparisons%2520of%2520their%2520effects%2520on%2520the%2520polymerization%2520of%2520purified%2520tubulin%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2003%26volume%3D38%26spage%3D1%26epage%3D21%26doi%3D10.1385%2FCBB%3A38%3A1%3A1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit53b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Verdier-Pinard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falck, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1124/mol.53.1.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;key=10.1124%2Fmol.53.1.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=62-67&author=P.+Verdier-Pinardauthor=J.-Y.+Laiauthor=H.-D.+Yooauthor=J.+Yuauthor=B.+Marquezauthor=D.+G.+Nagleauthor=M.+Nambuauthor=J.+D.+Whiteauthor=J.+R.+Falckauthor=W.+H.+Gerwickauthor=B.+W.+Dayauthor=E.+Hamel&title=Structure-activity+analysis+of+the+interaction+of+curacin+A%2C+the+potent+colchicine+site+antimitotic+agent%2C+with+tubulin+and+effects+of+analogs+on+the+growth+of+MCF-7+breast+cancer+cells&doi=10.1124%2Fmol.53.1.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=10.1124%2Fmol.53.1.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.53.1.62%26sid%3Dliteratum%253Aachs%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DJ.-Y.%26aulast%3DYoo%26aufirst%3DH.-D.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMarquez%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DD.%2BG.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DFalck%26aufirst%3DJ.%2BR.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure-activity%2520analysis%2520of%2520the%2520interaction%2520of%2520curacin%2520A%252C%2520the%2520potent%2520colchicine%2520site%2520antimitotic%2520agent%252C%2520with%2520tubulin%2520and%2520effects%2520of%2520analogs%2520on%2520the%2520growth%2520of%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26spage%3D62%26epage%3D67%26doi%3D10.1124%2Fmol.53.1.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span> <i>Molecular Operating
Environment (MOE 2015.10)</i>; <span class="NLM_publisher-name">Chemical Computing
Group, Inc.</span>: <span class="NLM_publisher-loc">Montreal, Quebec, Canada</span>, <span class="NLM_year">2015</span>. <a href="http://www.chemcomp.com" class="extLink">http://www.chemcomp.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating%0AEnvironment+%28MOE+2015.10%29%3B+Chemical+Computing%0AGroup%2C+Inc.%3A+Montreal%2C+Quebec%2C+Canada%2C+2015.+http%3A%2F%2Fwww.chemcomp.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMolecular%2520Operating%250AEnvironment%2520%2528MOE%25202015.10%2529%26pub%3DChemical%2520Computing%250AGroup%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span> <i>Schrödinger Release 2017-1: Maestro</i>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Schr%C3%B6dinger+Release+2017-1%3A+Maestro%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C%0ANY%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSchr%25C3%25B6dinger%2520Release%25202017-1%253A%2520Maestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0','PDB','1SA0'); return false;">PDB: 1SA0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M','PDB','2J6M'); return false;">PDB: 2J6M</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i68"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01391">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_74430"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01391">10.1021/acs.jmedchem.8b01391</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Antiproliferative activities of compounds <b>7a</b>–<b>d</b> (Table 1S) and <b>8a</b>–<b>l</b> (Table 2S); general procedures and references related to the preparation of methyl 3-aminothiophene-5-aryl/heteroaryl-2-carboxylate <b>9a</b>–<b>j</b>, ethyl 5-amino-2-anilinothiazole-4-carboxylate <b>9k</b>–<b>n</b>, and ethyl 2-aminothiophene-3-carboxylate <b>12c</b>–<b>l</b> derivatives; spectral data for the newly synthesized compounds <b>7a</b>–<b>d</b>, <b>10k</b>–<b>n</b>, <b>11k</b>–<b>n</b>, <b>13a</b>–<b>l</b>, and <b>14a</b>–<b>l</b>; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compounds <b>6a</b>–<b>j</b>; elemental microanalyses for compounds <b>6a</b>–<b>j</b>, <b>7a</b>–<b>d</b>, and <b>8a</b>–<b>l</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_003.pdf">PDF</a>)</p></li><li><p class="inline"><b>6b</b>–<b>e</b>–<b>g</b>-docking-<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0">1SA0</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_001.pdb">PDB</a>)</p></li><li><p class="inline"><b>6b</b>–<b>e</b>-docking-<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2J6M">2J6M</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_004.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_001.pdb">jm8b01391_si_001.pdb (355.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_002.pdb">jm8b01391_si_002.pdb (438.66 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_003.pdf">jm8b01391_si_003.pdf (2.54 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01391/suppl_file/jm8b01391_si_004.csv">jm8b01391_si_004.csv (3.14 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-3%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01391%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01391" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a65872ee23ddd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
